Plants having increased tolerance to herbicides

ABSTRACT

The present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of providing, at said site, a plant that comprises at least one nucleic acid comprising a nucleotide sequence encoding a wild-type hydroxyphenyl pyruvate dioxygenase or a mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD) which is resistant or tolerant to a HPPD-inhibiting herbicide and/or a nucleotide sequence encoding a wild-type homogentisate solanesyl transferase or a mutated homogentisate solanesyl transferase (mut-HST) which is resistant or tolerant to a HPPD-inhibiting herbicide, applying to said site an effective amount of said herbicide. The invention further refers to plants comprising mut-HPPD, and methods of obtaining such plants.

RELATED APPLICATIONS

This application is a national stage application under 35 U.S.C. § 371 of PCT/IB2014/061053, filed Apr. 28, 2014, which claims benefit of U.S. provisional application Nos. 61/817,330, filed Apr. 30, 2013 and 61/817,333, filed Apr. 30, 2013.

SUBMISSION OF SEQUENCE LISTING

The Sequence Listing associated with this application is filed in electronic format via EFS-Web and hereby incorporated by reference into the specification in its entirety. The name of the text file containing the Sequence Listing is PF75339_SEQLIST. The size of the text file is 195 KB, and the text file was created on Oct. 28, 2016.

FIELD OF THE INVENTION

The present invention relates in general to methods for conferring on plants agricultural levels of tolerance towards an herbicide. Particularly, the invention refers to plants having an increased tolerance to HPPD-inhibiting herbicides. More specifically, the present invention relates to methods and plants obtained by mutagenesis and cross-breeding and transformation that have an increased tolerance to “HPPD-inhibiting” herbicides.

BACKGROUND OF THE INVENTION

Herbicides that inhibit 4-hydroxyphenylpyruvate dioxygenase (4-HPPD; EC 1.13.11.27), a key enzyme in the biosynthesis of the prenylquinones plastoquinone and tocopherols, have been used for selective weed control since the early 1990s. They block the conversion of 4-hydroxyphenylpyruvate to homogentisate in the biosynthetic pathway (Matringe et al., 2005, Pest Manag Sci., vol. 61:269-276; Mitchell et al., 2001, Pest Manag Sci. vol 57:120-128). Plastoquinone is thought to be a necessary cofactor of the enzyme phytoene desaturase in carotenoid biosynthesis (Boeger and Sandmann, 1998, Pestic Outlook, vol 9:29-35). Its inhibition results in the depletion of the plant plastoquinone and vitamin E pools, leading to bleaching symptoms. The loss of carotenoids, particularly in their function as protectors of the photosystems against photooxidation, leads to oxidative degradation of chlorophyll and photosynthetic membranes in growing shoot tissues. Consequently, chloroplast synthesis and function are disturbed (Boeger and Sandmann, 1998). The enzyme homogentisate solanesyl transferase (HST) catalyses the step following HPPD in the plastoquinone biosynthetic pathway. HST is a prenyl transferase that both decarboxylates homogentisate and also transfers to it the solanesyl group from solanesyl diphosphate and thus forms 2-methyl-6-solanesyl-1,4-benzoquinol (MSBQ), an intermediate along the biosynthetic pathway to plastoquinone. HST enzymes are membrane bound and the genes that encode them include a plastid targeting sequence.

The most important chemical classes of commercial 4-HPPD-inhibiting herbicides include pyrazolones, triketones and isoxazoles. The inhibitors mimic the binding of the substrate 4-hydroxyphenylpyruvate to an enzyme-bound ferrous ion in the active site by forming a stable ion-dipole charge transfer complex. Among 4-HPPD-inhibiting herbicides, the triketone sulcotrione was the first example of this herbicide group to be used in agriculture and identified in its mechanism of action (Schulz et al., 1993, FEBS Lett. Vol 318:162-166) The triketones have been reported to be derivatives of leptospermone, a herbicidal component from the bottlebrush plant, Callistemon spp (Lee et al. 1997, Weed Sci. Vol 45, 162-166).

Some of these molecules have been used as herbicides since inhibition of the reaction in plants leads to whitening of the leaves of the treated plants and to the death of the said plants (Pallett, K. E. et al. 1997 Pestic. Sci. 50 83-84). The herbicides for which HPPD is the target, and which are described in the state of the art, are, in particular, isoxazoles (EP418175, EP470856, EP487352, EP527036, EP560482, EP682659, U.S. Pat. No. 5,424,276), in particular isoxaflutole, which is a selective herbicide for maize, diketonitriles (EP496630, EP496631), in particular 2-cyano-3-cyclopropyl-1-(2-SO₂CH₃-4-CF3 phenyl)propane-1,3-dione and 2-cyano-3-cyclopropyl-1-(2-SO₂CH₃-4-2,3Cl₂phenyl)propane-1,3-dione, triketones such as described in EP625505, EP625508, U.S. Pat. No. 5,506,195, in particular sulcotrione, or else pyrazolinates. Furthermore, the well-known herbicide topramezone elicits the same type of phytotoxic symptoms, with chlorophyll loss and necrosis in the growing shoot tissues, as 4-HPPD inhibiting, bleaching herbicides described supra in susceptible plant species. Topramezone belongs to the chemical class of pyrazolones or benzoyl pyrazoles and was commercially introduced in 2006. When applied postemergence, the compound selectively controls a wide spectrum of annual grass and broadleaf weeds in corn.

Three main strategies are available for making plants tolerant to herbicides, i.e. (1) detoxifying the herbicide with an enzyme which transforms the herbicide, or its active metabolite, into non-toxic products, such as, for example, the enzymes for tolerance to bromoxynil or to Basta (EP242236, EP337899); (2) mutating the target enzyme into a functional enzyme which is less sensitive to the herbicide, or to its active metabolite, such as, for example, the enzymes for tolerance to glyphosate (EP293356, Padgette S. R. et al., J. Biol. Chem., 266, 33, 1991); or (3) overexpressing the sensitive enzyme so as to produce quantities of the target enzyme in the plant which are sufficient in relation to the herbicide, in view of the kinetic constants of this enzyme, so as to have enough of the functional enzyme available despite the presence of its inhibitor. The third strategy was described for successfully obtaining plants which were tolerant to HPPD inhibitors (WO96/38567). US2009/0172831 discloses nucleotide sequences encoding amino acid sequences having enzymatic activity such that the amino acid sequences are resistant to HPPD inhibitor herbicidal chemicals, in particular triketone inhibitor specific HPPD mutants.

To date, the prior art has not described HPPD-inhibiting herbicide, preferably benzamide tolerant plants containing at least one mutated HPPD nucleic acid according to the present invention. What are needed in the art are crop plants and crop plants having increased tolerance to herbicides such as HPPD-inhibiting herbicide, preferably benzamide, and containing at least one mutated HPPD nucleic acid according to the present invention. Also needed are methods for controlling weed growth in the vicinity of such crop plants or crop plants. These compositions and methods would allow for the use of spray over techniques when applying herbicides to areas containing crop plant or crop plants.

SUMMARY OF THE INVENTION

The problem is solved by the present invention which refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of:

-   a) providing, at said site, a plant that comprises at least one     nucleic acid comprising     -   (i) a nucleotide sequence encoding a wild type hydroxyphenyl         pyruvate dioxygenase or a mutated hydroxyphenyl pyruvate         dioxygenase (mut-HPPD) which is resistant or tolerant to a         HPPD-inhibiting herbicide and/or     -   (ii) a nucleotide sequence encoding a wildtype homogentisate         solanesyl transferase or a mutated homogentisate solanesyl         transferase (mut-HST) which is resistant or tolerant to a         HPPD-inhibiting herbicide -   b) applying to said site an effective amount of said herbicide.

In addition, the present invention refers to a method for identifying a HPPD-inhibiting herbicide by using a mut-HPPD encoded by a nucleic acid which comprises the nucleotide sequence of SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, or a variant thereof, and/or by using a mut-HST encoded by a nucleic acid which comprises the nucleotide sequence of SEQ ID NO: 47 or 49 or a variant thereof.

Said method comprises the steps of:

-   a) generating a transgenic cell or plant comprising a nucleic acid     encoding a wildtype or mut-HPPD, wherein the wildtype or mut-HPPD is     expressed; -   b) applying a HPPD-inhibiting herbicide to the transgenic cell or     plant of a) and to a control cell or plant of the same variety; -   c) determining the growth or the viability of the transgenic cell or     plant and the control cell or plant after application of said test     compound, and -   d) selecting test compounds which confer reduced growth to the     control cell or plant as compared to the growth of the transgenic     cell or plant.

Another object refers to a method of identifying a nucleotide sequence encoding a mut-HPPD which is resistant or tolerant to a HPPD-inhibiting herbicide, the method comprising:

-   a) generating a library of mut-HPPD-encoding nucleic acids, -   b) screening a population of the resulting mut-HPPD-encoding nucleic     acids by expressing each of said nucleic acids in a cell or plant     and treating said cell or plant with a HPPD-inhibiting herbicide, -   c) comparing the HPPD-inhibiting herbicide-tolerance levels provided     by said population of mut-HPPD encoding nucleic acids with the     HPPD-inhibiting herbicide-tolerance level provided by a control     HPPD-encoding nucleic acid, -   d) selecting at least one mut-HPPD-encoding nucleic acid that     provides a significantly increased level of tolerance to a     HPPD-inhibiting herbicide as compared to that provided by the     control HPPD-encoding nucleic acid.

In a preferred embodiment, the mut-HPPD-encoding nucleic acid selected in step d) provides at least 2-fold as much or tolerance to a HPPD-inhibiting herbicide as compared to that provided by the control HPPD-encoding nucleic acid.

The resistance or tolerance can be determined by generating a transgenic plant comprising a nucleic acid sequence of the library of step a) and comparing said transgenic plant with a control plant.

Another object refers to a method of identifying a plant or algae containing a nucleic acid encoding a mut-HPPD or mut-HST which is resistant or tolerant to a HPPD-inhibiting herbicide, the method comprising:

-   a) identifying an effective amount of a HPPD-inhibiting herbicide in     a culture of plant cells or green algae. -   b) treating said plant cells or green algae with a mutagenizing     agent, -   c) contacting said mutagenized cells population with an effective     amount of HPPD-inhibiting herbicide, identified in a), -   d) selecting at least one cell surviving these test conditions, -   e) PCR-amplification and sequencing of HPPD and/or HST genes from     cells selected in d) and comparing such sequences to wild-type HPPD     or HST gene sequences, respectively.

In a preferred embodiment, the mutagenizing agent is ethylmethanesulfonate.

Another object refers to an isolated nucleic acid encoding a mut-HPPD, the nucleic acid being identifiable by a method as defined above.

In another embodiment, the invention refers to a plant cell transformed by a wild-type or a mut-HPPD nucleic acid or a plant which has been mutated to obtain a plant expressing, preferably over-expressing, a wild-type or a mut-HPPD nucleic acid, wherein expression of the nucleic acid in the plant cell results in increased resistance or tolerance to a HPPD-inhibiting herbicide as compared to a wild type variety of the plant cell.

In a preferred embodiment, the plant cell of the present is transformed by a wild-type or a mut-HPPD nucleic acid comprising a sequence of SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69 or a variant or derivative thereof.

In another embodiment, the invention refers to a transgenic plant comprising a plant cell according to the present invention, wherein expression of the nucleic acid in the plant results in the plants increased resistance to HPPD-inhibiting herbicide as compared to a wild type variety of the plant.

The plants of the present invention can be transgenic or non-transgenic.

Preferably, the expression of the nucleic acid in the plant results in the plants increased resistance to HPPD-inhibiting herbicide as compared to a wild type variety of the plant.

In another embodiment, the invention refers to a seed produced by a transgenic plant comprising a plant cell of the present invention, wherein the seed is true breeding for an increased resistance to a HPPD-inhibiting herbicide as compared to a wild type variety of the seed.

In another embodiment, the invention refers to a method of producing a transgenic plant cell with an increased resistance to a HPPD-inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a wild-type or a mut-HPPD nucleic acid.

In another embodiment, the invention refers to a method of producing a transgenic plant comprising, (a) transforming a plant cell with an expression cassette comprising a wild-type or a mut-HPPD nucleic acid, and (b) generating a plant with an increased resistance to HPPD-inhibiting herbicide from the plant cell.

Preferably, the expression cassette further comprises a transcription initiation regulatory region and a translation initiation regulatory region that are functional in the plant.

In another embodiment, the invention relates to using the mut-HPPD of the invention as selectable marker. The invention provides a method of identifying or selecting a transformed plant cell, plant tissue, plant or part thereof comprising a) providing a transformed plant cell, plant tissue, plant or part thereof, wherein said transformed plant cell, plant tissue, plant or part thereof comprises an isolated nucleic acid encoding a mut-HPPD polypeptide of the invention as described hereinafter, wherein the polypeptide is used as a selection marker, and wherein said transformed plant cell, plant tissue, plant or part thereof may optionally comprise a further isolated nucleic acid of interest; b) contacting the transformed plant cell, plant tissue, plant or part thereof with at least one HPPD-inhibiting inhibiting compound; c) determining whether the plant cell, plant tissue, plant or part thereof is affected by the inhibitor or inhibiting compound; and d) identifying or selecting the transformed plant cell, plant tissue, plant or part thereof.

The invention is also embodied in purified mut-HPPD proteins that contain the mutations described herein, which are useful in molecular modeling studies to design further improvements to herbicide tolerance. Methods of protein purification are well known, and can be readily accomplished using commercially available products or specially designed methods, as set forth for example, in Protein Biotechnology, Walsh and Headon (Wiley, 1994).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 Amino acid sequence alignment and conserved regions of HPPD enzymes from Chlamydomonas reinhardtii (Cr_HPPD1a, SEQ ID NO:55, Cr_HPPD1b; SEQ ID NO 57), Physcomitrella patens (Pp_HPPD1; SEQ ID NO:58), Oryza sativa (Osj_HPPD1; SEQ ID NO:59), Triticum aestivum (Ta_HPPD1; SEQ ID NO:60), Zea mays (Zm_HPPD1; SEQ ID NO:61**, SEQ ID NO:67*), Arabidopsis thaliana (At_HPPD; SEQ ID NO:53), Glycine max (Gm_HPPD; SEQ ID NO:62) and Vitis vinifera (Vv_HPPD; SEQ ID NO:63), and Hordeum vulgare (Hv_HPPD; SEQ ID NO:2). *Sequence derived from genome sequencing project. Locus ID: GRMZM2G088396**Amino acid sequence based on NCBI GenPept accession CAG25475

FIG. 2 shows a vector map of a plant transformation vector which is used for soybean transformation with HPPD/HST sequences.

FIG. 3 shows a herbicide spray test with transgenic Arabidopsis plants expressing mutated variants of Arabidopsis HPPD or Hordeum HPPD. Non-transgenic control plants are treated in parallel and pictures are taken 14 days after treatment. Plants were sprayed with different concentrations of 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2).

FIG. 4 shows a herbicide spray test with transgenic corn plants overexpressing mutated variants of Arabidopsis HPPD. Non-transgenic control plants are treated in parallel and pictures are taken 14 days after treatment. A) Unsprayed control and B) corn plants sprayed with 125 g/ha of 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3).

1: AtHPPD I393L,L385V (Event 1)

2: AtHPPD I393L,L385V (Event 2)

3: AtHPPD M335H

4: At HPPD Q293S

5: untransformed control

FIG. 5 shows a herbicide spray test with transgenic Soy plants overexpressing mutated variants of Arabidopsis HPPD, wild-type Arabidopsis HPPD and Glycine max HPPD. Non-transgenic control plants (Jake) are treated in parallel and pictures are taken 14 days after treatment. A) Unsprayed control and B) soy plants sprayed with 62.5 g/ha of 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3).

1: overexpression of wild-type Arabidopsis HPPD

2: AtHPPD L385V,I393L

3: AtHPPD P336A,E363Q,L385V,I393L

4: AtHPPD M335H

5: AtHPPD M335Y

6: GmHPPD1

7: untransformed control

SEQUENCE LISTING

TABLE 1 SEQ Accession ID NO: Description Organism Locus number 1 HPPD nucleic acid Hordeum 51 HPPD nucl acid opt Hordeum 2 HPPD amino acid Hordeum 3 HPPD nucleic acid Fragilariopsis 4 HPPD nucl acid opt Fragilariopsis 5 HPPD amino acid Fragilariopsis 6 HPPD nucleic acid Chlorella 7 HPPD nucl acid opt Chlorella 8 HPPD amino acid Chlorella 9 HPPD nucleic acid Thalassiosira 10 HPPD nucl acid opt Thalassiosira 11 HPPD amino acid Thalassiosira 12 HPPD nucleic acid Cyanothece 13 HPPD nucl acid opt Cyanothece 14 HPPD amino acid Cyanothece 15 HPPD nucleic acid Acaryochloris 16 HPPD nucl acid opt Acaryochloris 17 HPPD amino acid Acaryochloris 18 HPPD nucleic acid Synechocystis 19 HPPD nucl acid opt Synechocystis 20 HPPD amino acid Synechocystis 21 HPPD nucleic acid1 Alopecurus 22 HPPD amino acid1 Alopecurus 23 HPPD nucleic acid2 Alopecurus 24 HPPD amino acid2 Alopecurus 25 HPPD nucleic acid1 Sorghum 26 HPPD amino acid1 Sorghum 27 HPPD nucleic acid2 Sorghum 28 HPPD amino acid2 Sorghum 29 HPPD nucleic acid1 Poa 30 HPPD amino acid1 Poa 31 HPPD nucleic acid2 Poa 32 HPPD amino acid2 Poa 33 HPPD nucleic acid Lolium 34 HPPD amino acid Lolium 35 HPPD nucleic acid Synechococcus 36 HPPD amino acid Synechococcus 37 HPPD nucleic acid Blepharisma 38 HPPD amino acid Blepharisma 39 HPPD nucleic acid Picrophilus 40 HPPD amino acid Picrophilus 41 HPPD nucleic acid Kordia 42 HPPD amino acid Kordia 43 HPPD nucleic acid1 Rhodococcus 44 HPPD amino acid1 Rhodococcus 45 HPPD nucleic acid2 Rhodococcus 46 HPPD amino acid2 Rhodococcus 47 HST nucleic acid Arabidopsis At3g11945 DQ231060 48 HST amino acid Arabidopsis At3g11945 Q1ACB3 49 HST nucleic acid Chlamydomonas AM285678 50 HST amino acid Chlamydomonas A1JHN0 52 HPPD nucleic acid Arabidopsis At1g06570 AF047834 53 HPPD amino acid Arabidopsis At1g06570 AAC15697 54 HPPD nucleic acid1 Chlamydomonas 55 HPPD amino acid1 Chlamydomonas 56 HPPD nucleic acid2 Chlamydomonas XM_001694671.1 57 HPPD amino acid2 Chlamydomonas Q70ZL8 58 HPPD amino acid Physcomitrella A9RPY0 59 HPPD amino acid Oryza Os02g07160 60 HPPD amino acid Triticum Q45FE8 61 HPPD amino acid Zea CAG25475 62 HPPD amino acid Glycine A5Z1N7 63 HPPD amino acid Vitis A5ADC8 64 HPPD amino acid Pseudomonas AXW96633 fluorescens strain 87-79 65 HPPD amino acid Pseudomonas ADR00548 fluorescens 66 HPPD amino acid Avena sativa AXW96634 67 HPPD amino acid Zea mays variant 68 HPPD nucleic acid Zea mays mut 10 codon-optimised 69 HPPD nucleic acid Zea mays mut 406 codon-optimised

DETAILED DESCRIPTION

The articles “a” and “an” are used herein to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one or more elements.

As used herein, the word “comprising,” or variations such as “comprises” or “comprising,” will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

The inventors of the present invention have found, that the tolerance or resistance of a plant to a HPPD-inhibiting herbicide could be remarkably increased by overexpressing wild type or mutated HPPD enzymes comprising SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67.

Consequently, the present invention refers to a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of:

-   a) providing, at said site, a plant that comprises at least one     nucleic acid comprising     -   (i) a nucleotide sequence encoding a wild-type hydroxyphenyl         pyruvate dioxygenase (HPPD) or a mutated hydroxyphenyl pyruvate         dioxygenase (mut-HPPD) which is resistant or tolerant to a         “HPPD-inhibiting herbicide” and/or     -   (ii) a nucleotide sequence encoding a wild-type homogentisate         solanesyl transferase (HST) or a mutated homogentisate solanesyl         transferase (mut-HST) which is resistant or tolerant to a         “HPPD-inhibiting herbicide” -   b) applying to said site an effective amount of said herbicide.

The term “control of undesired vegetation” is to be understood as meaning the killing of weeds and/or otherwise retarding or inhibiting the normal growth of the weeds. Weeds, in the broadest sense, are understood as meaning all those plants which grow in locations where they are undesired. The weeds of the present invention include, for example, dicotyledonous and monocotyledonous weeds. Dicotyledonous weeds include, but are not limited to, weeds of the genera: Sinapis, Lepidium, Galium, Stellaria, Matricaria, Anthemis, Galinsoga, Chenopodium, Urtica, Senecio, Amaranthus, Portulaca, Xanthium, Convolvulus, Ipomoea, Polygonum, Sesbania, Ambrosia, Cirsium, Carduus, Sonchus, Solanum, Rorippa, Rotala, Lindemia, Lamium, Veronica, Abutilon, Emex, Datura, Viola, Galeopsis, Papaver, Centaurea, Trifolium, Ranunculus, and Taraxacum. Monocotyledonous weeds include, but are not limited to, weeds of the genera: Echinochloa, Setaria, Panicum, Digitaria, Phleum, Poa, Festuca, Eleusine, Brachiaria, Lolium, Bromus, Avena, Cyperus, Sorghum, Agropyron, Cynodon, Monochoria, Fimbristyslis, Sagittaria, Eleocharis, Scirpus, Paspalum, Ischaemum, Sphenoclea, Dactyloctenium, Agrostis, Alopecurus, and Apera. In addition, the weeds of the present invention can include, for example, crop plants that are growing in an undesired location. For example, a volunteer maize plant that is in a field that predominantly comprises soybean plants can be considered a weed, if the maize plant is undesired in the field of soybean plants.

The term “plant” is used in its broadest sense as it pertains to organic material and is intended to encompass eukaryotic organisms that are members of the Kingdom Plantae, examples of which include but are not limited to vascular plants, vegetables, grains, flowers, trees, herbs, bushes, grasses, vines, ferns, mosses, fungi and algae, etc, as well as clones, offsets, and parts of plants used for asexual propagation (e.g. cuttings, pipings, shoots, rhizomes, underground stems, clumps, crowns, bulbs, corms, tubers, rhizomes, plants/tissues produced in tissue culture, etc.). The term “plant” further encompasses whole plants, ancestors and progeny of the plants and plant parts, including seeds, shoots, stems, leaves, roots (including tubers), flowers, florets, fruits, pedicles, peduncles, stamen, anther, stigma, style, ovary, petal, sepal, carpel, root tip, root cap, root hair, leaf hair, seed hair, pollen grain, microspore, cotyledon, hypocotyl, epicotyl, xylem, phloem, parenchyma, endosperm, a companion cell, a guard cell, and any other known organs, tissues, and cells of a plant, and tissues and organs, wherein each of the aforementioned comprise the gene/nucleic acid of interest. The term “plant” also encompasses plant cells, suspension cultures, callus tissue, embryos, meristematic regions, gametophytes, sporophytes, pollen and microspores, again wherein each of the aforementioned comprises the gene/nucleic acid of interest.

Plants that are particularly useful in the methods of the invention include all plants which belong to the superfamily Viridiplantae, in particular monocotyledonous and dicotyledonous plants including fodder or forage legumes, ornamental plants, food crops, trees or shrubs selected from the list comprising Acer spp., Actinidia spp., Abelmoschus spp., Agave sisalana, Agropyron spp., Agrostis stolonifera, Allium spp., Amaranthus spp., Ammophila arenaria, Ananas comosus, Annona spp., Apium graveolens, Arachis spp, Artocarpus spp., Asparagus officinalis, Avena spp. (e.g. Avena sativa, Avena fatua, Avena byzantina, Avena fatua var. sativa, Avena hybrida), Averrhoa carambola, Bambusa sp., Benincasa hispida, Bertholletia excelsea, Beta vulgaris, Brassica spp. (e.g. Brassica napus, Brassica rapa ssp. [canola, oilseed rape, tumip rape]), Cadaba farinosa, Camellia sinensis, Canna indica, Cannabis sativa, Capsicum spp., Carex elata, Carica papaya, Carissa macrocarpa, Carya spp., Carthamus tinctorius, Castanea spp., Ceiba pentandra, Cichorium endivia, Cinnamomum spp., Citrullus lanatus, Citrus spp., Cocos spp., Coffea spp., Colocasia esculenta, Cola spp., Corchorus sp., Coriandrum sativum, Corylus spp., Crataegus spp., Crocus sativus, Cucurbita spp., Cucumis spp., Cynara spp., Daucus carota, Desmodium spp., Dimocarpus longan, Dioscorea spp., Diospyros spp., Echinochloa spp., Elaeis (e.g. Elaeis guineensis, Elaeis oleifera), Eleusine coracana, Eragrostis tef, Erianthus sp., Eriobotrya japonica, Eucalyptus sp., Eugenia uniflora, Fagopyrum spp., Fagus spp., Festuca arundinacea, Ficus carica, Fortunella spp., Fragaria spp., Ginkgo biloba, Glycine spp. (e.g. Glycine max, Soja hispida or Soja max), Gossypium hirsutum, Helianthus spp. (e.g. Helianthus annuus), Hemerocallis fulva, Hibiscus spp., Hordeum spp. (e.g. Hordeum vulgare), Ipomoea batatas, Juglans spp., Lactuca sativa, Lathyrus spp., Lens culinaris, Linum usitatissimum, Litchi chinensis, Lotus spp., Luffa acutangula, Lupinus spp., Luzula sylvatica, Lycopersicon spp. (e.g. Lycopersicon esculentum, Lycopersicon lycopersicum, Lycopersicon pyriforme), Macrotyloma spp., Malus spp., Malpighia emarginata, Mammea americana, Mangifera indica, Manihot spp., Manilkara zapota, Medicago sativa, Melilotus spp., Mentha spp., Miscanthus sinensis, Momordica spp., Morus nigra, Musa spp., Nicotiana spp., Olea spp., Opuntia spp., Omithopus spp., Oryza spp. (e.g. Oryza sativa, Oryza latifolia), Panicum miliaceum, Panicum virgatum, Passiflora edulis, Pastinaca sativa, Pennisetum sp., Persea spp., Petroselinum crispum, Phalaris arundinacea, Phaseolus spp., Phleum pratense, Phoenix spp., Phragmites australis, Physalis spp., Pinus spp., Pistacia vera, Pisum spp., Poa spp., Populus spp., Prosopis spp., Prunus spp., Psidium spp., Punica granatum, Pyrus communis, Quercus spp., Raphanus sativus, Rheum rhabarbarum, Ribes spp., Ricinus communis, Rubus spp., Saccharum spp., Salix sp., Sambucus spp., Secale cereale, Sesamum spp., Sinapis sp., Solanum spp. (e.g. Solanum tuberosum, Solanum integrifolium or Solanum lycopersicum), Sorghum bicolor, Spinacia spp., Syzygium spp., Tagetes spp., Tamarindus indica, Theobroma cacao, Trifolium spp., Tripsacum dactyloides, Triticosecale rimpaui, Triticum spp. (e.g. Triticum aestivum, Triticum durum, Triticum turgidum, Triticum hybemum, Triticum macha, Triticum sativum, Triticum monococcum or Triticum vulgare), Tropaeolum minus, Tropaeolum majus, Vaccinium spp., Vicia spp., Vigna spp., Viola odorata, Vitis spp., Zea mays, Zizania palustris, Ziziphus spp., amaranth, artichoke, asparagus, broccoli, Brussels sprouts, cabbage, canola, carrot, cauliflower, celery, collard greens, flax, kale, lentil, oilseed rape, okra, onion, potato, rice, soybean, strawberry, sugar beet, sugar cane, sunflower, tomato, squash, tea and algae, amongst others. According to a preferred embodiment of the present invention, the plant is a crop plant. Examples of crop plants include inter alia soybean, sunflower, canola, alfalfa, rapeseed, cotton, tomato, potato or tobacco. Further preferably, the plant is a monocotyledonous plant, such as sugarcane. Further preferably, the plant is a cereal, such as rice, maize, wheat, barley, millet, rye, sorghum or oats.

In a preferred embodiment, the plant has been previously produced by a process comprising recombinantly preparing a plant by introducing and over-expressing a wild-type or mut-HPPD and/or wild-type or mut-HST transgene, as described in greater detail hereinafter.

In another preferred embodiment, the plant has been previously produced by a process comprising in situ mutagenizing plant cells, to obtain plant cells which express a mut-HPPD and/or mut-HST.

As disclosed herein, the nucleic acids of the invention find use in enhancing the herbicide tolerance of plants that comprise in their genomes a gene encoding a herbicide-tolerant wild-type or mut-HPPD and/or wild-type or mut-HST protein. Such a gene may be an endogenous gene or a transgene, as described hereinafter.

Therefore, in a other embodiment the present invention refers to a method of increasing or enhancing the HPPD-inhibiting herbicide tolerance or resistance of a plant, the method comprising overexpressing a nucleic acid encoding a wild type or mut HPPD enzymes comprising SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67.

In one embodiment, the wild type HPPD enzyme comprises SEQ ID NO: 40, 44, or 46.

Additionally, in certain embodiments, the nucleic acids of the present invention can be stacked with any combination of polynucleotide sequences of interest in order to create plants with a desired phenotype. For example, the nucleic acids of the present invention may be stacked with any other polynucleotides encoding polypeptides having pesticidal and/or insecticidal activity, such as, for example, the Bacillus thuringiensis toxin proteins (described in U.S. Pat. Nos. 5,366,892; 5,747,450; 5,737,514; 5,723,756; 5,593,881; and Geiser et al (1986) Gene 48: 109). The combinations generated can also include multiple copies of any one of the polynucleotides of interest.

By way of example, polynucleotides that may be stacked with the nucleic acids of the present invention include nucleic acids encoding polypeptides conferring resistance to pests/pathogens such as viruses, nematodes, insects or fungi, and the like. Exemplary polynucleotides that may be stacked with nucleic acids of the invention include polynucleotides encoding: polypeptides having pesticidal and/or insecticidal activity, such as other Bacillus thuringiensis toxic proteins (described in U.S. Pat. Nos. 5,366,892; 5,747,450; 5,737,514; 5,723,756; 5,593,881; and Geiser et al., (1986) Gene 48:109), lectins (Van Damme et al. (1994) Plant Mol. Biol. 24:825, pentin (described in U.S. Pat. No. 5,981,722), and the like; traits desirable for disease or herbicide resistance (e.g., fumonisin detoxification genes (U.S. Pat. No. 5,792,931); avirulence and disease resistance genes (Jones et al. (1994) Science 266:789; Martin et al., (1993) Science 262:1432; Mindrinos et al. (1994) Cell 78:1089); acetolactate synthase (ALS) mutants that lead to herbicide resistance such as the S4 and/or Hra mutations; glyphosate resistance (e.g., 5-enol-pyrovyl-shikimate-3-phosphate-synthase (EPSPS) gene, described in U.S. Pat. Nos. 4,940,935 and 5,188,642; or the glyphosate N-acetyltransferase (GAT) gene, described in Castle et al. (2004) Science, 304:1151-1154; and in U.S. Patent App. Pub. Nos. 20070004912, 20050246798, and 20050060767)); glufosinate resistance (e.g., phosphinothricin acetyl transferase genes PAT and BAR, described in U.S. Pat. Nos. 5,561,236 and 5,276,268); resistance to herbicides including sulfonyl urea, DHT (2,4D), and PPO herbicides (e.g., glyphosate acetyl transferase, aryloxy alkanoate dioxygenase, acetolactate synthase, and protoporphyrinogen oxidase); a cytochrome P450 or variant thereof that confers herbicide resistance or tolerance to, inter alia, HPPD herbicides (U.S. patent application Ser. No. 12/156,247; U.S. Pat. Nos. 6,380,465; 6,121,512; 5,349,127; 6,649,814; and 6,300,544; and PCT Patent App. Pub. No. WO2007000077); and traits desirable for processing or process products such as high oil (e.g., U.S. Pat. No. 6,232,529); modified oils (e.g., fatty acid desaturase genes (U.S. Pat. No. 5,952,544; WO 94/11516)); modified starches (e.g., ADPG pyrophosphorylases (AGPase), starch synthases (SS), starch branching enzymes (SBE), and starch debranching enzymes (SDBE)); and polymers or bioplastics (e.g., U.S. Pat. No. 5,602,321; beta-ketothiolase, polyhydroxybutyrate synthase, and acetoacetyl-CoA reductase (Schubert et al. (1988) J. Bacteriol. 170:5837-5847) facilitate expression of polyhydroxyalkanoates (PHAs)); the disclosures of which are herein incorporated by reference.

In a particularly preferred embodiment, the plant comprises at least one additional heterologous nucleic acid comprising (iii) a nucleotide sequence encoding a herbicide tolerance enzyme selected, for example, from the group consisting of 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS), Glyphosate acetyl transferase (GAT), Cytochrome P450, phosphinothricin acetyltransferase (PAT), Acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS), Protoporphyrinogen oxidase (PPGO), Phytoene desaturase (PD) and dicamba degrading enzymes as disclosed in WO 02/068607.

Generally, the term “herbicide” is used herein to mean an active ingredient that kills, controls or otherwise adversely modifies the growth of plants. The preferred amount or concentration of the herbicide is an “effective amount” or “effective concentration.” By “effective amount” and “effective concentration” is intended an amount and concentration, respectively, that is sufficient to kill or inhibit the growth of a similar, wild-type, plant, plant tissue, plant cell, or host cell, but that said amount does not kill or inhibit as severely the growth of the herbicide-resistant plants, plant tissues, plant cells, and host cells of the present invention. Typically, the effective amount of a herbicide is an amount that is routinely used in agricultural production systems to kill weeds of interest. Such an amount is known to those of ordinary skill in the art. Herbicidal activity is exhibited by HPPD-inhibiting herbicide useful for the present invention when they are applied directly to the plant or to the locus of the plant at any stage of growth or before planting or emergence. The effect observed depends upon the plant species to be controlled, the stage of growth of the plant, the application parameters of dilution and spray drop size, the particle size of solid components, the environmental conditions at the time of use, the specific compound employed, the specific adjuvants and carriers employed, the soil type, and the like, as well as the amount of chemical applied. These and other factors can be adjusted as is known in the art to promote nonselective or selective herbicidal action. Generally, it is preferred to apply the HPPD-inhibiting herbicide postemergence to relatively immature undesirable vegetation to achieve the maximum control of weeds.

By a “herbicide-tolerant” or “herbicide-resistant” plant, it is intended that a plant that is tolerant or resistant to at least one herbicide at a level that would normally kill, or inhibit the growth of, a normal or wild-type plant. By “herbicide-tolerant mut-HPPD protein” or “herbicide-resistant mut-HPPD protein”, it is intended that such a mut-HPPD protein displays higher HPPD activity, relative to the HPPD activity of a wild-type mut-HPPD protein, when in the presence of at least one herbicide that is known to interfere with HPPD activity and at a concentration or level of the herbicide that is known to inhibit the HPPD activity of the wild-type mut-HPPD protein. Furthermore, the HPPD activity of such a herbicide-tolerant or herbicide-resistant mut-HPPD protein may be referred to herein as “herbicide-tolerant” or “herbicide-resistant” HPPD activity.

The HPPD-inhibiting herbicides which are particularly useful for the present invention encompasses the compounds as depicted in the following Table 2.

TABLE 2 Possible Substituents as defined in: Application number Publication No: General Structure and reference Number 1

PCT/EP2012/072469 PF72974 WO 2013/072300 2

US 61/639079 PF73635 WO 2013/083859

The above referenced application, in particular the disclosures referring to the compounds of Table 2 and their possible substitutents are entirely incorporated by reference.

In one embodiment of the present invention, the HPPD-inhibiting herbicide refers to a benzamide shown in Number 1 of Table 2 above having the above formula I:

-   -   wherein     -   X is selected from the group consisting of hydrogen, cyano,         nitro, halogen, C₁-C₆-alkyl, C₃-C₇cycloalkyl,         C₃-C₇cycloalkyl-C₁-C₄-alkyl, where the C₃-C₇-cycloalkyl groups         in the two aformentioned radicals are unsubstituted or partially         or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl,         C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl,         C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, O—R^(a),         R^(b)—S(O)_(n)—Z, R^(c)—C(═O)—Z, OR^(d)—C(═O)—Z,         NR^(e)R^(f)—C(═O)—Z, NR^(g)R^(h)—Z, phenyl-Z and heterocyclyl-Z,         where heterocyclyl is a 5- or 6-membered monocyclic or 8-, 9- or         10-membered bicyclic saturated, partially unsaturated or         aromatic heterocycle, which contains 1, 2, 3 or 4 heteroatoms as         ring members, which are selected from the group consisting of O,         N and S, where phenyl and heterocyclyl are unsubstituted or         substituted by 1, 2, 3 or 4 groups R′, which are identical or         different;

In one embodiment of the present invention, the HPPD-inhibiting herbicide refers to a benzamide shown in Number 2 of Table 2 above having the above formula II:

-   -   where     -   B is N or CH;     -   Y is selected from the group consisting of hydrogen,         C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl-C₁-C₄-alkyl,         where the C₃-C₇-cycloalkyl groups in the two aforementioned         radicals are unsubstituted or partially or completely         halogenated, C₁-C₄-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl,         C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,         C₁-C₄-haloalkoxy-C₁-C₄-alkyl, R^(b)—S(O)_(n)—Z, R^(c)—C(═O)—Z,         R^(d)O—C(═O)—Z, R^(e)R^(f)N—C(═O)—Z, R^(g)R^(h)N—Z, phenyl-Z and         heterocyclyl-Z, where heterocyclyl is a 5- or 6-membered         monocyclic or 8-, 9- or 10-membered bicyclic saturated,         partially unsaturated or aromatic heterocycle, which contains 1,         2, 3 or 4 heteroatoms as ring members, which are selected from         the group consisting of O, N and S, where phenyl and         heterocyclyl are unsubstituted or substituted by 1, 2, 3 or 4         groups R′, which are identical or different;

For both formula I and II, the following definitions apply:

-   R^(f) is selected from the group consisting of cyano-Z¹, halogen,     nitro, C₁-C₈-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkynyl, C₁-C₈-haloalkyl,     C₁-C₈-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl,     C₁-C₄-alkoxy-C₁-C₄-alkoxy-Z¹, C₁-C₄-alkylthio-C₁-C₄-alkyl,     C₁-C₄-alkylthio-C₁-C₄-alkylthio-Z¹, C₂-C₆-alkenyloxy,     C₂-C₆-alkynyloxy, C₁-C₆-haloalkoxy, C₁-C₄-haloalkoxy-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkoxy-Z^(f), R^(1b)—S(O)_(k)—Z¹, phenoxy-Z¹,     and heterocyclyloxy-Z¹, where heterocyclyloxy is an oxygen bound 5-     or 6-membered monocyclic or 8-, 9- or 10-membered bicyclic     saturated, partially unsaturated or aromatic heterocycle, which     contains 1, 2, 3 or 4 heteroatoms as ring members, which are     selected from the group consisting of O, N and S, where the cyclic     groups in phenoxy and heterocyclyloxy are unsubstituted or     substituted by 1, 2, 3 or 4 groups R¹¹, which are identical or     different; -   R², R³ are identical or different and independently selected from     the group consisting of hydrogen, halogen, OH—Z², NO₂—Z², cyano-Z²,     C₁-C₆-alkyl, C₂-C₈-alkenyl, C₂-C₈-alkynyl, C₃-C₁₀-cycloalkyl-Z²,     C₃-C₁₀-cycloalkoxy-Z², where the C₃-C₁₀-cycloalkyl groups in the two     aforementioned radicals are unsubstituted or partially or completely     halogenated, C₁-C₈-haloalkyl, C₁-C₈-alkoxy-Z², C₁-C₈-haloalkoxy-Z²,     C₁-C₄-alkoxy-C₁-C₄-alkoxy-Z², C₁-C₄-alkylthio-C₁-C₄-alkylthio-Z²,     C₂-C₈-alkenyloxy-Z², C₂-C₈-alkynyloxy-Z², C₂-C₈-haloalkenyloxy-Z²,     C₂-C₈-haloalkynyloxy-Z², C₁-C₄-haloalkoxy-C₁-C₄-alkoxy-Z²,     (tri-C₁-C₄-alkyl)silyl-Z², R^(2b)—S(O)_(k)—Z², R^(2c)—C(═O)—Z²,     R^(2d)O—C(═O)—Z², R^(2e)R^(2f)N—C(═O)—Z², R^(2g)R^(2h)N—Z²,     phenyl-Z^(2a) and heterocyclyl-Z^(2a), where heterocyclyl is a 3-,     4-, 5- or 6-membered monocyclic or 8-, 9- or 10-membered bicyclic     saturated, partially unsaturated or aromatic heterocycle, which     contains 1, 2, 3 or 4 heteroatoms as ring members, which are     selected from the group consisting of O, N and S, where the cyclic     groups in phenyl-Z^(2a) and heterocyclyl-Z^(2a) are unsubstituted or     substituted by 1, 2, 3 or 4 groups R²¹, which are identical or     different; -   R⁴ is selected from the group consisting of hydrogen, halogen,     cyano, nitro, C₁-C₄-alkyl and C₁-C₄-haloalkyl; -   R⁵ is selected from the group consisting of hydrogen, halogen,     C₁-C₄-alkyl and C₁-C₄-haloalkyl;     -   provided that at least one of the radicals R⁴ and R⁵ is         different from hydrogen; -   n is 0, 1 or 2; -   k is 0, 1 or 2; -   R′, R¹¹, R²¹ independently of each other are selected from the group     consisting of halogen, NO₂, CN, C₁-C₆-alkyl, C₃-C₇-cycloalkyl,     C₃-C₇-halocycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl,     C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₆-alkoxy,     C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl,     C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy,     C₃-C₇-cycloalkoxy and C₁-C₆-haloalkyloxy, or two vicinal radicals     R′, R¹¹ or R²¹ together may form a group ═O; -   Z, Z¹, Z² independently of each other are selected from the group     consisting of a covalent bond and C₁-C₄-alkanediyl; -   Z^(2a) is selected from the group consisting of a covalent bond,     C₁-C₄-alkanediyl, O—C₁-C₄-alkanediyl, C₁-C₄-alkanediyl-O and     C₁-C₄-alkanediyl-O—C₁-C₄-alkanediyl;     -   R^(a) is selected from the group consisting of hydrogen,         C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl-C₁-C₄-alkyl,         where the C₃-C₇-cycloalkyl groups in the two aformentioned         radicals are unsubstituted or partially or completely         halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl,         C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl,         phenyl and benzyl, where phenyl and benzyl are unsubstituted or         substituted by 1, 2, 3 or 4 groups, which are identical or         different and selected from the group consisting of halogen,         C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R^(b), R^(1b), R^(2b) independently of each other are selected from     the group consisting of C₁-C₆-alkyl, C₃-C₇-cycloalkyl,     C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl,     C₂-C₆-haloalkynyl, phenyl and heterocyclyl, where heterocyclyl is a     5- or 6-membered monocyclic saturated, partially unsaturated or     aromatic heterocycle, which contains 1, 2, 3 or 4 heteroatoms as     ring members, which are selected from the group consisting of O, N     and S, where phenyl and heterocyclyl are unsubstituted or     substituted by 1, 2, 3 or 4 groups, which are identical or different     and selected from the group consisting of halogen, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R^(c), R^(2c) independently of each other are selected from the     group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₇cycloalkyl,     C₃-C₇cycloalkyl-C₁-C₄-alkyl, where the C₃-C₇-cycloalkyl groups in     the two aforementioned radicals are unsubstituted or partially or     completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl,     C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl, benzyl and heterocyclyl, where     heterocyclyl is a 5- or 6-membered monocyclic saturated, partially     unsaturated or aromatic heterocycle, which contains 1, 2, 3 or 4     heteroatoms as ring members, which are selected from the group     consisting of O, N and S, where phenyl, benzyl and heterocyclyl are     unsubstituted or substituted by 1, 2, 3 or 4 groups, which are     identical or different and selected from the group consisting of     halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy; -   R^(d), R^(2d) independently of each other are selected from the     group consisting of C₁-C₆-alkyl, C₃-C₇cycloalkyl,     C₃-C₇-cycloalkyl-C₁-C₄-alkyl, where the C₃-C₇-cycloalkyl groups in     the two aforementioned radicals are unsubstituted or partially or     completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl,     C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl, where phenyl and benzyl     are unsubstituted or substituted by 1, 2, 3 or 4 groups, which are     identical or different and selected from the group consisting of     halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy; -   R^(e), R^(f) independently of each other are selected from the group     consisting of hydrogen, C₁-C₆-alkyl, C₃-C₇cycloalkyl,     C₃-C₇cycloalkyl-C₁-C₄-alkyl, where the C₃-C₇-cycloalkyl groups in     the two aforementioned radicals are unsubstituted or partially or     completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl,     C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl,     C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl, where phenyl and benzyl     are unsubstituted or substituted by 1, 2, 3 or 4 groups, which are     identical or different and selected from the group consisting of     halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and     C₁-C₄-haloalkoxy, or -   R^(e), R^(f) together with the nitrogen atom, to which they are     bound may form a 5-, 6 or 7-membered, saturated or unsaturated     N-bound heterocyclic radical, which may carry as a ring member a     further heteroatom selected from O, S and N and which is     unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical     or different and selected from the group consisting of halogen,     C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R^(2e), R^(2f) independently of each other have the meanings given     for R^(e), R^(f); -   R^(g) is selected from the group consisting of hydrogen,     C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₄-alkyl, where     the C₃-C₇-cycloalkyl groups in the two aforementioned radicals are     unsubstituted or partially or completely halogenated,     C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl,     C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl,     where phenyl and benzyl are unsubstituted or substituted by 1, 2, 3     or 4 groups, which are identical or different and selected from the     group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl,     C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R^(h) is selected from the group consisting of hydrogen,     C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₃-C₇ cycloalkyl-C₁-C₄-alkyl, where     the C₃-C₇-cycloalkyl groups in the two aforementioned radicals are     unsubstituted or partially or completely halogenated,     C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl,     C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, a radical C(═O)—R^(k),     phenyl and benzyl, where phenyl and benzyl are unsubstituted or     substituted by 1, 2, 3 or 4 groups, which are identical or different     and selected from the group consisting of halogen, C₁-C₄-alkyl,     C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy, or -   R^(g), R^(h) together with the nitrogen atom, to which they are     bound may form a 5-, 6 or 7-membered, saturated or unsaturated     N-bound heterocyclic radical, which may carry as a ring member a     further heteroatom selected from O, S and N and which is     unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical     or different and selected from the group consisting of ═O, halogen,     C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy and C₁-C₄-haloalkoxy; -   R^(2g), R^(2h) independently of each other have the meanings given     for R^(g), R^(h); and -   R^(k) has the meanings given for R^(c);     or an N-oxide or an agriculturally suitable salt thereof.

Depending on the substitution pattern, the compounds of the formula I or formula II may have one or more centers of chirality, in which case they are present as mixtures of enantiomers or diastereomers. Useful are both the pure enantiomers or pure diastereomers of the compounds of formula I or formula II, and their mixtures and the use according to the invention of the pure enantiomers or pure diastereomers of the compound of formula I or formula II or its mixtures. Suitable compounds of the formula I or formula II also include all possible geometrical stereoisomers (cis/trans isomers) and mixtures thereof. Cis/trans isomers may be present with respect to an alkene, carbon-nitrogen double-bond, nitrogen-sulfur double bond or amide group. The term “stereoisomer(s)” encompasses both optical isomers, such as enantiomers or diastereomers, the latter existing due to more than one center of chirality in the molecule, as well as geometrical isomers (cis/trans isomers).

Depending on the substitution pattern, the compounds of the formula I or formula II may be present in the form of their tautomers. Hence the invention also relates to the tautomers of the formula I or formula II and the stereoisomers, salts and N-oxides of said tautomers.

The term “N-oxide” includes any compound of the present invention which has at least one tertiary nitrogen atom that is oxidized to an N-oxide moiety. N-oxides in compounds I or II can in particular be prepared by oxidizing the ring nitrogen atom(s) of the oxadiazole-, N(tetrazol-5-yl)- and N-(triazol-5-yl)arylcarboxamide ring with a suitable oxidizing agent, such as peroxo carboxylic acids or other peroxides, or the ring nitrogen atom(s) of a heterocyclic substituent X and Y, respectively, R¹, R² or R³.

The HPPD-inhibiting herbicide, in particular the benzamides, as described herein relates to compounds as defined herein, wherein one or more of the atoms depicted in formula I or formula II have been replaced by its stable, preferably non-radioactive isotope (e.g., hydrogen by deuterium, ¹²C by ¹³C, ¹⁴N by ¹⁵N, ¹⁶O by ¹⁸O) and in particular wherein at least one hydrogen atom has been replaced by a deuterium atom. Of course, the compounds according to the invention contain more of the respective isotope than this naturally occurs and thus is anyway present in the compounds I.

The HPPD-inhibiting herbicide, in particular the benzamides, as described herein may be amorphous or may exist in one ore more different crystalline states (polymorphs) which may have different macroscopic properties such as stability or show different biological properties such as activities. The present invention includes both amorphous and crystalline compounds of formula I or formula II, their enantiomers or diastereomers, mixtures of different crystalline states of the respective compound of formula I or formula II, its enantiomers or diastereomers, as well as amorphous or crystalline salts thereof.

Salts of the HPPD-inhibiting herbicide, in particular the benzamides, as described herein, are preferably agriculturally suitable salts. They can be formed in a customary method, e.g. by reacting the compound with an acid if the compound of the present invention has a basic functionality or by reacting the compound with a suitable base if the compound of the present invention has an acidic functionality.

Useful agriculturally suitable salts are especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, do not have any adverse effect on the herbicidal action of the compounds according to the present invention. Suitable cations are in particular the ions of the alkali metals, preferably lithium, sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, and of the transition metals, preferably manganese, copper, zinc and iron, and also ammonium (NH₄ ⁺) and substituted ammonium in which one to four of the hydrogen atoms are replaced by C₁-C₄-alkyl, C₁-C₄-hydroxyalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, hydroxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl or benzyl. Examples of substituted ammonium ions comprise methylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trimethylammonium, tetramethylammonium, tetraethylammonium, tetrabutylammonium, 2-hydroxyethylammonium, 2-(2-hydroxyethoxy)ethylammonium, bis(2-hydroxyethyl)ammonium, benzyltrimethylammonium and benzl-triethylammonium, furthermore phosphonium ions, sulfonium ions, preferably tri(C₁-C₄-alkyl)sulfonium, and sulfoxonium ions, preferably tri(C₁-C₄-alkyl)sulfoxonium.

Anions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogensulfate, sulfate, dihydrogenphosphate, hydrogenphosphate, phosphate, nitrate, bicarbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of C₁-C₄-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting compounds of the present invention with an acid of the corresponding anion, preferably with hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.

The organic moieties mentioned in the above definitions of the variables are—like the term halogen—collective terms for individual listings of the individual group members. The prefix C_(n)-C_(m) indicates in each case the possible number of carbon atoms in the group.

The term “halogen” denotes in each case fluorine, bromine, chlorine or iodine, in particular fluorine, chlorine or bromine.

The term “partially or completely halogenated” will be taken to mean that 1 or more, e.g. 1, 2, 3, 4 or 5 or all of the hydrogen atoms of a given radical have been replaced by a halogen atom, in particular by fluorine or chlorine. A partially or completely halogenated radical is termed below also “halo-radical”. For example, partially or completely halogenated alkyl is also termed haloalkyl.

The term “alkyl” as used herein (and in the alkyl moieties of other groups comprising an alkyl group, e.g. alkoxy, alkylcarbonyl, alkoxycarbonyl, alkylthio, alkylsulfonyl and alkoxyalkyl) denotes in each case a straight-chain or branched alkyl group having usually from 1 to 10 carbon atoms, frequently from 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms and in particular from 1 to 3 carbon atoms. Examples of C₁-C₄-alkyl are methyl, ethyl, n-propyl, iso-propyl, n-butyl, 2-butyl (sec-butyl), isobutyl and tert-butyl. Examples for C₁-C₆-alkyl are, apart those mentioned for C₁-C₄-alkyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, n-hexyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl. Examples for C₁-C₁₀-alkyl are, apart those mentioned for C₁-C₆-alkyl, n-heptyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1-ethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 1-methyloctyl, 2-methylheptyl, 1-ethylhexyl, 2-ethylhexyl, 1,2-dimethylhexyl, 1-propylpentyl, 2-propylpentyl, nonyl, decyl, 2-propylheptyl and 3-propylheptyl.

The term “alkylene” (or alkanediyl) as used herein in each case denotes an alkyl radical as defined above, wherein one hydrogen atom at any position of the carbon backbone is replaced by one further binding site, thus forming a bivalent moiety.

The term “haloalkyl” as used herein (and in the haloalkyl moieties of other groups comprising a haloalkyl group, e.g. haloalkoxy, haloalkylthio, haloalkylcarbonyl, haloalkylsulfonyl and haloalkylsulfinyl) denotes in each case a straight-chain or branched alkyl group having usually from 1 to 8 carbon atoms (“C₁-C₈-haloalkyl”), frequently from 1 to 6 carbon atoms (“C₁-C₆-haloalkyl”), more frequently 1 to 4 carbon atoms (“C₁-C₄-haloalkyl”), wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms. Preferred haloalkyl moieties are selected from C₁-C₄-haloalkyl, more preferably from C₁-C₂-haloalkyl, more preferably from halomethyl, in particular from C₁-C₂-fluoroalkyl. Halomethyl is methyl in which 1, 2 or 3 of the hydrogen atoms are replaced by halogen atoms. Examples are bromomethyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl and the like. Examples for C₁-C₂-fluoroalkyl are fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like. Examples for C₁-C₂-haloalkyl are, apart those mentioned for C₁-C₂-fluoroalkyl, chloromethyl, dichloromethyl, trichloromethyl, bromomethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 2-chloroethyl, 2,2,-dichloroethyl, 2,2,2-trichloroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 1-bromoethyl, and the like. Examples for C₁-C₄-haloalkyl are, apart those mentioned for C₁-C₂-haloalkyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 3,3-difluoropropyl, 3,3,3-trifluoropropyl, heptafluoropropyl, 1,1,1-trifluoroprop-2-yl, 3-chloropropyl, 4-chlorobutyl and the like.

The term “cycloalkyl” as used herein (and in the cycloalkyl moieties of other groups comprising a cycloalkyl group, e.g. cycloalkoxy and cycloalkylalkyl) denotes in each case a mono- or bicyclic cycloaliphatic radical having usually from 3 to 10 carbon atoms (“C₃-C₁₀-cycloalkyl”), preferably 3 to 7 carbon atoms (“C₃-C₇-cycloalkyl”) or in particular 3 to 6 carbon atoms (“C₃-C₆-cycloalkyl”). Examples of monocyclic radicals having 3 to 6 carbon atoms comprise cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of monocyclic radicals having 3 to 7 carbon atoms comprise cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. Examples of bicyclic radicals having 7 or 8 carbon atoms comprise bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl and bicyclo[3.2.1]octyl.

The term “halocycloalkyl” as used herein (and in the halocycloalkyl moieties of other groups comprising an halocycloalkyl group, e.g. halocycloalkylmethyl) denotes in each case a mono- or bicyclic cycloaliphatic radical having usually from 3 to 10 carbon atoms, preferably 3 to 7 carbon atoms or in particular 3 to 6 carbon atoms, wherein at least one, e.g. 1, 2, 3, 4 or 5 of the hydrogen atoms are replaced by halogen, in particular by fluorine or chlorine. Examples are 1- and 2-fluorocyclopropyl, 1,2-, 2,2- and 2,3-difluorocyclopropyl, 1,2,2-trifluorocyclopropyl, 2,2,3,3-tetrafluorocyclpropyl, 1- and 2-chlorocyclopropyl, 1,2-, 2,2- and 2,3-dichlorocyclopropyl, 1,2,2-trichlorocyclopropyl, 2,2,3,3-tetrachlorocyclpropyl, 1-,2- and 3-fluorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-difluorocyclopentyl, 1-,2- and 3-chlorocyclopentyl, 1,2-, 2,2-, 2,3-, 3,3-, 3,4-, 2,5-dichlorocyclopentyl and the like.

The term “cycloalkyl-alkyl” used herein denotes a cycloalkyl group, as defined above, which is bound to the remainder of the molecule via an alkylene group. The term “C₃-C₇-cycloalkyl-C₁-C₄-alkyl” refers to a C₃-C₇-cycloalkyl group as defined above which is bound to the remainder of the molecule via a C₁-C₄-alkyl group, as defined above. Examples are cyclopropylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclobutylmethyl, cyclobutylethyl, cyclobutylpropyl, cyclopentylmethyl, cyclopentylethyl, cyclopentylpropyl, cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, and the like.

The term “alkenyl” as used herein denotes in each case a monounsaturated straight-chain or branched hydrocarbon radical having usually 2 to 8 (“C₂-C₈-alkenyl”), preferably 2 to 6 carbon atoms (“C₂-C₆-alkenyl”), in particular 2 to 4 carbon atoms (“C₂-C₄-alkenyl”), and a double bond in any position, for example C₂-C₄-alkenyl, such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl or 2-methyl-2-propenyl; C₂-C₆-alkenyl, such as ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, 1,1-dimethyl-3-butenyl, 1,2-dimethyl-1-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, 1,3-dimethyl-2-butenyl, 1,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1,1,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl, 1-ethyl-2-methyl-2-propenyl and the like, or C₂-C₈-alkenyl, such as the radicals mentioned for C₂-C₆-alkenyl and additionally 1-heptenyl, 2-heptenyl, 3-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl and the positional isomers thereof.

The term “haloalkenyl” as used herein, which may also be expressed as “alkenyl which is substituted by halogen”, and the haloalkenyl moieties in haloalkenyloxy and the like refers to unsaturated straight-chain or branched hydrocarbon radicals having 2 to 8 (“C₂-C₈-haloalkenyl”) or 2 to 6 (“C₂-C₆-haloalkenyl”) or 2 to 4 (“C₂-C₄-haloalkenyl”) carbon atoms and a double bond in any position, where some or all of the hydrogen atoms in these groups are replaced by halogen atoms as mentioned above, in particular fluorine, chlorine and bromine, for example chlorovinyl, chloroallyl and the like.

The term “alkynyl” as used herein denotes unsaturated straight-chain or branched hydrocarbon radicals having usually 2 to 8 (“C₂-C₈-alkynyl”), frequently 2 to 6 (“C₂-C₆-alkynyl”), preferably 2 to 4 carbon atoms (“C₂-C₄-alkynyl”) and one or two triple bonds in any position, for example C₂-C₄-alkynyl, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl and the like, C₂-C₆-alkynyl, such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1,1-dimethyl-2-butynyl, 1,1-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl, 1-ethyl-1-methyl-2-propynyl and the like.

The term “haloalkynyl” as used herein, which is also expressed as “alkynyl which is substituted by halogen”, refers to unsaturated straight-chain or branched hydrocarbon radicals having usually 3 to 8 carbon atoms (“C₂-C₈-haloalkynyl”), frequently 2 to 6 (“C₂-C₆-haloalkynyl”), preferably 2 to 4 carbon atoms (“C₂-C₄-haloalkynyl”), and one or two triple bonds in any position (as mentioned above), where some or all of the hydrogen atoms in these groups are replaced by halogen atoms as mentioned above, in particular fluorine, chlorine and bromine.

The term “alkoxy” as used herein denotes in each case a straight-chain or branched alkyl group usually having from 1 to 8 carbon atoms (“C₁-C₈-alkoxy”), frequently from 1 to 6 carbon atoms (“C₁-C₆-alkoxy”), preferably 1 to 4 carbon atoms (“C₁-C₄-alkoxy”), which is bound to the remainder of the molecule via an oxygen atom. C₁-C₂-Alkoxy is methoxy or ethoxy. C₁-C₄-Alkoxy is additionally, for example, n-propoxy, 1-methylethoxy (isopropoxy), butoxy, 1-methylpropoxy (sec-butoxy), 2-methylpropoxy (isobutoxy) or 1,1-dimethylethoxy (tert-butoxy). C₁-C₆-Alkoxy is additionally, for example, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 2,2-dimethylpropoxy, 1-ethylpropoxy, hexoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1-methylpropoxy or 1-ethyl-2-methylpropoxy. C₁-C₈-Alkoxy is additionally, for example, heptyloxy, octyloxy, 2-ethylhexyloxy and positional isomers thereof.

The term “haloalkoxy” as used herein denotes in each case a straight-chain or branched alkoxy group, as defined above, having from 1 to 8 carbon atoms (“C₁-C₈-haloalkoxy”), frequently from 1 to 6 carbon atoms (“C₁-C₆-haloalkoxy”), preferably 1 to 4 carbon atoms (“C₁-C₄-haloalkoxy”), more preferably 1 to 3 carbon atoms (“C₁-C₃-haloalkoxy”), wherein the hydrogen atoms of this group are partially or totally replaced with halogen atoms, in particular fluorine atoms. C₁-C₂-Haloalkoxy is, for example, OCH₂F, OCHF₂, OCF₃, OCH₂Cl, OCHCl₂, OCCl₃, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2-bromoethoxy, 2-iodoethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2-difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy or OC₂F₅. C₁-C₄-Haloalkoxy is additionally, for example, 2-fluoropropoxy, 3-fluoropropoxy, 2,2-difluoropropoxy, 2,3-difluoropropoxy, 2-chloropropoxy, 3-chloropropoxy, 2,3-dichloropropoxy, 2-bromopropoxy, 3-bromopropoxy, 3,3,3-trifluoropropoxy, 3,3,3-trichloropropoxy, OCH₂—C₂F₅, OCF₂—C₂F₅, 1-(CH₂F)-2-fluoroethoxy, 1-(CH₂Cl)-2-chloroethoxy, 1-(CH₂Br)-2-bromoethoxy, 4-fluorobutoxy, 4-chlorobutoxy, 4-bromobutoxy or nonafluorobutoxy. C₁-C₆-Haloalkoxy is additionally, for example, 5-fluoropentoxy, 5-chloropentoxy, 5-bromopentoxy, 5-iodopentoxy, undecafluoropentoxy, 6-fluorohexoxy, 6-chlorohexoxy, 6-bromohexoxy, 6-iodohexoxy or dodecafluorohexoxy.

The term “alkoxyalkyl” as used herein denotes in each case alkyl usually comprising 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein 1 carbon atom carries an alkoxy radical usually comprising 1 to 8, frequently 1 to 6, in particular 1 to 4, carbon atoms as defined above. “C₁-C₆-alkoxy-C₁-C₆-alkyl” is a C₁-C₆-alkyl group, as defined above, in which one hydrogen atom is replaced by a C₁-C₆-alkoxy group, as defined above. Examples are CH₂OCH₃, CH₂—OC₂H₅, n-propoxymethyl, CH₂—OCH(CH₃)₂, n-butoxymethyl, (1-methylpropoxy)-methyl, (2-methylpropoxy)methyl, CH₂—OC(CH₃)₃, 2-(methoxy)ethyl, 2-(ethoxy)ethyl, 2-(n-propoxy)-ethyl, 2-(1-methylethoxy)-ethyl, 2-(n-butoxy)ethyl, 2-(1-methylpropoxy)-ethyl, 2-(2-methylpropoxy)-ethyl, 2-(1,1-dimethylethoxy)-ethyl, 2-(methoxy)-propyl, 2-(ethoxy)-propyl, 2-(n-propoxy)-propyl, 2-(1-methylethoxy)-propyl, 2-(n-butoxy)-propyl, 2-(1-methylpropoxy)-propyl, 2-(2-methylpropoxy)-propyl, 2-(1,1-dimethylethoxy)-propyl, 3-(methoxy)-propyl, 3-(ethoxy)-propyl, 3-(n-propoxy)-propyl, 3-(1-methylethoxy)-propyl, 3-(n-butoxy)-propyl, 3-(1-methylpropoxy)-propyl, 3-(2-methylpropoxy)-propyl, 3-(1,1-dimethylethoxy)-propyl, 2-(methoxy)-butyl, 2-(ethoxy)-butyl, 2-(n-propoxy)-butyl, 2-(1-methylethoxy)-butyl, 2-(n-butoxy)-butyl, 2-(1-methylpropoxy)-butyl, 2-(2-methyl-propoxy)-butyl, 2-(1,1-dimethylethoxy)-butyl, 3-(methoxy)-butyl, 3-(ethoxy)-butyl, 3-(n-propoxy)-butyl, 3-(1-methylethoxy)-butyl, 3-(n-butoxy)-butyl, 3-(1-methylpropoxy)-butyl, 3-(2-methylpropoxy)-butyl, 3-(1,1-dimethylethoxy)-butyl, 4-(methoxy)-butyl, 4-(ethoxy)-butyl, 4-(n-propoxy)-butyl, 4-(1-methylethoxy)-butyl, 4-(n-butoxy)-butyl, 4-(1-methylpropoxy)-butyl, 4-(2-methylpropoxy)-butyl, 4-(1,1-dimethylethoxy)-butyl and the like.

The term “haloalkoxy-alkyl” as used herein denotes in each case alkyl as defined above, usually comprising 1 to 6 carbon atoms, preferably 1 to 4 carbon atoms, wherein 1 carbon atom carries an haloalkoxy radical as defined above, usually comprising 1 to 8, frequently 1 to 6, in particular 1 to 4, carbon atoms as defined above. Examples are fluoromethoxymethyl, difluoromethoxymethyl, trifluoromethoxymethyl, 1-fluoroethoxymethyl, 2-fluoroethoxymethyl, 1,1-difluoroethoxymethyl, 1,2-difluoroethoxymethyl, 2,2-difluoroethoxymethyl, 1,1,2-trifluoroethoxymethyl, 1,2,2-trifluoroethoxymethyl, 2,2,2-trifluoroethoxymethyl, pentafluoroethoxymethyl, 1-fluoroethoxy-1-ethyl, 2-fluoroethoxy-1-ethyl, 1,1-difluoroethoxy-1-ethyl, 1,2-difluoroethoxy-1-ethyl, 2,2-difluoroethoxy-1-ethyl, 1,1,2-trifluoroethoxy-1-ethyl, 1,2,2-trifluoroethoxy-1-ethyl, 2,2,2-trifluoroethoxy-1-ethyl, pentafluoroethoxy-1-ethyl, 1-fluoroethoxy-2-ethyl, 2-fluoroethoxy-2-ethyl, 1,1-difluoroethoxy-2-ethyl, 1,2-difluoroethoxy-2-ethyl, 2,2-difluoroethoxy-2-ethyl, 1,1,2-trifluoroethoxy-2-ethyl, 1,2,2-trifluoroethoxy-2-ethyl, 2,2,2-trifluoroethoxy-2-ethyl, pentafluoroethoxy-2-ethyl, and the like.

The term “alkylthio” (also alkylsulfanyl, “alkyl-S” or “alkyl-S(O)_(k)” (wherein k is 0)) as used herein denotes in each case a straight-chain or branched saturated alkyl group as defined above, usually comprising 1 to 8 carbon atoms (“C₁-C₆-alkylthio”), frequently comprising 1 to 6 carbon atoms (“C₁-C₆-alkylthio”), preferably 1 to 4 carbon atoms (“C₁-C₄-alkylthio”), which is attached via a sulfur atom at any position in the alkyl group. C₁-C₂-Alkylthio is methythio or ethythio. C₁-C₄-Alkylthio is additionally, for example, n-propythio, 1-methylethythio (iso-propythio), butylthio, 1-methylpropythio (sec-butythio), 2-methylpropythio (isobutylthio) or 1,1-dimethylethythio (tert-butylthio). C₁-C₆-Alkylthio is additionally, for example, pentylthio, 1-methylbutylthio, 2-methylbutylthio, 3-methylbutylthio, 1,1-dimethylpropythio, 1,2-dimethylpropythio, 2,2-dimethylpropythio, 1-ethylpropythio, hexylthio, 1-methylpentythio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1-dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropythio, 1,2,2-trimethylpropylthio, 1-ethyl-1-methylpropylthio or 1-ethyl-2-methylpropylthio. C₁-C₈-Alkylthio is additionally, for example, heptylthio, octylthio, 2-ethylhexylthio and positional isomers thereof.

The term “haloalkythio” as used herein refers to an alkylthio group as defined above wherein the hydrogen atoms are partially or completely substituted by fluorine, chlorine, bromine and/or iodine. C₁-C₂-Haloalkylthio is, for example, SCH₂F, SCHF₂, SCF₃, SCH₂Cl, SCHCl₂, SCCl₃, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethythio, 2-fluoroethylthio, 2-chloroethylthio, 2-bromoethythio, 2-iodoethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethythio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio or SC₂F₅. C₁-C₄-Haloalkylthio is additionally, for example, 2-fluoropropylthio, 3-fluoropropylthio, 2,2-difluoropropylthio, 2,3-difluoropropylthio, 2-chloropropylthio, 3-chloropropylthio, 2,3-dichloropropythio, 2-bromopropythio, 3-bromopropylthio, 3,3,3-trifluoropropylthio, 3,3,3-trichloropropythio, SCH₂—C₂F₅, SCF₂—C₂F₅, 1-(CH₂F)-2-fluoroethylthio, 1-(CH₂Cl)-2-chloroethylthio, 1-(CH₂Br)-2-bromoethythio, 4-fluorobutylthio, 4-chlorobutylthio, 4-bromobutylthio or nonafluorobutylthio. C₁-C₆-Haloalkylthio is additionally, for example, 5-fluoropentylthio, 5-chloropentythio, 5-brompentythio, 5-iodopentylthio, undecafluoropentythio, 6-fluorohexylthio, 6-chlorohexythio, 6-bromohexythio, 6-iodohexylthio or dodecafluorohexythio.

The terms “alkylsulfinyl” and “alkyl-S(O)_(k)” (wherein k is 1) are equivalent and, as used herein, denote an alkyl group, as defined above, attached via a sulfinyl [S(O)] group. For example, the term “C₁-C₂-alkylsulfinyl” refers to a C₁-C₂-alkyl group, as defined above, attached via a sulfinyl [S(O)] group. The term “C₁-C₄-alkylsulfinyl” refers to a C₁-C₄-alkyl group, as defined above, attached via a sulfinyl [S(O)] group. The term “C₁-C₆-alkylsulfinyl” refers to a C₁-C₆-alkyl group, as defined above, attached via a sulfinyl [S(O)] group. C₁-C₂-alkylsulfinyl is methylsulfinyl or ethylsulfinyl. C₁-C₄-alkylsulfinyl is additionally, for example, n-propylsulfinyl, 1-methylethylsulfinyl (isopropylsulfinyl), butylsulfinyl, 1-methylpropylsulfinyl (sec-butylsulfinyl), 2-methylpropylsulfinyl (isobutylsulfinyl) or 1,1-dimethylethylsulfinyl (tert-butylsulfinyl). C₁-C₆-alkylsulfinyl is additionally, for example, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methylbutylsulfinyl, 1,1-dimethylpropylsulfinyl, 1,2-dimethylpropylsulfinyl, 2,2-dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, 1-methylpentylsulfinyl, 2-methylpentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, 1,1-dimethylbutylsulfinyl, 1,2-dimethylbutylsulfinyl, 1,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1-ethylbutylsulfinyl, 2-ethylbutylsulfinyl, 1,1,2-trimethylpropylsulfinyl, 1,2,2-trimethylpropylsulfinyl, 1-ethyl-1-methylpropylsulfinyl or 1-ethyl-2-methylpropylsulfinyl.

The terms “alkylsulfonyl” and “alkyl-S(O)_(k)” (wherein k is 2) are equivalent and, as used herein, denote an alkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. The term “C₁-C₂-alkylsulfonyl” refers to a C₁-C₂-alkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. The term “C₁-C₄-alkylsulfonyl” refers to a C₁-C₄-alkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. The term “C₁-C₆-alkylsulfonyl” refers to a C₁-C₆-alkyl group, as defined above, attached via a sulfonyl [S(O)₂] group. C₁-C₂-alkylsulfonyl is methylsulfonyl or ethylsulfonyl. C₁-C₄-alkylsulfonyl is additionally, for example, n-propylsulfonyl, 1-methylethylsulfonyl (isopropylsulfonyl), butylsulfonyl, 1-methylpropylsulfonyl (sec-butylsulfonyl), 2-methylpropylsulfonyl (isobutylsulfonyl) or 1,1-dimethylethylsulfonyl (tert-butylsulfonyl). C₁-C₆-alkylsulfonyl is additionally, for example, pentylsulfonyl, 1-methylbutylsulfonyl, 2-methylbutylsulfonyl, 3-methylbutylsulfonyl, 1,1-dimethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, 2,2-dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1-dimethylbutylsulfonyl, 1,2-dimethylbutylsulfonyl, 1,3-dimethylbutylsulfonyl, 2,2-dimethylbutylsulfonyl, 2,3-dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 2-ethylbutylsulfonyl, 1,1,2-trimethylpropylsulfonyl, 1,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methylpropylsulfonyl or 1-ethyl-2-methylpropylsulfonyl.

The term “alkylamino” as used herein denotes in each case a group —R*HN—, wherein R* is a straight-chain or branched alkyl group usually having from 1 to 6 carbon atoms (“C₁-C₅-alkylamino”), preferably 1 to 4 carbon atoms (“C₁-C₄-alkylamino”). Examples of C₁-C₆-alkylamino are methylamino, ethylamino, n-propylamino, isopropylamino, n-butylamino, 2-butylamino, iso-butylamino, tert-butylamino, and the like.

The term “dialkylamino” as used herein denotes in each case a group R*R^(o)N—, wherein R* and R^(o), independently of each other, are a straight-chain or branched alkyl group each usually having from 1 to 6 carbon atoms (“di-(C₁-C₆-alkyl)-amino”), preferably 1 to 4 carbon atoms (“di-(C₁-C₄-alkyl)-amino”). Examples of a di-(C₁-C₆-alkyl)-amino group are dimethylamino, diethylamino, dipropylamino, dibutylamino, methyl-ethyl-amino, methyl-propyl-amino, methyl-isopropylamino, methyl-butyl-amino, methyl-isobutyl-amino, ethyl-propyl-amino, ethyl-isopropylamino, ethyl-butyl-amino, ethyl-isobutyl-amino, and the like.

The suffix “-carbonyl” in a group denotes in each case that the group is bound to the remainder of the molecule via a carbonyl C═O group. This is the case e.g. in alkylcarbonyl, haloalkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, haloalkoxycarbonyl.

The term “aryl” as used herein refers to a mono-, bi- or tricyclic aromatic hydrocarbon radical such as phenyl or naphthyl, in particular phenyl.

The term “het(ero)aryl” as used herein refers to a mono-, bi- or tricyclic heteroaromatic hydrocarbon radical, preferably to a monocyclic heteroaromatic radical, such as pyridyl, pyrimidyl and the like.

The term “5- or 6-membered monocyclic or 8-, 9- or 10-membered bicyclic saturated, unsaturated or aromatic heterocycle containing 1, 2, 3 or 4 heteroatoms as ring members selected from the groups consisting of N, O and S” as used herein denotes monocyclic or bicyclic heterocyclic radicals, the monocyclic or bicyclic heterocyclic radicals being saturated, unsaturated or aromatic. An unsaturated heterocyclic radical contains at least one C—C and/or C—N and/or N—N double bond(s). A partially unsaturated heterocyclic radical contains less conjugated C—C and/or C—N and/or N—N double bonds than maximally allowed by the size(s) of the ring(s). A fully unsaturated heterocyclic radical contains as many conjugated C—C and/or C—N and/or N—N double bonds as allowed by the size(s) of the ring(s). An aromatic monocyclic heterocyclic radical is a fully unsaturated 5- or 6-membered monocyclic heterocyclic radical. An aromatic bicyclic heterocyclic radical is an 8-, 9- or 10-membered bicyclic heterocyclic radical consisting of a 5- or 6-membered heteroaromatic ring which is fused to a phenyl ring or to another 5- or 6-membered heteroaromatic ring. The heterocyclic radical may be attached to the remainder of the molecule via a carbon ring member or via a nitrogen ring member. As a matter of course, the heterocyclic ring contains at least one carbon ring atom. If the ring contains more than one O ring atom, these are not adjacent.

Examples of a 3-, 4-, 5- or 6-membered monocyclic saturated heterocycle include: oxirane-2-yl, aziridine-1-yl, aziridine-2-yl, oxetan-2-yl, azetidine-1-yl, azetidine-2-yl, azetidine-3-yl, thietane-1-yl, thietan-2-yl, thietane-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrothien-2-yl, tetrahydrothien-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrazolidin-1-yl, pyrazolidin-3-yl, pyrazolidin-4-yl, pyrazolidin-5-yl, imidazolidin-1-yl, imidazolidin-2-yl, imidazolidin-4-yl, oxazolidin-2-yl, oxazolidin-3-yl, oxazolidin-4-yl, oxazolidin-5-yl, isoxazolidin-2-yl, isoxazolidin-3-yl, isoxazolidin-4-yl, isoxazolidin-5-yl, thiazolidin-2-yl, thiazolidin-3-yl, thiazolidin-4-yl, thiazolidin-5-yl, isothiazolidin-2-yl, isothiazolidin-3-yl, isothiazolidin-4-yl, isothiazolidin-5-yl, 1,2,4-oxadiazolidin-3-yl, 1,2,4-oxadiazolidin-5-yl, 1,2,4-thiadiazolidin-3-yl, 1,2,4-thiadiazolidin-5-yl, 1,2,4-triazolidin-3-yl, 1,3,4-oxadiazolidin-2-yl, 1,3,4-thiadiazolidin-2-yl, 1,3,4-triazolidin-1-yl, 1,3,4-triazolidin-2-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 1,3-dioxan-5-yl, 1,4-dioxan-2-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, hexahydropyridazin-3-yl, hexahydropyridazin-4-yl, hexahydropyrimidin-2-yl, hexahydropyrimidin-4-yl, hexahydropyrimidin-5-yl, piperazin-1-yl, piperazin-2-yl, 1,3,5-hexahydrotriazin-1-yl, 1,3,5-hexahydrotriazin-2-yl and 1,2,4-hexahydrotriazin-3-yl, morpholin-2-yl, morpholin-3-yl, morpholin-4-yl, thiomorpholin-2-yl, thiomorpholin-3-yl, thiomorpholin-4-yl, 1-oxothiomorpholin-2-yl, 1-oxothiomorpholin-3-yl, 1-oxothiomorpholin-4-yl, 1,1-dioxothiomorpholin-2-yl, 1,1-dioxothiomorpholin-3-yl, 1,1-dioxothiomorpholin-4-yl and the like.

Examples of a 5- or 6-membered monocyclic partially unsaturated heterocycle include: 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4-isoxazolin-3-yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxazolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothiazolin-5-yl, 2,3-dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5-dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 2-, 3-, 4-, 5- or 6-di- or tetrahydropyridinyl, 3-di- or tetrahydropyridazinyl, 4-di- or tetrahydropyridazinyl, 2-di- or tetrahydropyrimidinyl, 4-di- or tetrahydropyrimidinyl, 5-di- or tetrahydropyrimidinyl, di- or tetrahydropyrazinyl, 1,3,5-di- or tetrahydrotriazin-2-yl and 1,2,4-di- or tetrahydrotriazin-3-yl.

A 5- or 6-membered monocyclic fully unsaturated (including aromatic) heterocyclic ring is e.g. a 5- or 6-membered monocyclic fully unsaturated (including aromatic) heterocyclic ring. Examples are: 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 1-imidazolyl, 2-imidazolyl, 4-imidazolyl, 1,3,4-triazol-1-yl, 1,3,4-triazol-2-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 1-oxopyridin-2-yl, 1-oxopyridin-3-yl, 1-oxopyridin-4-yl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl.

Examples of a 5- or 6-membered heteroaromatic ring fused to a phenyl ring or to a 5- or 6-membered heteroaromatic radical include benzofuranyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, benzoxathiazolyl, benzoxadiazolyl, benzothiadiazolyl, benzoxazinyl, chinolinyl, isochinolinyl, purinyl, 1,8-naphthyridyl, pteridyl, pyrido[3,2-d]pyrimidyl or pyridoimidazolyl and the like.

If two radicals bound on the same nitrogen atom (for example R^(e) and R^(f) or R^(2e) and R^(2f) or R^(g) and R^(h) or R^(2g) and R^(2h)) together with the nitrogen atom, to which they are bound, form a 5-, 6 or 7-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N, this is for example pyrrolidine-1-yl, pyrazolidin-1-yl, imidazolidin-1-yl, oxazolidin-3-yl, thiazolidin-3-yl, isoxazolidin-2-yl, isothiazolin-2-yl, [1,2,3]-triazolidin-1-yl, [1,2,3]-triazolidin-2-yl, [1,2,4]-triazolidin-1-yl, [1,2,4]-triazolidin-4-yl, [1,2,3]-oxadiazolidin-2-yl, [1,2,3]-oxadiazolidin-3-yl, [1,2,5]-oxadiazolidin-2-yl, [1,2,4]-oxadiazolidin-2-yl, [1,2,4]-oxadiazolidin-4-yl, [1,3,4]-oxadiazolidin-3-yl, [1,2,3]-thiadiazolidin-2-yl, [1,2,3]-thiadiazolidin-3-yl, [1,2,5]-thiadiazolidin-2-yl, [1,2,4]-thiadiazolidin-2-yl, [1,2,4]-thiadiazolidin-4-yl, [1,3,4]-thiadiazolidin-3-yl, piperdin-1-yl, piperazine-1-yl, morpholin-1-yl, thiomorpholin-1-yl, 1-oxothiomorpholin-1-yl, 1,1-dioxothiomorpholin-1-yl, azepan-1-yl, 1,4-diazepan-1-yl, pyrrolin-1-yl, pyrazolin-1-yl, imidazolin-1-yl, oxazolin-3-yl, isoxazolin-2-yl, thiazolin-3-yl, isothiazolin-1-yl, 1,2-dihydropyridin-1-yl, 1,2,3,4-tetrahydropyridin-1-yl, 1,2,5,6-tetrahydropyridin-1-yl, 1,2-dihydropyridazin, 1,6-dihydropyridazin, 1,2,3,4-tetrahydropyridazin-1-yl, 1,2,5,6-tetrahydropyridazin-1-yl, 1,2-dihydropyrimidin, 1,6-dihydropyrimidin, 1,2,3,4-tetrahydropyrimidin-1-yl, 1,2,5,6-tetrahydropyrimidin-1-yl, 1,2-dihydropyrazin-1-yl, 1,2,3,4-tetrahydropyrazin-1-yl, 1,2,5,6-tetrahydropyrazin-1-yl, pyrrol-1-yl, pyrazol-1-yl, imidazol-1-yl, [1,2,3]-1H-triazol-1-yl, [1,2,3]-2H-triazol-2-yl, [1,2,4]-1H-triazol-1-yl and [1,2,4]-4H-triazol-4-yl.

The term “fused 5-, 6-, 7-, 8-, 9- and 10-membered carbocycle or 5-, 6-, 7-, 8-, 9- and 10-membered heterocycle” refers to a carbo- or heterocycle that is adjoined at two consecutive positions with the phenyl group of the radical Cyc-1 or Cyc-1 in such a way that both rings share the ring atoms at said two positions. The fused carbo- and heterocycles may be saturated, partially unsaturated or fully unsaturated and in addition may be mono-, bi- or tricyclic, where each one of the two or three rings of the bi- and tricyclic fused carbo- and heterocycles is either fused to one or two of the other rings, i.e. two rings share two ring atoms, or spiro-linked, i.e. two rings share 1 ring atom. Examples of 5-, 6-, 7-, 8-, 9- and 10-membered fused carbocycles are cyclopentane, cyclohexane, cycloheptane, cyclo[3.3.0]octane, cyclo[4.3.0]nonane, cyclo[4.4.0]decane cyclopentene, cyclohexene and benzene. Examples of 5-, 6-, 7-, 8-, 9- and 10-membered fused carbocycles are pyrrolidine, tetrahydrofuran, tetrahydrothiophen, dihydrofuran, dihydrothiophen, pyrrole, furan, thiopene, thiazole, thiazine, piperidine, tetrahydropyran, tetrahydrothiopyrane, dioxane, piperazine, morpholine, pyridine, azepane, oxepane, thiepane, azepine, oxepine, thiepine, pyrazole, pyrazoline, imidazole, benzimidazole, imidazoline, indole, indoline, chinoline, isochinoline, pyrimidine, oxazole, isoxazole, oxazoline, isoxazoline and the like.

The remarks made below as to preferred embodiments of the variables (substituents) of the compounds of formula I or II are valid on their own as well as preferably in combination with each other, as well as in combination with the stereoisomers, salts, tautomers or N-oxides thereof.

The remarks made below concerning preferred embodiments of the variables further are valid on their own as well as preferably in combination with each other concerning the compounds of formula I or II, where applicable, as well as concerning the uses and methods according to the invention and the composition according to the invention.

Preferred compounds according to the invention are compounds of formula I or II or a stereoisomer, salt or N-oxide thereof, wherein the salt is an agriculturally suitable salt. Further preferred compounds according to the invention are compounds of formula I or II or an N-oxide or salt thereof, especially an agriculturally suitable salt. Particularly preferred compounds according to the invention are compounds of formula I or II or a salt thereof, especially an agriculturally suitable salt thereof.

According to a preferred embodiment of the invention the variable X in the compounds of formula I is selected from the group consisting of halogen, cyano, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₅-haloalkyl, C(═O)—R^(c), C(═O)—OR^(d), C(═O)—NR^(e)R^(f), NH—C(═O)R^(k) and NR^(g)R^(h); where R^(c), R^(d), R^(e), R^(f), R^(k), R^(g) and R^(h) are as defined above and which preferably have on their own or in particular in combination the following meanings:

R^(c) is hydrogen, C₁-C₆-alkyl C₃-C₇-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₁-C₆-haloalkyl or phenyl, in particular C₁-C₄-alkyl or C₁-C₄-haloalkyl;

R^(d) is C₁-C₆-alkyl or C₁-C₆-haloalkyl, in particular C₁-C₄-alkyl,

R^(e), R^(f) are independently of each other selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl and benzyl, and in particular from the group consisting of hydrogen and C₁-C₄-alkyl, or

R^(e), R^(f) together with the nitrogen atom, to which they are bound form a 5-, 6- or 7-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-haloalkyl, and in particular R^(e), R^(f) together with the nitrogen atom, to which they are bound may form a 5-, 6- or 7-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups;

R^(g), R^(h) are independently of each other selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl and benzyl and in particular from the group consisting of hydrogen or C₁-C₄-alkyl, or

R^(g), R^(h) together with the nitrogen atom, to which they are bound form a 5-, 6 or 7-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-haloalkyl, and in particular R^(g), R^(h) together with the nitrogen atom, to which they are bound may form a 5-, 6- or 7-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups; and

R^(k) is H, C₁-C₄-alkyl, C₁-C₄-haloalkyl or phenyl, in particular C₁-C₄-alkyl.

According to a more preferred embodiment the variable X of the compounds of the formula I is selected from the group consisting of halogen, cyano, nitro, NH₂, C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-haloalkyl, C(═O)—R^(c), C(═O)—OR^(d), C(═O)—NR^(e)R^(f) and NH—C(═O)R^(k), where R^(c), R^(d), R^(e), R^(f) and R^(k) are as defined above and which preferably have on their own or in particular in combination the following meanings:

R^(c) is C₁-C₄-alkyl or C₁-C₄-haloalkyl,

R^(d) is C₁-C₄-alkyl,

R^(e) is hydrogen or C₁-C₄-alkyl,

R^(f) is hydrogen or C₁-C₄-alkyl, or

R^(e), R^(f) together with the nitrogen atom, to which they are bound may form a 5-, 6 or 7-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups, and

R^(k) is C₁-C₄-alkyl.

According to a particular preferred embodiment of the invention the variable X in the compounds of formula I is selected from halogen, cyano, nitro, C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-haloalkyl, acetylamino, methoxycarbonyl, ethoxycarbonyl, methylcarbonyl, piperidinylcarbonyl, trifluoromethylcarbonyl, amino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl and methoxymethyl, in particular from Cl, Br, F, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, CF₃, CHF₂, CClF₂, CH₂CF₃, CF₂CF₃, CH₂Cl, CHCl₂, cyano, nitro, acetylamino, methoxycarbonyl, ethoxycarbonyl, methylcarbonyl, piperidinylcarbonyl, trifluoromethylcarbonyl, amino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl and methoxymethyl.

According to a further preferred embodiment of the invention the variable X in the compounds of formula I is a radical OR^(a), where R^(a) is as defined above and in particular selected from the group consisting of H, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl, preferably from H, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, and in particular from H, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, C₂-C₄-alkynyl, C₂-C₄-haloalkynyl and C₃-C₆-cycloalkyl. In this context R^(a) specifically is H, CH₃, CH₂H₃, CH(CH₃)₂, CH₂CH₂CH₃, cylcopropyl, cyclobutyl, cyclopentyl, cyclohexyl, CH₂Cl, C(CH₃)₃, CHF₂, CF₃, CH₂CH═CH₂, CH₂C—CH, CH₂OCH₃, CH₂CH₂OCH₃ and CH₂CH₂OCH₂CH₃.

According to another preferred embodiment of the invention the variable X in the compounds of formula I is phenyl or heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic or 8-, 9- or 10-membered bicyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2, 3 or 4 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2, 3 or 4 groups R′ which are as defined above and which are independently from one another are preferably selected from the group consisting of halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₁-C₆-haloalkyloxy, more preferably from halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy, in particular from halogen, methyl, ethyl, methoxy and trifluoromethyl, and specifically from Cl, F, Br, methyl, methoxy and trifluoromethyl.

According to a more preferred embodiment of the invention the variable X in the compounds of formula I is phenyl or heterocyclyl, where heterocyclyl is a partially unsaturated or aromatic 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heterocycle containing 1, 2, 3 or 4 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where the bicyclic heterocycle consists of a 5- or 6-membered heteroaromatic ring which is fused to a phenyl ring, and where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2, 3 or 4 groups R′ which independently from one another have the aforementioned preferred meanings.

According to particular preferred embodiments the variable X in the compounds of the formula I is phenyl or heterocyclyl selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, benzisoxazole-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, 1-ethylbenzimidazol-2-yl, 4-methylthiazol-2-yl, thiophen-2-yl, furan-2-yl, furan-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, isoxazol-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, oxazol-2-yl, oxazol-3-yl, oxazol-4-yl, oxazol-5-yl, pyrrol-2-yl, pyrrol-3-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,5-triazol-3-yl, 1,3,4-triazol-2-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,5-thiadiazol-3-yl, 2H-1,2,3,4-tetrazol-5-yl, 1H-1,2,3,4-tetrazol-1-yl, 1,2,3,4-oxatriazol-5-yl, 1,2,3,5-oxatriazol-4-yl, 1,2,3,4-thiatriazol-5-yl, 1,2,3,5-thiatriazol-4-yl, pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl and pyridazin-4-yl, where phenyl and heterocyclyl are unsubstituted or carry 1, 2, or 3 groups R′ which independently from one another have the aforementioned preferred meanings.

According to a preferred embodiment of the invention the variable X in the compounds of formula I is S(O)_(n)—R^(b), where R^(b) is as defined above and in particular selected from the group consisting of C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2 or 3 groups, which are identical or different and preferably selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₂-haloalkyl and C₁-C₂-alkoxy.

According to a more preferred embodiment of the invention the variable X in the compounds of formula I is S(O)_(n)—R^(b), where R^(b) is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₇-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S.

According to an even more preferred embodiment of the invention the variable X in the compounds of formula I is S(O)_(n)—R^(b), where R^(b) is selected from C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₃-C₇-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 6-membered aromatic heterocyclic radical having 1 or 2 nitrogen atoms as ring members.

According to a particularly preferred embodiment of the invention the variable X in the compounds of formula I is S(O)₂—R^(b), where R^(b) is CH₃, CH₂H₃, CH(CH₃)₂, CH₂CH₂CH₃, CH₂CH═CH₂, CH₂C≡CH or phenyl.

According to specifically preferred embodiments of the invention the variable X in the compounds of formula I is selected from the group consisting of Cl, Br, F, methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, CF₃, CHF₂, CClF₂, CH₂CF₃, CF₂CF₃, CH₂Cl, CHF₂, CHCl₂, cyano, nitro, acetylamino, benzoylamino, methoxycarbonyl, ethoxycarbonyl, benzoyl, methylcarbonyl, piperidinylcarbonyl, trifluoromethylcarbonyl, amino, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methoxymethyl, OH, OCH₃, OCH₂H₃, OCH(CH₃)₂, OCH₂CH₂CH₃, O-cylcopropyl, O-cyclobutyl, O-cyclopentyl, O-cyclohexyl, O—CH₂Cl, O—C(CH₃)₃, O—CHF₂, O—CF₃, O—CH₂CH═CH₂, O—CH₂C═CH, O—CH₂OCH₃, O—CH₂CH₂OCH₃, O—CH₂CH₂OCH₂CH₃, S(O)₂—CH₃, S(O)₂—CH₂CH₃, S(O)₂—CH(CH₃)₂, S(O)₂—CH₂CH₂CH₃, S(O)₂—CH₂CH═CH₂, S(O)₂—CH₂C═CH and S(O)₂-phenyl and in particular from methyl, ethyl and methoxy.

According to one embodiment of the invention the variable B in the compounds of formula II is N.

According to another embodiment of the invention the variable B in the compounds of formula II is CH.

According to a preferred embodiment of the invention the variable Y in the compounds of formula II is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-haloalkyl, R^(c)—C(═O)—C₁-C₂-alkyl, R^(d)O—C(═O)—C₁-C₂-alkyl, R^(e)R^(f)N—C(═O)—C₁-C₂-alkyl and R^(k)—C(═O)NH—C₁-C₂-alkyl; where R^(c), R^(d), R, R^(f), R^(k), R^(g) and R^(h) are as defined above and which preferably have on their own or in particular in combination the following meanings:

-   R^(c) is hydrogen, C₁-C₆-alkyl C₃-C₇-cycloalkyl, C₂-C₆-alkenyl,     C₂-C₆-haloalkenyl, C₁-C₆-haloalkyl or phenyl, in particular     C₁-C₄-alkyl or C₁-C₄-haloalkyl; -   R^(d) is C₁-C₆-alkyl or C₁-C₆-haloalkyl, in particular C₁-C₄-alkyl, -   R^(e), R^(f) are independently of each other selected from hydrogen,     C₁-C₆-alkyl, C₁-C₆-haloalkyl and benzyl, and in particular from the     group consisting of hydrogen and C₁-C₄-alkyl, or -   R^(e), R^(f) together with the nitrogen atom, to which they are     bound form a 5-, 6- or 7-membered, saturated or unsaturated N-bound     heterocyclic radical, which may carry as a ring member a further     heteroatom selected from O, S and N and which is unsubstituted or     may carry 1, 2, 3 or 4 groups, which are identical or different and     selected from the group consisting of halogen, C₁-C₄-alkyl and     C₁-C₄-haloalkyl, and in particular R^(e), R^(f) together with the     nitrogen atom, to which they are bound may form a 5-, 6- or     7-membered, saturated N-bound heterocyclic radical, which may carry     as a ring member a further heteroatom selected from O, S and N and     which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups; -   R^(g), R^(h) are independently of each other selected from hydrogen,     C₁-C₆-alkyl, C₁-C₆-haloalkyl and benzyl and in particular from the     group consisting of hydrogen or C₁-C₄-alkyl, or -   R^(g), R^(h) together with the nitrogen atom, to which they are     bound form a 5-, 6 or 7-membered, saturated or unsaturated N-bound     heterocyclic radical, which may carry as a ring member a further     heteroatom selected from O, S and N and which is unsubstituted or     may carry 1, 2, 3 or 4 groups, which are identical or different and     selected from the group consisting of halogen, C₁-C₄-alkyl and     C₁-C₄-haloalkyl, and in particular R^(g), R^(h) together with the     nitrogen atom, to which they are bound may form a 5-, 6- or     7-membered, saturated N-bound heterocyclic radical, which may carry     as a ring member a further heteroatom selected from O, S and N and     which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups; and -   R^(k) is H, C₁-C₄-alkyl, C₁-C₄-haloalkyl or phenyl, in particular     C₁-C₄-alkyl.

According to a more preferred embodiment the variable Y of the compounds of the formula II is selected from the group consisting of C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-haloalkyl, R^(c)—C(═O)—C₁-C₂-alkyl, R^(d)O—C(═O)—C₁-C₂-alkyl, R^(e)R^(f)N—C(═O)—C₁-C₂-alkyl and R^(k)—C(═O)NH—C—C₂-alkyl, where R^(c), R^(d), R^(e), R^(f) and R^(k) are as defined above and which preferably have on their own or in particular in combination the following meanings:

R^(c) is C₁-C₄-alkyl or C₁-C₄-haloalkyl,

R^(d) is C₁-C₄-alkyl,

R^(e) is hydrogen or C₁-C₄-alkyl,

R^(f) is hydrogen or C₁-C₄-alkyl, or

R^(e), R^(f) together with the nitrogen atom, to which they are bound may form a 5-, 6 or 7-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 methyl groups, and

-   R^(k) is C₁-C₄-alkyl.

According to a particular preferred embodiment of the invention the variable Y in the compounds of formula II is selected from C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy-C₁-C₄-alkyl, in particular from methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, CF₃, CHF₂, CClF₂, CH₂CF₃, CF₂CF₃, CH₂Cl, CHCl₂, ethoxyethyl, ethoxymethyl, methoxyethyl and methoxymethyl.

According to another particular preferred embodiment of the invention the variable Y in the compounds of formula II is selected from C₁-C₄-alkyl, C₃-C₇-cycloalkyl, C₁-C₄-haloalkyl, methoxyethyl and methoxymethyl, in particular from methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, CF₃, CHF₂, CClF₂, CH₂CF₃, CF₂CF₃, CH₂Cl, CHCl₂, methoxyethyl and methoxymethyl.

According to another preferred embodiment of the invention the variable Y in the compounds of formula II is phenyl or heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic or 8-, 9- or 10-membered bicyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2, 3 or 4 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2, 3 or 4 groups R′ which are as defined above and which are independently from one another are preferably selected from the group consisting of halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₁-C₆-haloalkyloxy, more preferably from halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy, in particular from halogen, methyl, ethyl, methoxy and trifluoromethyl, and specifically from Cl, F, Br, methyl, methoxy and trifluoromethyl.

According to a more preferred embodiment of the invention the variable Y in the compounds of formula II is phenyl or heterocyclyl, where heterocyclyl is a partially unsaturated or aromatic 5- or 6-membered monocyclic or 9- or 10-membered bicyclic heterocycle containing 1, 2, 3 or 4 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where the bicyclic heterocycle consists of a 5- or 6-membered heteroaromatic ring which is fused to a phenyl ring, and where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2, 3 or 4 groups R′ which independently from one another have the aforementioned preferred meanings.

According to particular preferred embodiments the variable Y in the compounds of the formula II is phenyl or heterocyclyl selected from pyridin-2-yl, pyridin-3-yl, pyridin-4-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, benzisoxazole-2-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-triazol-3-yl, 1-ethylbenzimidazol-2-yl, 4-methylthiazol-2-yl, thiophen-2-yl, furan-2-yl, furan-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, isoxazol-2-yl, isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, oxazol-2-yl, oxazol-3-yl, oxazol-4-yl, oxazol-5-yl, pyrrol-2-yl, pyrrol-3-yl, imidazol-2-yl, imidazol-4-yl, imidazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, 1,2,3-triazol-4-yl, 1,2,3-triazol-5-yl, 1,2,5-triazol-3-yl, 1,3,4-triazol-2-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,2,5-oxadiazol-3-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,3,4-thiadiazol-2-yl, 1,2,3-thiadiazol-4-yl, 1,2,3-thiadiazol-5-yl, 1,2,5-thiadiazol-3-yl, 2H-1,2,3,4-tetrazol-5-yl, 1H-1,2,3,4-tetrazol-1-yl, 1,2,3,4-oxatriazol-5-yl, 1,2,3,5-oxatriazol-4-yl, 1,2,3,4-thiatriazol-5-yl, 1,2,3,5-thiatriazol-4-yl, pyrazin-2-yl, pyrazin-3-yl, pyrimidin-2-yl, pyrimidin-4-yl, pyrimidin-5-yl, pyridazin-3-yl and pyridazin-4-yl, where phenyl and heterocyclyl are unsubstituted or carry 1, 2, or 3 groups R′ which independently from one another have the aforementioned preferred meanings.

According to a preferred embodiment of the invention the variable Y in the compounds of formula II is R^(b)—S(O)_(n)—C₁-C₃-alkyl, where R^(b) is as defined above and in particular selected from the group consisting of C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2 or 3 groups, which are identical or different and preferably selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₂-haloalkyl and C₁-C₂-alkoxy.

According to a more preferred embodiment of the invention the variable Y in the compounds of formula II is R^(b)—S(O)_(n)—C—C₃-alkyl, where R^(b) is selected from the group consisting of C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₂-C₆-haloalkenyl, C₂-C₆-haloalkynyl, C₃-C₇-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S.

According to an even more preferred embodiment of the invention the variable Y in the compounds of formula II is R^(b)—S(O)_(n)—C₁-C₂-alkyl, where R^(b) is selected from C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₃-C₇-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 6-membered aromatic heterocyclic radical having 1 or 2 nitrogen atoms as ring members.

According to a particularly preferred embodiment of the invention the variable Y in the compounds of formula II is R^(b)—S(O)₂—C₁-C₂₋alkyl, where R^(b) is CH₃, CH₂H₃, CH(CH₃)₂, CH₂CH₂CH₃, CH₂CH═CH₂, CH₂C≡CH or phenyl.

According to specifically preferred embodiments of the invention the variable Y in the compounds of formula II is selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, CF₃, CHF₂, CClF₂, CH₂CF₃, CF₂CF₃, CH₂Cl, CHCl₂, methoxyethyl, methoxymethyl, and in particular from methyl and ethyl.

Preferred compounds according to the invention are compounds of formula I or formula II, wherein R¹ is selected from the group consisting of CN, halogen, nitro, C₁-C₆-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-haloalkyl, C₁-C₆-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-Z¹, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkylthio-Z¹, C₂-C₆-alkenyloxy, C₂-C₆-alkynyloxy, C₁-C₆-haloalkoxy, C₁-C₄-haloalkoxy-C₁-C₄-alkoxy and R^(1b)—S(O)_(k), where k and Z¹ are as defined herein and where Rib is as defined above and in particular selected from the group consisting of C₁-C₄-alkyl and C₁-C₄-haloalkyl. In this context Z¹ is in particular a covalent bond.

More preferably, R¹ is selected from halogen, CN, nitro, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₃-C₄-alkenyloxy, C₃-C₄-alkynyloxy, C₁-C₄-alkoxy-C₁-C₄-alkoxy, C₁-C₄-haloalkoxy-C₁-C₄-alkoxy, C₁-C₄-alkyl-S(O)_(k) and C₁-C₄-haloalkyl-S(O)_(k), where k is 0 or 2.

In particular, R¹ is selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C—C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio and C₁-C₄-alkylsulfonyl, specifically R¹ is F, Cl, Br, CH₃, CF₃, OCH₃, OCF₃, SCF₃, SO₂CH₃ or CH₂OCH₂CH₂OCH₃, and more specifically R¹ is Cl, CH₃, CF₃ or SO₂CH₃.

In one group of embodiments of the invention, the variable R² is hydrogen.

In one group of embodiments of the invention the variable R² of the compounds of formula I or formula II has any one of the meanings given above for R² with the exception of hydrogen.

According to preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is a 5- or 6-membered heterocyclyl, where heterocyclyl is a saturated, partially unsaturated or aromatic heterocyclic radical, which contains as ring member 1 heteroatom selected from the group consisting of O, N and S and 0, 1, 2 or 3 further nitrogen atom(s), where heterocyclyl is unsubstituted or carries 1, 2 or 3 radicals R²¹, as defined herein, which are identical or different.

According to an even more preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is a 5- or 6-membered heterocyclyl selected from the group consisting of isoxazolinyl (4,5-dihydroisoxazolyl), 1,2-dihydrotetrazolonyl, 1,4-dihydrotetrazolonyl, tetrahydrofuryl, dioxolanyl, piperidinyl, morpholinyl, piperazinyl, isoxazolyl, pyrazolyl, thiazolyl, oxazolyl, furyl, pyridinyl, pyrimidinyl and pyrazinyl, where heterocyclyl is unsubstituted or carries 1, 2 or 3 radicals R²¹ which are identical or different and are selected from the group consisting of C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₁-C₄-alkylthio-C₁-C₄-alkyl.

According to a particular embodiment of the invention the variable R² in the compounds of formula I or formula II is a 5- or 6-membered heterocyclyl selected from 4,5-dihydroisoxazol-3-yl, which is unsubstituted or substituted in position 5 with CH₃, CH₂F or CHF₂, 4,5-dihydroisoxazol-5-yl, which is unsubstituted or substituted in position 3 with CH₃, OCH₃, CH₂OCH₃, CH₂SCH₃, 1-methyl-5-oxo-1,5-dihydrotetrazol-2-yl, 4-methyl-5-oxo-4,5-dihydrotetrazol-1-yl, morpholin-4-yl, isoxazol-3-yl, 5-methyl-isoxazol-3-yl, isoxazol-5-yl, 3-methyl-isoxazol-5-yl, 1-methyl-1H-pyrazol-3-yl, 2-methyl-2H-pyrazol-3-yl and thiazol-2-yl.

According to a preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is phenyl-Z^(2a), where Z^(2a) is as defined herein, and where phenyl is unsubstituted or carries 1, 2 or 3 radicals R²¹ which are identical or different and as defined above and which are in particular selected from halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₁-C₄-alkoxy-C₁-C₄-alkoxy, and preferably from halogen, C₁-C₂-alkyl, C₁-C₂-alkoxy, C₁-C₂-haloalkyl and C₁-C₂-alkoxy-C₁-C₂-alkoxy.

According to a more preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is a radical of the following formula:

in which # denotes the bond through which the group R² is attached and:

-   R^(P1) is hydrogen or halogen, preferably hydrogen, Cl, Br or F, and     in particular H or F; -   R^(P2) is hydrogen, halogen or C₁-C₂-alkoxy, preferably hydrogen,     Cl, Br, F, OCH₃ or OCH₂CH₃, and in particular H, F, CI or OCH₃; and -   R^(P3) is hydrogen, halogen, C₁-C₂-alkyl, C₁-C₂-haloalkyl,     C₁-C₂-alkoxy, C₁-C₂-alkoxy-C₁-C₂-alkoxy, preferably hydrogen, Cl,     Br, F, CH₃, C₂H₅, CF₃, CHF₂, CH₂F, CCl₂F, CF₂Cl, CH₂CF₃, CH₂CHF₂,     CF₂CF₃, OCH₃, OCH₂CH₃, OCH₂OCH₃, OCH₂CH₂OCH₂CH₃, OCH₂OCH₂CH₃ or     OCH₂CH₂OCH₃, and in particular is H, F, Cl, CH₃, CF₃, OCH₃, OCH₂CH₃,     OCH₂OCH₃ or OCH₂CH₂OCH₃.

According to a particular embodiment of the invention the variable R² in the compounds of formula I or formula II is phenyl which is unsubstituted or carries one radical R²¹, where R²¹ is preferably attached to position 4 of the phenyl group and is as defined above and in particular selected from C₁-C₂-alkyl, C₁-C₂-alkoxy, C₁-C₂-haloalkyl and C₁-C₂-alkoxy-C₁-C₂-alkoxy, preferably form CH₃, C₂H₅, OCH₃, OC₂H₅, CHF₂, CF₃, OCH₂OCH₃ and OCH₂CH₂OCH₃, and specifically from OCH₃ and OC₂H₅.

According to a preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is selected from the group consisting of hydrogen, halogen, C₁-C₆-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₄-alkoxy, C₂-C₄-haloalkoxy, C₃-C₆-alkenyloxy, C₃-C₆-alkynyloxy, C₃-C₆-haloalkenyloxy, C₃-C₆-haloalkynyloxy, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkyl-S(O)_(k), k is 0, 1, 2, and C₁-C₄-haloalkyl-S(O)₂.

According to another preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is selected from the group consisting of halogen, C₁-C₆-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-haloalkoxy-C₁-C₄-alkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₄-alkoxy, C₂-C₄-haloalkoxy, C₃-C₆-alkenyloxy, C₃-C₆-alkynyloxy, C₃-C₆-haloalkenyloxy, C₃-C₆-haloalkynyloxy, C₁-C₄-alkoxycarbonyl, C₁-C₄-alkyl-S(O)₂ and C₁-C₄-haloalkyl-S(O)₂.

According to a more preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is selected from C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₂-C₄-alkoxy, C₁-C₂-haloalkoxy-C₁-C₂-alkyl, C₃-C₄-alkenyloxy, C₃-C₄-alkynyloxy, C₁-C₄-alkoxycarbonyl and C₁-C₄-alkyl-S(O₂), and in particular from CH═CH₂, CH═CHCH₃, CH₂OCH₂CF₃, OC₂H₅, OCH₂CH═CH₂, OCH₂C≡CH, C(O)OCH₃, C(O)OC₂H₅, SO₂CH₃, SO₂C₂H₅ and SO₂CH(CH₃)₂.

According to a specifically preferred embodiment of the invention the variable R² in the compounds of formula I or formula II is selected from the group consisting of hydrogen, 4,5-dihydroisoxazol-3-yl, which is unsubstituted or substituted in position 5 with CH₃, CH₂F or CHF₂, 4,5-dihydroisoxazol-5-yl, which is unsubstituted or substituted in position 3 with CH₃, OCH₃, CH₂OCH₃, CH₂SCH₃, 1-methyl-5-oxo-1,5-dihydrotetrazol-2-yl, 4-methyl-5-oxo-4,5-dihydrotetrazol-1-yl, morpholin-4-yl, isoxazol-3-yl, 5-methyl-isoxazol-3-yl, isoxazol-5-yl, 3-methyl-isoxazol-5-yl, 1-methyl-1H-pyrazol-3-yl, 2-methyl-2H-pyrazol-3-yl, thiazol-2-yl, 4-CH₃-phenyl, 4-C₂H₅-phenyl, 4-OCH₃-phenyl, 4-OC₂H₅-phenyl, 4-CHF₂-phenyl, 4-CF₃-phenyl, 4-OCH₂OCH₃-phenyl, 4-OCH₂CH₂OCH₃-phenyl, CH═CH₂, CH═CHCH₃, CH₂OCH₂CF₃, OC₂H₅, OCH₂CH═CH₂, OCH₂C≡CH, C(O)OCH₃, C(O)OC₂H₅, SO₂CH₃, SO₂C₂H₅ and SO₂CH(CH₃)₂, in particular selected from hydrogen, halogen, methyl, CH₂OCH₂CF₃, methylsulfonyl, methylsulfanyl, methylsulfinyl, 3-isoxazolinyl, 5-methyl-3-isoxazolinyl, 5-isoxazolinyl, 3-methyl-5-isoxazolinyl, 3-isoxazolyl, 5-methyl-3-isoxazolyl, 5-isoxazolyl and 3-methyl-5-isoxazolyl, and specifically selected from hydrogen, chlorine, methylsulfonyl, methylsulfanyl, methylsulfinyl, CH₂OCH₂CF₃, 3-isoxazolinyl, 5-methyl-3-isoxazolinyl, 3-methyl-5-isoxazolinyl, 3-isoxazolyl, 5-methyl-3-isoxazolyl and 3-methyl-5-isoxazolyl.

Preferred compounds according to the invention are compounds of formula I or formula II, wherein R³ is selected from the group consisting of hydrogen, cyano, halogen, nitro, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₂-C₄-alkenyloxy, C₂-C₄-alkynyloxy or R²—S(O)_(k), where the variables k and R^(2b) have one of the herein defined meanings.

More preferably, R³ is selected from the group consisting of hydrogen, halogen, CN, NO₂, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio, C₁-C₄-alkyl-S(O)₂ and C₁-C₄-haloalkyl-S(O)₂.

In particular, R³ is selected from the group consisting of hydrogen, halogen, CN, NO₂, C₁-C₂-alkyl, C₁-C₂-haloalkyl, C₁-C₂-alkoxy, C₁-C₂-haloalkoxy, C₁-C₂-alkylthio, C₁-C₂-haloalkylthio, C₁-C₂-alkyl-S(O)₂ and C₁-C₂-haloalkyl-S(O)₂, specifically from H, Cl, F, CN, NO₂, CH₃, CF₃, CHF₂, OCH₃, OCF₃, OCHF₂, SCH₃, SCF₃, SCHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃, and more specifically from Cl, F, CN, CF₃ and S(O)₂CH₃.

Preferred compounds according to the invention are compounds of formula I or formula II, wherein R⁴ is selected from the group consisting of hydrogen, cyano, halogen, nitro, C₁-C₂-alkyl and C₁-C₂-haloalkyl, in particular from the group consisting of hydrogen, CHF₂, CF₃, CN, NO₂, CH₃ and halogen, and specifically from hydrogen, CHF₂, CF₃, CN, NO₂, CH₃, Cl, Br and F.

Preferred compounds according to the invention are compounds of formula I or formula II, wherein R⁵ is selected from the group consisting of hydrogen, halogen, C₁-C₂-alkyl and C₁-C₂-haloalkyl, and in particular from the group consisting of hydrogen, CHF₂, CF₃ and halogen.

According to a particular embodiment of the invention either R⁴ is hydrogen and R⁵ is chlorine or fluorine, or R⁵ is hydrogen and R⁴ is chlorine or fluorine.

In this context, the variables R′, R¹¹, R²¹, Z, Z¹, Z², Z², R^(a), R^(b), R^(1b), R^(2b), R^(c), R^(2c), R^(d), R^(2d), R^(e), R^(2e), R^(f), R^(2f), R^(g), R^(2g), R^(h), R^(2h), R^(k), n and k, independently of each other, preferably have one of the following meanings:

R′, R¹¹, R²¹ independently of each other are selected from halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₃-C₆-halocycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy and C₁-C₆-haloalkyloxy, more preferably from halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy.

More preferably R′, R¹¹, R²¹ independently of each other are selected from the group consisting of halogen, C₁-C₄-alkyl, C₃-C₆-cycloalkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkylthio-C₁-C₄-alkyl and C₁-C₄-alkoxy-C₁-C₄-alkoxy; in particular selected from halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₁-C₄-alkoxy-C₁-C₄-alkoxy; and specifically from Cl, F, Br, methyl, ethyl, methoxy and trifluoromethyl.

Z, Z¹, Z² independently of each other are selected from a covalent bond, methanediyl and ethanediyl, and in particular are a covalent bond.

Z^(2a) is selected from a covalent bond, C₁-C₂-alkanediyl, O—C₁-C₂-alkanediyl, C₁-C₂-alkanediyl-O and C₁-C₂-alkanediyl-O—C₁-C₂-alkanediyl; more preferably from a covalent bond, methanediyl, ethanediyl, O-methanediyl, O-ethanediyl, methanediyl-O, and ethanediyl-O; and in particular from a covalent bond, methanediyl and ethanediyl.

R^(a) is selected from hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl.

More preferably R^(a) is selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, and in particular selected from H, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, C₂-C₄-alkynyl and C₃-C₆-cycloalkyl.

R^(b), R^(1b), R^(2b) independently of each other are selected from C₁-C₆-alkyl, C₃-C₇-cycloalkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl and heterocyclyl are unsubstituted or substituted by 1, 2 or 3 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₂-haloalkyl and C₁-C₂-alkoxy.

More preferably R^(b), R^(1b), R^(2b) independently of each other are selected from the group consisting of C₁-C₄-alkyl, C₂-C₄-alkenyl, C₂-C₄-alkynyl, C₁-C₄-haloalkyl, C₂-C₄-haloalkenyl, C₂-C₄-haloalkynyl, C₃-C₆-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S.

In particular, R^(b), R^(1b), R^(2b) independently of each other are selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, C₂-C₄-alkynyl, C₃-C₆-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered aromatic heterocyclic radical having 1 or 2 nitrogen atoms as ring members.

R^(c), R^(2c), R^(k) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl, benzyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S, where phenyl, benzyl and heterocyclyl are unsubstituted or substituted by 1, 2 or 3 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy.

More preferably R^(c), R^(2c), R^(k) independently of each other are selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₃-C₆-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered monocyclic saturated, partially unsaturated or aromatic heterocycle, which contains 1, 2 or 3 heteroatoms as ring members, which are selected from the group consisting of O, N and S.

In particular, R^(c), R^(2c), R^(k) independently of each other are selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, C₃-C₆-cycloalkyl, phenyl and heterocyclyl, where heterocyclyl is a 5- or 6-membered aromatic heterocyclic radical having 1 or 2 nitrogen atoms as ring members.

R^(d), R^(2d) independently of each other are selected from C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl.

More preferably R^(d), R^(2d) independently of each other are selected from C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, and in particular selected from C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, C₂-C₄-alkynyl and C₃-C₆-cycloalkyl.

R^(e), R^(f), R^(2e), R^(2f) independently of each other are selected from the group consisting of hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partially or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl, where phenyl and benzyl are unsubstituted or substituted by 1, 2 or 3 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy, or R^(e) and R^(f) or R^(2e) and R^(2f) together with the nitrogen atom, to which they are bound may form a 5-, 6 or 7-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl and C₁-C₄-alkoxy.

More preferably R^(e), R^(f), R^(2e), R^(2f) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl and benzyl, or R^(e) and R^(f) or R^(2e) and R^(2f) together with the nitrogen atom, to which they are bound may form a 5- or 6-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2 or 3 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-haloalkyl.

In particular, R^(e), R^(f), R^(2e), R^(2f) independently of each other are selected from hydrogen and C₁-C₄-alkyl, or R^(e) and R^(f) or R^(2e) and R^(2f) together with the nitrogen atom, to which they are bound may form a 5- or 6-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2 or 3 methyl groups.

R^(g), R^(2g) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl and benzyl.

More preferably R^(g), R^(2g) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, benzyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, and in particular selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, benzyl and C₃-C₆-cycloalkyl.

R^(h), R^(2h) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, C₂-C₆-alkynyl, C₂-C₆-haloalkynyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, phenyl, benzyl and a radical C(═O)—R^(k), where FR is H, C₁-C₄-alkyl, C₁-C₄-haloalkyl or phenyl.

More preferably R^(h), R^(2h) independently of each other are selected from hydrogen, C₁-C₆-alkyl, C₁-C₆-haloalkyl, C₂-C₆-alkenyl, C₂-C₆-haloalkenyl, benzyl, C₁-C₄-alkoxy-C₁-C₄-alkyl and C₃-C₇-cycloalkyl, which is unsubstituted or partly or completely halogenated, and in particular selected from hydrogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₂-C₄-alkenyl, C₂-C₄-haloalkenyl, benzyl and C₃-C₆-cycloalkyl; or

R^(g) and R^(h) or R^(2g) and R^(2h) together with the nitrogen atom, to which they are bound may form a 5-, 6 or 7-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2, 3 or 4 groups, which are identical or different and selected from the group consisting of ═O, halogen, C₁-C₄-alkyl and C₁-C₄-haloalkyl and C₁-C₄-alkoxy;

more preferably R^(g) and R^(h) or R^(2g) and R^(2h) together with the nitrogen atom, to which they are bound may form a 5- or 6-membered, saturated or unsaturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2 or 3 groups, which are identical or different and selected from the group consisting of halogen, C₁-C₄-alkyl and C₁-C₄-haloalkyl;

and in particular, R^(g) and R^(h) or R^(2g) and R^(2h) together with the nitrogen atom, to which they are bound may form a 5- or 6-membered, saturated N-bound heterocyclic radical, which may carry as a ring member a further heteroatom selected from O, S and N and which is unsubstituted or may carry 1, 2 or 3 methyl groups.

n and k independently of each other are 0 or 2, and in particular 2.

Particularly preferred are compounds of formula I or formula II, wherein the variables R¹ and R³ have the following meanings:

R¹ is selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy-C₁-C₄-alkoxy-C₁-C₄-alkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-alkylthio, C₁-C₄-haloalkylthio and C₁-C₄-alkylsulfonyl, in particular from F, Cl, Br, CH₃, CF₃, OCH₃, SCH₃, OCF₃, SCF₃, SO₂CH₃, CH₂OCH₃ and CH₂OCH₂CH₂OCH₃; and

R³ is selected from the group consisting of hydrogen, halogen, CN, NO₂, C₁-C₄-alkyl, C₁-C₄-haloalkyl, C₁-C₄-alkoxy, C₁-C₄-haloalkoxy, C₁-C₄-haloalkylthio and C₁-C₄-alkylsulfonyl, in particular from H, Cl, F, CN, NO₂, CH₃, CF₃, CHF₂, OCH₃, OCF₃, OCHF₂, SCH₃, SCF₃, SCHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃.

Especially preferred are compounds of formula I, wherein the variables X, R¹, R², R³, R⁴ and R⁵ have the following meanings:

X is selected from the group consisting of C₁-C₄-alkyl and C₁-C₄-alkoxy, in particular from CH₃, CH₂CH₃, CH(CH₃)₂, C(CH₃)₃, OCH₃, OCH₂CH₃ and OCH(CH₃)₂;

R¹ is selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl and S(O)₂—C₁-C₄-alkyl, in particular from Cl, Br, F, CH₃, CH₂CH₃, CH(CH₃)₂, CF₃, CHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃;

R² is selected from the group consisting of hydrogen, C₁-C₂-alkoxy-C₁-C₂-alkyl, C₁-C₂-haloalkoxy-C₁-C₂-alkyl, S(O)₂—C₁-C₄-alkyl, isoxazolyl and isoxazolinyl, where the last two mentioned radicals may be substituted or carry 1 or 2 radicals selected from halogen and C₁-C₄-alkyl. In particular, R² is selected from CH₂OCH₃, CH₂OCH₂CH₃, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₃, CH₂OCF₃, CH₂OCHF₂, CH₂OCH₂F, CH₂OCH₂CHF₂, CH₂OCH₂CF₃, CH₂OCF₂CF₃, S(O)₂CH₃, S(O)₂CH₂CH₃, isoxazolyl and isoxazolinyl;

R³ is selected from the group consisting of halogen, CN, C₁-C₄-haloalkyl and S(O)₂—C₁-C₄-alkyl, in particular from Cl, F, CN, CF₃, CHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃;

R⁴ is selected from the group consisting of hydrogen, CN, CHF₂, CF₃, CH₃, NO₂ and halogen, in particular from hydrogen, CHF₂, CF₃, CH₃, CI and F; and

R⁵ is selected from the group consisting of hydrogen, halogen, CHF₂ and CF₃, in particular from hydrogen, Cl, F, CHF₂ and CF₃, provided that at least one of the radicals R⁴ and R⁵ is different from hydrogen.

Specifically preferred are compounds of formula I, wherein the variables X, R¹, R², R³, R⁴ and R⁵ have the following meanings:

X is selected from the group consisting of methyl, ethyl and methoxy;

R¹ is selected from the group consisting of chlorine, methyl, trifluoromethyl and methylsulfonyl;

R² is selected from the group consisting of hydrogen, methyl, methylsulfonyl, 3-isoxazolinyl, 5-methyl-3-isoxazolinyl, 5-isoxazolinyl, 3-methyl-5-isoxazolinyl, 3-isoxazolyl, 5-methyl-3-isoxazolyl, 5-isoxazolyl and 3-methyl-5-isoxazolyl;

R³ is selected from the group consisting of fluorine, chlorine, trifluoromethyl, CN and methylsulfonyl;

and either R⁴ is hydrogen and R⁵ is chlorine or fluorine, or R⁵ is hydrogen and R⁴ is chlorine or fluorine.

Especially preferred are compounds of formula II, wherein B is CH and the variables Y, R¹, R², R³, R⁴ and R⁵ have the following meanings:

Y is selected from C₁-C₄-alkyl, in particular from CH₃, CH₂CH₃, CH(CH₃)₂ and C(CH₃)₃;

R¹ is selected from the group consisting of halogen, C₁-C₄-alkyl, C₁-C₄-haloalkyl and C₁-C₄-alkyl-S(O)₂, in particular from Cl, Br, F, CH₃, CH₂CH₃, CH(CH₃)₂, CF₃, CHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃;

R² is selected from the group consisting of hydrogen, halogen, C₁-C₂-alkoxy-C₁-C₂-alkyl, C₁-C₂-haloalkoxy-C₁-C₂-alkyl, C₁-C₄-alkyl-S(O)₂, C₁-C₄-alkylthio, isoxazolyl and isoxazolinyl, where the last two mentioned radicals may be unsubstituted or carry 1 or 2 radicals selected from halogen and C₁-C₄-alkyl. In particular, R² is selected from CH₂OCH₃, CH₂OCH₂CH₃, CH₂CH₂OCH₃, CH₂CH₂OCH₂CH₃, CH₂OCF₃, CH₂OCHF₂, CH₂OCH₂F, CH₂OCH₂CHF₂, CH₂OCH₂CF₃, CH₂OCF₂CF₃, S(O)₂CH₃, S(O)₂CH₂CH₃, isoxazolyl and isoxazolinyl;

R³ is selected from the group consisting of hydrogen, halogen, CN, C₁-C₄-haloalkyl and C₁-C₄-alkyl-S(O)₂, in particular from Cl, F, CN, CF₃, CHF₂, S(O)₂CH₃ and S(O)₂CH₂CH₃;

R⁴ is selected from the group consisting of hydrogen, CN, CHF₂, CF₃, CH₃, NO₂ and halogen, in particular from hydrogen, CHF₂, CF₃, CH₃, Cl and F; and

R⁵ is selected from the group consisting of hydrogen, halogen, CHF₂ and CF₃, in particular from hydrogen, Cl, F, CHF₂ and CF₃, provided that at least one of the radicals R⁴ and R⁵ is different from hydrogen.

Specifically preferred are compounds of formula II, wherein B is CH and the variables Y, R¹, R², R³, R⁴ and R⁵ have the following meanings:

Y is selected from the group consisting of methyl and ethyl;

R¹ is selected from the group consisting of chlorine, methyl, trifluoromethyl and methylsulfonyl;

R² is selected from the group consisting of hydrogen, Cl, F, methyl, methylsulfonyl, methylsulfinyl, methylsulfanyl, 3-isoxazolinyl, 5-methyl-3-isoxazolinyl, 5-isoxazolinyl, 3-methyl-5-isoxazolinyl, 3-isoxazolyl, 5-methyl-3-isoxazolyl, 5-isoxazolyl and 3-methyl-5-isoxazolyl;

R³ is selected from the group consisting of hydrogen, fluorine, chlorine, trifluoromethyl, CN and methylsulfonyl;

and either R⁴ is hydrogen and R⁵ is chlorine or fluorine, or R⁵ is hydrogen and R⁴ is chlorine or fluorine.

Also specifically preferred are compounds of formula II, wherein B is CH and the variables Y, R¹, R², R³, R⁴ and R⁵ have the following meanings:

Y is selected from the group consisting of methoxyethyl and methoxymethyl;

R¹ is selected from the group consisting of chlorine, methyl, trifluoromethyl and methylsulfonyl;

R² is selected from the group consisting of hydrogen, Cl, F, methyl, methylsulfonyl, methylsulfinyl, methylsulfanyl, 3-isoxazolinyl, 5-methyl-3-isoxazolinyl, 5-isoxazolinyl, 3-methyl-5-isoxazolinyl, 3-isoxazolyl, 5-methyl-3-isoxazolyl, 5-isoxazolyl and 3-methyl-5-isoxazolyl;

R³ is selected from the group consisting of hydrogen, fluorine, chlorine, trifluoromethyl, CN and methylsulfonyl;

and either R⁴ is hydrogen and R⁵ is chlorine or fluorine, or R⁵ is hydrogen and R⁴ is chlorine or fluorine.

According to a preferred embodiment of the invention the radicals R¹, R², R³, R⁴ and R⁵ together form one of the following substitution patterns on the phenyl ring of compounds of formula I or formula II, provided that position 1 is the attachment point of the phenyl ring to the remainder of the molecule:

2-Br-4,6-Cl₂, 2,6-Cl₂-4-CN, 2,4,6-Cl₃, 2,6-Cl₂-4-F, 2,6-Cl₂-4-CF₃, 2,6-Cl₂-4-S(O)₂CH₃, 2-CF₃-4-CN-6-Cl, 2-CF₃-4,6-Cl₂, 2-CF₃-4-CF₃-6-Cl, 2-CF₃-4-S(O)₂CH₃-6-Cl, 2-CF₃-4-F-6-Cl, 2-CH₃—CN-6-Cl, 2-CH₃-4,6-Cl₂, 2-CH₃-4-CF₃-6-Cl, 2-CH₃-4-S(O)₂CH₃-6-Cl, 2-CH₃-4-F-6-Cl, 2-S(O)₂CH₃-4-CN-6-Cl, 2-S(O)₂CH₃-4,6-Cl₂, 2-S(O)₂CH₃-4-CF₃-6-Cl, 2-S(O)₂CH₃-4-S(O)₂CH₃-6-Cl, 2-S(O)₂CH₃-4-F-6-Cl, 2-Cl-4-CN-6-F, 2-Cl-4-CF₃-6-F, 2-Cl-4-S(O)₂CH₃-6-F, 2,4-Cl₂-6-F, 2-Cl-4,6-F₂, 2-CF₃-4-CN-6-F, 2-CF₃-4-CF₃-6-F, 2-CF₃-4-S(O)₂CH₃-6-F, 2-CF₃-4-Cl-6-F, 2-CF₃-4,6-F₂, 2-CH₃-4-CN-6-F, 2-CH₃-4-CF₃-6-F, 2-CH₃-4-S(O)₂CH₃-6-F, 2-CH₃-4-Cl-6-F, 2-CH₃-4,6-F₂, 2-S(O)₂CH₃-4-CN-6-F, 2-S(O)₂CH₃-4-CF₃-6-F, 2-S(O)₂CH₃-4-S(O)₂CH₃-6-F, 2-S(O)₂CH₃-4-Cl-6-F, 2-S(O)₂CH₃-4,6-F₂, 2,5-Cl₂- 4-CN, 2,4,5-Cl₃, 2,5-Cl₂-4-F, 2,5-Cl₂-4-CF₃, 2,5-Cl₂-4-S(O)₂CH₃, 2-CF₃-4-CN-5-Cl, 2-CF₃-4,5-C₂, 2-CF₃-4-CF₃-5-Cl, 2-CF₃-4-S(O)₂CH₃-5-Cl, 2-CF₃-4-F-5-Cl, 2-CH₃-4-CN-5-Cl, 2-CH₃-4,5-C₂, 2-CH₃-4-CF₃-5-Cl, 2-CH₃-4-S(O)₂CH₃-5-Cl, 2-CH₃-4-F-5-Cl, 2-S(O)₂CH₃-4-CN-5-Cl, 2-S(O)₂CH₃-4,5-C₂, 2-S(O)₂CH₃-4-CF₃-5-Cl, 2-S(O)₂CH₃-4-S(O)₂CH₃-5-Cl, 2-S(O)₂CH₃-4-F-5-Cl, 2-Cl-4-CN-5-F, 2-Cl-4-CF₃-5-F, 2-Cl-4-S(O)₂CH₃-5-F, 2,4-Cl₂-5-F, 2-C₁₋₄,5-F₂, 2-CF₃-4-CN-5-F, 2-CF₃-4-CF₃-5-F, 2-CF₃-4-S(O)₂CH₃-5-F, 2-CF₃-4-Cl-5-F, 2-CF₃-4,5-F₂, 2-CH₃-4-CN-5-F, 2-CH₃-4-CF₃-5-F, 2-CH₃-4-S(O)₂CH₃-5-F, 2-CH₃-4-Cl-5-F, 2-CH₃-4,5-F₂, 2-S(O)₂CH₃-4-CN-5-F, 2-S(O)₂CH₃-4-CF₃-5-F, 2-S(O)₂CH₃-4-S(O)₂CH₃-5-F, 2-S(O)₂CH₃-4-Cl-5-F or 2-S(O)₂CH₃-4,5-F₂.

According to another preferred embodiment of the invention the radicals R¹, R², R³, R⁴ and R⁵ together form one of the following substitution patterns on the phenyl ring of compounds of formula I or formula II, provided that position 1 is the attachment point of the phenyl ring to the remainder of the molecule:

2,6-Cl₂-3-(3-isoxazolinyl)-4-CN, 2,4,6-Cl₃-3-(3-isoxazolinyl), 2,6-Cl₂-3-(3-isoxazolinyl)-4-F, 2,6-Cl₂-(3-isoxazolinyl)-4-CF₃, 2,6-Cl₂-3-(3-isoxazolinyl)-4-S(O)₂CH₃, 2-CF₃-3-(3-isoxazolinyl)-4-CN-6-Cl, 2-CF₃-3-(3-isoxazolinyl)-4,6-Cl₂, 2-CF₃₋₃-(3-isoxazolinyl)-4-CF₃-6-Cl, 2-CF₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-6-Cl, 2-CF₃-3-(3-isoxazolinyl)-4-F-6-Cl, 2-CH₃-3-(3-isoxazlinyl)-4-CN-6-Cl, 2-CH₃-3-(3-isoxazolinyl)-4,6-Cl₂, 2-CH₃-3-(3-isoxazlinyl)-4-CF₃-6-Cl, 2-CH₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-6-Cl, 2-CH₃-3-(3-isoxazlinyl)-4-F-6-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CN-6-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4,6-Cl₂, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CF₃-6-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-6-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-F-6-Cl, 2-Cl-3-(3-isoxazolinyl)-4-CN-6-F, 2-Cl-3-(3-isoxazolinyl)-4-CF₃-6-F, 2-Cl-3-(3-isoxazolinyl)-4-S(O) 2C H₃-6-F, 2,4-Cl₂-3-(3-isoxazolinyl)-6-F, 2-Cl-3-(3-isoxazolinyl)-4,6-F₂, 2-CF₃-3-(3-isoxazolinyl)-4-CN-6-F, 2-CF₃-3-(3-isoxazolinyl)-4-CF₃-6-F, 2-CF₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-6-F, 2-CF₃-3-(3-isoxazolinyl)-4-Cl-6-F, 2-CF₃-3-(3-isoxazlinyl)-4,6-F₂, 2-CH₃-3-(3-isoxazolinyl)-4-CN-6-F, 2-CH₃-3-(3-isoxazolinyl)-4-CF₃-6-F, 2-CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-6-F, 2-CH₃-3-(3-isoxazolinyl)-4-Cl-6-F, 2-CH₃-3-(3-isoxazolinyl)-4,6-F₂, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CN-6-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CF₃-6-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-6-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-Cl-6-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4,6-F₂, 2,5-Cl₂-3-(3-isoxazolinyl)-4-CN, 2,4,5-Cl₃-3-(3-isoxazolinyl), 2,5-Cl₂-3-(3-isoxazolinyl)-4-F, 2,5-Cl₂-3-(3-isoxazolinyl)-4-CF₃, 2,5-Cl₂-3-(3-isoxazolinyl)-4-S(O)₂CH₃, 2-CF₃-3-(3-isoxazlinyl)-4-CN-5-Cl, 2-CF₃-3-(3-isoxazolinyl)-4,5-Cl₂, 2-CF₃-3-(3-isoxazlinyl)-4-CF₃-5-Cl, 2-CF₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-5-Cl, 2-CF₃-3-(3-isoxazlinyl)-4-F-5-Cl, 2-CH₃-3-(3-isoxazolinyl)-4-CN-5-Cl, 2-CH₃-3-(3-isoxazlinyl)-4,5-Cl₂, 2-CH₃-3-(3-isoxazolinyl)-4-CF₃-5-Cl, 2-CH₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-5-Cl, 2-CH₃-3-(3-isoxazolinyl)-4-F-5-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CN-5-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4,5-Cl₂, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CF₃-5-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-5-Cl, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-F-5-Cl, 2-Cl-3-(3-isoxazolinyl)-4-CN-5-F, 2-Cl-3-(3-isoxazolinyl)-4-CF₃-5-F, 2-Cl-3-(3-isoxazolinyl)-4-S(O)₂C H₃-5-F, 2,4-Cl₂-3-(3-isoxazolinyl)-5-F, 2-Cl-3-(3-isoxazolinyl)-4,5-F₂, 2-CF₃-3-(3-isoxazolinyl)-4-CN-5-F, 2-CF₃-3-(3-isoxazolinyl)-4-CF₃-5-F, 2-CF₃-3-(3-isoxazlinyl)-4-S(O)₂CH₃-5-F, 2-CF₃-3-(3-isoxazolinyl)-4-Cl-5-F, 2-CF₃-3-(3-isoxazlinyl)-4,5-F₂, 2-CH₃-3-(3-isoxazolinyl)-4-CN-5-F, 2-CH₃-3-(3-isoxazlinyl)-4-CF₃-5-F, 2-CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-5-F, 2-CH₃-3-(3-isoxazolinyl)-4-Cl-5-F, 2-CH₃-3-(3-isoxazolinyl)-4,5-F₂, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CN-5-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-CF₃-5-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-S(O)₂CH₃-5-F, 2-S(O)₂CH₃-3-(3-isoxazolinyl)-4-Cl-5-F, 2-S(O)₂CH₃-3-(3-isoxazlinyl)-4,5-F₂, 2,6-Cl₂-3-(CH₂—O—CH₂CF₃)-4-CN, 2,4,6-Cl₃-3-(3-isoxazolinyl), 2,6-Cl₂-3-(CH₂—O—CH₂CF₃)-4-F, 2,6-Cl₂-3-(CH₂—O—CH₂CF₃)-4-CF₃, 2,6-Cl₂-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4,6-C₂, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-F-6-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4,6-C₂, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-F-6-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4,6-C₂, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-F-6-Cl, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-CN-6-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-F, 2,4-Cl₂-3-(CH₂—O—CH₂CF₃)-6-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4,6-F₂, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-Cl-6-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)4,6-F₂, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-Cl-6-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)4,6-F₂, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-6-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-6-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-6-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-Cl-6-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)4,6- F₂, 2,5-Cl₂-3-(CH₂—O—CH₂CF₃)-4-CN, 2,4,5-Cl₃-3-(CH₂—O—CH₂CF₃), 2,5-Cl₂-3-(CH₂—O—CH₂CF₃)-4-F, 2,5-Cl₂-3-(CH₂—O—CH₂CF₃)-4-CF₃, 2,5-Cl₂-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4,5-C₂, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-Cl, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-F-5-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4,5-C₂, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-Cl, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-F-5-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4,5-Cl₂, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-Cl, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-F-5-Cl, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-CN-5-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-F, 2,4-Cl₂-3-(CH₂—O—CH₂CF₃)-5-F, 2-Cl-3-(CH₂—O—CH₂CF₃)-4,5-F₂, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4-Cl-5-F, 2-CF₃-3-(CH₂—O—CH₂CF₃)-4,5-F₂, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4-Cl-5-F, 2-CH₃-3-(CH₂—O—CH₂CF₃)-4,5-F₂, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CN-5-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-CF₃-5-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-S(O)₂CH₃-5-F, 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4-Cl-5-F or 2-S(O)₂CH₃-3-(CH₂—O—CH₂CF₃)-4,5- F₂.

Examples of preferred compounds are the individual compounds compiled in Tables 1 to 10 below. Moreover, the meanings mentioned below for the individual variables in the Tables are per se, independently of the combination in which they are mentioned, a particularly preferred embodiment of the substituents in question.

Table 1 Compounds of formula I (1.A-1-1.A-1442) in which X is methyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 2 Compounds of formula I (2.A-1-2.A-1442) in which X is ethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 3 Compounds of formula II (3.A-1-3.A-1442) in which B is CH and Y is methyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 4 Compounds of formula II (4.A-1-4.A-1442) in which B is CH and Y is ethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 5 Compounds of formula II (5.A-1-5.A-1442) in which B is CH and Y is methoxymethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 6 Compounds of formula II (6.A-1-6.A-1442) in which B is CH and Y is methoxyethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 7 Compounds of formula II (7.A-1-7.A-1442) in which B is N and Y is methyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 8 Compounds of formula II (8.A-1-8.A-1442) in which B is N and Y is ethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 9 Compounds of formula II (9.A-1-9.A-1442) in which B is N and Y is methoxymethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

Table 10 Compounds of formula II (10.A-1-10.A-1442) in which B is N and Y is methoxyethyl and the combination of R¹, R², R³, R⁴ and R⁵ for a compound corresponds in each case to one row of Table A;

TABLE A R¹ R² R³ R⁴ R⁵ A-1 Cl H Cl H F A-2 Cl H Cl H Cl A-3 Cl H Cl F F A-4 Cl H Cl F Cl A-5 Cl H Cl F H A-6 Cl H Cl Cl F A-7 Cl H Cl Cl Cl A-8 Cl H Cl Cl H A-9 Cl H F H F A-10 Cl H F H Cl A-11 Cl H F F F A-12 Cl H F F Cl A-13 Cl H F F H A-14 Cl H F Cl F A-15 Cl H F Cl Cl A-16 Cl H F Cl H A-17 Cl H CF₃ H F A-18 Cl H CF₃ H Cl A-19 Cl H CF₃ F F A-20 Cl H CF₃ F Cl A-21 Cl H CF₃ F H A-22 Cl H CF₃ Cl F A-23 Cl H CF₃ Cl Cl A-24 Cl H CF₃ Cl H A-25 Cl H SO₂CH₃ H F A-26 Cl H SO₂CH₃ H Cl A-27 Cl H SO₂CH₃ F F A-28 Cl H SO₂CH₃ F Cl A-29 Cl H SO₂CH₃ F H A-30 Cl H SO₂CH₃ Cl F A-31 Cl H SO₂CH₃ Cl Cl A-32 Cl H SO₂CH₃ Cl H A-33 Cl H CN H F A-34 Cl H CN H Cl A-35 Cl H CN F F A-36 Cl H CN F Cl A-37 Cl H CN F H A-38 Cl H CN Cl F A-39 Cl H CN Cl Cl A-40 Cl H CN Cl H A-41 Cl SO₂CH₃ Cl H F A-42 Cl SO₂CH₃ Cl H Cl A-43 Cl SO₂CH₃ Cl F F A-44 Cl SO₂CH₃ Cl F Cl A-45 Cl SO₂CH₃ Cl F H A-46 Cl SO₂CH₃ Cl Cl F A-47 Cl SO₂CH₃ Cl Cl Cl A-48 Cl SO₂CH₃ Cl Cl H A-49 Cl SO₂CH₃ F H F A-50 Cl SO₂CH₃ F H Cl A-51 Cl SO₂CH₃ F F F A-52 Cl SO₂CH₃ F F Cl A-53 Cl SO₂CH₃ F F H A-54 Cl SO₂CH₃ F Cl F A-55 Cl SO₂CH₃ F Cl Cl A-56 Cl SO₂CH₃ F Cl H A-57 Cl SO₂CH₃ CF₃ H F A-58 Cl SO₂CH₃ CF₃ H Cl A-59 Cl SO₂CH₃ CF₃ F F A-60 Cl SO₂CH₃ CF₃ F Cl A-61 Cl SO₂CH₃ CF₃ F H A-62 Cl SO₂CH₃ CF₃ Cl F A-63 Cl SO₂CH₃ CF₃ Cl Cl A-64 Cl SO₂CH₃ CF₃ Cl H A-65 Cl SO₂CH₃ SO₂CH₃ H F A-66 Cl SO₂CH₃ SO₂CH₃ H Cl A-67 Cl SO₂CH₃ SO₂CH₃ F F A-68 Cl SO₂CH₃ SO₂CH₃ F Cl A-69 Cl SO₂CH₃ SO₂CH₃ F H A-70 Cl SO₂CH₃ SO₂CH₃ Cl F A-71 Cl SO₂CH₃ SO₂CH₃ Cl Cl A-72 Cl SO₂CH₃ SO₂CH₃ Cl H A-73 Cl SO₂CH₃ CN H F A-74 Cl SO₂CH₃ CN H Cl A-75 Cl SO₂CH₃ CN F F A-76 Cl SO₂CH₃ CN F Cl A-77 Cl SO₂CH₃ CN F H A-78 Cl SO₂CH₃ CN Cl F A-79 Cl SO₂CH₃ CN Cl Cl A-80 Cl SO₂CH₃ CN Cl H A-81 Cl CH₂OCH₂CF₃ Cl H F A-82 Cl CH₂OCH₂CF₃ Cl H Cl A-83 Cl CH₂OCH₂CF₃ Cl F F A-84 Cl CH₂OCH₂CF₃ Cl F Cl A-85 Cl CH₂OCH₂CF₃ Cl F H A-86 Cl CH₂OCH₂CF₃ Cl Cl F A-87 Cl CH₂OCH₂CF₃ Cl Cl Cl A-88 Cl CH₂OCH₂CF₃ Cl Cl H A-89 Cl CH₂OCH₂CF₃ F H F A-90 Cl CH₂OCH₂CF₃ F H Cl A-91 Cl CH₂OCH₂CF₃ F F F A-92 Cl CH₂OCH₂CF₃ F F Cl A-93 Cl CH₂OCH₂CF₃ F F H A-94 Cl CH₂OCH₂CF₃ F Cl F A-95 Cl CH₂OCH₂CF₃ F Cl Cl A-96 Cl CH₂OCH₂CF₃ F Cl H A-97 Cl CH₂OCH₂CF₃ CF₃ H F A-98 Cl CH₂OCH₂CF₃ CF₃ H Cl A-99 Cl CH₂OCH₂CF₃ CF₃ F F A-100 Cl CH₂OCH₂CF₃ CF₃ F Cl A-101 Cl CH₂OCH₂CF₃ CF₃ F H A-102 Cl CH₂OCH₂CF₃ CF₃ Cl F A-103 Cl CH₂OCH₂CF₃ CF₃ Cl Cl A-104 Cl CH₂OCH₂CF₃ CF₃ Cl H A-105 Cl CH₂OCH₂CF₃ SO₂CH₃ H F A-106 Cl CH₂OCH₂CF₃ SO₂CH₃ H Cl A-107 Cl CH₂OCH₂CF₃ SO₂CH₃ F F A-108 Cl CH₂OCH₂CF₃ SO₂CH₃ F Cl A-109 Cl CH₂OCH₂CF₃ SO₂CH₃ F H A-110 Cl CH₂OCH₂CF₃ SO₂CH₃ Cl F A-111 Cl CH₂OCH₂CF₃ SO₂CH₃ Cl Cl A-112 Cl CH₂OCH₂CF₃ SO₂CH₃ Cl H A-113 Cl CH₂OCH₂CF₃ CN H F A-114 Cl CH₂OCH₂CF₃ CN H Cl A-115 Cl CH₂OCH₂CF₃ CN F F A-116 Cl CH₂OCH₂CF₃ CN F Cl A-117 Cl CH₂OCH₂CF₃ CN F H A-118 Cl CH₂OCH₂CF₃ CN Cl F A-119 Cl CH₂OCH₂CF₃ CN Cl Cl A-120 Cl CH₂OCH₂CF₃ CN Cl H A-121 Cl Isoxazolin-3-yl Cl H F A-122 Cl Isoxazolin-3-yl Cl H Cl A-123 Cl Isoxazolin-3-yl Cl F F A-124 Cl Isoxazolin-3-yl Cl F Cl A-125 Cl Isoxazolin-3-yl Cl F H A-126 Cl Isoxazolin-3-yl Cl Cl F A-127 Cl Isoxazolin-3-yl Cl Cl Cl A-128 Cl Isoxazolin-3-yl Cl Cl H A-129 Cl Isoxazolin-3-yl F H F A-130 Cl Isoxazolin-3-yl F H Cl A-131 Cl Isoxazolin-3-yl F F F A-132 Cl Isoxazolin-3-yl F F Cl A-133 Cl Isoxazolin-3-yl F F H A-134 Cl Isoxazolin-3-yl F Cl F A-135 Cl Isoxazolin-3-yl F Cl Cl A-136 Cl Isoxazolin-3-yl F Cl H A-137 Cl Isoxazolin-3-yl CF₃ H F A-138 Cl Isoxazolin-3-yl CF₃ H Cl A-139 Cl Isoxazolin-3-yl CF₃ F F A-140 Cl Isoxazolin-3-yl CF₃ F Cl A-141 Cl Isoxazolin-3-yl CF₃ F H A-142 Cl Isoxazolin-3-yl CF₃ Cl F A-143 Cl Isoxazolin-3-yl CF₃ Cl Cl A-144 Cl Isoxazolin-3-yl CF₃ Cl H A-145 Cl Isoxazolin-3-yl SO₂CH₃ H F A-146 Cl Isoxazolin-3-yl SO₂CH₃ H Cl A-147 Cl Isoxazolin-3-yl SO₂CH₃ F F A-148 Cl Isoxazolin-3-yl SO₂CH₃ F Cl A-149 Cl Isoxazolin-3-yl SO₂CH₃ F H A-150 Cl Isoxazolin-3-yl SO₂CH₃ Cl F A-151 Cl Isoxazolin-3-yl SO₂CH₃ Cl Cl A-152 Cl Isoxazolin-3-yl SO₂CH₃ Cl H A-153 Cl Isoxazolin-3-yl CN H F A-154 Cl Isoxazolin-3-yl CN H Cl A-155 Cl Isoxazolin-3-yl CN F F A-156 Cl Isoxazolin-3-yl CN F Cl A-157 Cl Isoxazolin-3-yl CN F H A-158 Cl Isoxazolin-3-yl CN Cl F A-159 Cl Isoxazolin-3-yl CN Cl Cl A-160 Cl Isoxazolin-3-yl CN Cl H A-161 Cl 5-Methyl-isoxazolin-3-yl Cl H F A-162 Cl 5-Methyl-isoxazolin-3-yl Cl H Cl A-163 Cl 5-Methyl-isoxazolin-3-yl Cl F F A-164 Cl 5-Methyl-isoxazolin-3-yl Cl F Cl A-165 Cl 5-Methyl-isoxazolin-3-yl Cl F H A-166 Cl 5-Methyl-isoxazolin-3-yl Cl Cl F A-167 Cl 5-Methyl-isoxazolin-3-yl Cl Cl Cl A-168 Cl 5-Methyl-isoxazolin-3-yl Cl Cl H A-169 Cl 5-Methyl-isoxazolin-3-yl F H F A-170 Cl 5-Methyl-isoxazolin-3-yl F H Cl A-171 Cl 5-Methyl-isoxazolin-3-yl F F F A-172 Cl 5-Methyl-isoxazolin-3-yl F F Cl A-173 Cl 5-Methyl-isoxazolin-3-yl F F H A-174 Cl 5-Methyl-isoxazolin-3-yl F Cl F A-175 Cl 5-Methyl-isoxazolin-3-yl F Cl Cl A-176 Cl 5-Methyl-isoxazolin-3-yl F Cl H A-177 Cl 5-Methyl-isoxazolin-3-yl CF₃ H F A-178 Cl 5-Methyl-isoxazolin-3-yl CF₃ H Cl A-179 Cl 5-Methyl-isoxazolin-3-yl CF₃ F F A-180 Cl 5-Methyl-isoxazolin-3-yl CF₃ F Cl A-181 Cl 5-Methyl-isoxazolin-3-yl CF₃ F H A-182 Cl 5-Methyl-isoxazolin-3-yl CF₃ Cl F A-183 Cl 5-Methyl-isoxazolin-3-yl CF₃ Cl Cl A-184 Cl 5-Methyl-isoxazolin-3-yl CF₃ Cl H A-185 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ H F A-186 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ H Cl A-187 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ F F A-188 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ F Cl A-189 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ F H A-190 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl F A-191 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl Cl A-192 Cl 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl H A-193 Cl 5-Methyl-isoxazolin-3-yl CN H F A-194 Cl 5-Methyl-isoxazolin-3-yl CN H Cl A-195 Cl 5-Methyl-isoxazolin-3-yl CN F F A-196 Cl 5-Methyl-isoxazolin-3-yl CN F Cl A-197 Cl 5-Methyl-isoxazolin-3-yl CN F H A-198 Cl 5-Methyl-isoxazolin-3-yl CN Cl F A-199 Cl 5-Methyl-isoxazolin-3-yl CN Cl Cl A-200 Cl 5-Methyl-isoxazolin-3-yl CN Cl H A-201 Cl Isoxazol-3-yl Cl H F A-202 Cl Isoxazol-3-yl Cl H Cl A-203 Cl Isoxazol-3-yl Cl F F A-204 Cl Isoxazol-3-yl Cl F Cl A-205 Cl Isoxazol-3-yl Cl F H A-206 Cl Isoxazol-3-yl Cl Cl F A-207 Cl Isoxazol-3-yl Cl Cl Cl A-208 Cl Isoxazol-3-yl Cl Cl H A-209 Cl Isoxazol-3-yl F H F A-210 Cl Isoxazol-3-yl F H Cl A-211 Cl Isoxazol-3-yl F F F A-212 Cl Isoxazol-3-yl F F Cl A-213 Cl Isoxazol-3-yl F F H A-214 Cl Isoxazol-3-yl F Cl F A-215 Cl Isoxazol-3-yl F Cl Cl A-216 Cl Isoxazol-3-yl F Cl H A-217 Cl Isoxazol-3-yl CF₃ H F A-218 Cl Isoxazol-3-yl CF₃ H Cl A-219 Cl Isoxazol-3-yl CF₃ F F A-220 Cl Isoxazol-3-yl CF₃ F Cl A-221 Cl Isoxazol-3-yl CF₃ F H A-222 Cl Isoxazol-3-yl CF₃ Cl F A-223 Cl Isoxazol-3-yl CF₃ Cl Cl A-224 Cl Isoxazol-3-yl CF₃ Cl H A-225 Cl Isoxazol-3-yl SO₂CH₃ H F A-226 Cl Isoxazol-3-yl SO₂CH₃ H Cl A-227 Cl Isoxazol-3-yl SO₂CH₃ F F A-228 Cl Isoxazol-3-yl SO₂CH₃ F Cl A-229 Cl Isoxazol-3-yl SO₂CH₃ F H A-230 Cl Isoxazol-3-yl SO₂CH₃ Cl F A-231 Cl Isoxazol-3-yl SO₂CH₃ Cl Cl A-232 Cl Isoxazol-3-yl SO₂CH₃ Cl H A-233 Cl Isoxazol-3-yl CN H F A-234 Cl Isoxazol-3-yl CN H Cl A-235 Cl Isoxazol-3-yl CN F F A-236 Cl Isoxazol-3-yl CN F Cl A-237 Cl Isoxazol-3-yl CN F H A-238 Cl Isoxazol-3-yl CN Cl F A-239 Cl Isoxazol-3-yl CN Cl Cl A-240 Cl Isoxazol-3-yl CN Cl H A-241 Cl 5-Methyl-isoxazol-3-yl Cl H F A-242 Cl 5-Methyl-isoxazol-3-yl Cl H Cl A-243 Cl 5-Methyl-isoxazol-3-yl Cl F F A-244 Cl 5-Methyl-isoxazol-3-yl Cl F Cl A-245 Cl 5-Methyl-isoxazol-3-yl Cl F H A-246 Cl 5-Methyl-isoxazol-3-yl Cl Cl F A-247 Cl 5-Methyl-isoxazol-3-yl Cl Cl Cl A-248 Cl 5-Methyl-isoxazol-3-yl Cl Cl H A-249 Cl 5-Methyl-isoxazol-3-yl F H F A-250 Cl 5-Methyl-isoxazol-3-yl F H Cl A-251 Cl 5-Methyl-isoxazol-3-yl F F F A-252 Cl 5-Methyl-isoxazol-3-yl F F Cl A-253 Cl 5-Methyl-isoxazol-3-yl F F H A-254 Cl 5-Methyl-isoxazol-3-yl F Cl F A-255 Cl 5-Methyl-isoxazol-3-yl F Cl Cl A-256 Cl 5-Methyl-isoxazol-3-yl F Cl H A-257 Cl 5-Methyl-isoxazol-3-yl CF₃ H F A-258 Cl 5-Methyl-isoxazol-3-yl CF₃ H Cl A-259 Cl 5-Methyl-isoxazol-3-yl CF₃ F F A-260 Cl 5-Methyl-isoxazol-3-yl CF₃ F Cl A-261 Cl 5-Methyl-isoxazol-3-yl CF₃ F H A-262 Cl 5-Methyl-isoxazol-3-yl CF₃ Cl F A-263 Cl 5-Methyl-isoxazol-3-yl CF₃ Cl Cl A-264 Cl 5-Methyl-isoxazol-3-yl CF₃ Cl H A-265 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ H F A-266 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ H Cl A-267 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ F F A-268 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ F Cl A-269 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ F H A-270 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl F A-271 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl Cl A-272 Cl 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl H A-273 Cl 5-Methyl-isoxazol-3-yl CN H F A-274 Cl 5-Methyl-isoxazol-3-yl CN H Cl A-275 Cl 5-Methyl-isoxazol-3-yl CN F F A-276 Cl 5-Methyl-isoxazol-3-yl CN F Cl A-277 Cl 5-Methyl-isoxazol-3-yl CN F H A-278 Cl 5-Methyl-isoxazol-3-yl CN Cl F A-279 Cl 5-Methyl-isoxazol-3-yl CN Cl Cl A-280 Cl 5-Methyl-isoxazol-3-yl CN Cl H A-281 Cl 3-Methyl-isoxazolin-5-yl Cl H F A-282 Cl 3-Methyl-isoxazolin-5-yl Cl H Cl A-283 Cl 3-Methyl-isoxazolin-5-yl Cl F F A-284 Cl 3-Methyl-isoxazolin-5-yl Cl F Cl A-285 Cl 3-Methyl-isoxazolin-5-yl Cl F H A-286 Cl 3-Methyl-isoxazolin-5-yl Cl Cl F A-287 Cl 3-Methyl-isoxazolin-5-yl Cl Cl Cl A-288 Cl 3-Methyl-isoxazolin-5-yl Cl Cl H A-289 Cl 3-Methyl-isoxazolin-5-yl F H F A-290 Cl 3-Methyl-isoxazolin-5-yl F H Cl A-291 Cl 3-Methyl-isoxazolin-5-yl F F F A-292 Cl 3-Methyl-isoxazolin-5-yl F F Cl A-293 Cl 3-Methyl-isoxazolin-5-yl F F H A-294 Cl 3-Methyl-isoxazolin-5-yl F Cl F A-295 Cl 3-Methyl-isoxazolin-5-yl F Cl Cl A-296 Cl 3-Methyl-isoxazolin-5-yl F Cl H A-297 Cl 3-Methyl-isoxazolin-5-yl CF₃ H F A-298 Cl 3-Methyl-isoxazolin-5-yl CF₃ H Cl A-299 Cl 3-Methyl-isoxazolin-5-yl CF₃ F F A-300 Cl 3-Methyl-isoxazolin-5-yl CF₃ F Cl A-301 Cl 3-Methyl-isoxazolin-5-yl CF₃ F H A-302 Cl 3-Methyl-isoxazolin-5-yl CF₃ Cl F A-303 Cl 3-Methyl-isoxazolin-5-yl CF₃ Cl Cl A-304 Cl 3-Methyl-isoxazolin-5-yl CF₃ Cl H A-305 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ H F A-306 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ H Cl A-307 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ F F A-308 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ F Cl A-309 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ F H A-310 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl F A-311 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl Cl A-312 Cl 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl H A-313 Cl 3-Methyl-isoxazolin-5-yl CN H F A-314 Cl 3-Methyl-isoxazolin-5-yl CN H Cl A-315 Cl 3-Methyl-isoxazolin-5-yl CN F F A-316 Cl 3-Methyl-isoxazolin-5-yl CN F Cl A-317 Cl 3-Methyl-isoxazolin-5-yl CN F H A-318 Cl 3-Methyl-isoxazolin-5-yl CN Cl F A-319 Cl 3-Methyl-isoxazolin-5-yl CN Cl Cl A-320 Cl 3-Methyl-isoxazolin-5-yl CN Cl H A-321 Cl 3-Methyl-isoxazol-5-yl Cl H F A-322 Cl 3-Methyl-isoxazol-5-yl Cl H Cl A-323 Cl 3-Methyl-isoxazol-5-yl Cl F F A-324 Cl 3-Methyl-isoxazol-5-yl Cl F Cl A-325 Cl 3-Methyl-isoxazol-5-yl Cl F H A-326 Cl 3-Methyl-isoxazol-5-yl Cl Cl F A-327 Cl 3-Methyl-isoxazol-5-yl Cl Cl Cl A-328 Cl 3-Methyl-isoxazol-5-yl Cl Cl H A-329 Cl 3-Methyl-isoxazol-5-yl F H F A-330 Cl 3-Methyl-isoxazol-5-yl F H Cl A-331 Cl 3-Methyl-isoxazol-5-yl F F F A-332 Cl 3-Methyl-isoxazol-5-yl F F Cl A-333 Cl 3-Methyl-isoxazol-5-yl F F H A-334 Cl 3-Methyl-isoxazol-5-yl F Cl F A-335 Cl 3-Methyl-isoxazol-5-yl F Cl Cl A-336 Cl 3-Methyl-isoxazol-5-yl F Cl H A-337 Cl 3-Methyl-isoxazol-5-yl CF₃ H F A-338 Cl 3-Methyl-isoxazol-5-yl CF₃ H Cl A-339 Cl 3-Methyl-isoxazol-5-yl CF₃ F F A-340 Cl 3-Methyl-isoxazol-5-yl CF₃ F Cl A-341 Cl 3-Methyl-isoxazol-5-yl CF₃ F H A-342 Cl 3-Methyl-isoxazol-5-yl CF₃ Cl F A-343 Cl 3-Methyl-isoxazol-5-yl CF₃ Cl Cl A-344 Cl 3-Methyl-isoxazol-5-yl CF₃ Cl H A-345 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ H F A-346 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ H Cl A-347 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ F F A-348 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ F Cl A-349 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ F H A-350 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl F A-351 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl Cl A-352 Cl 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl H A-353 Cl 3-Methyl-isoxazol-5-yl CN H F A-354 Cl 3-Methyl-isoxazol-5-yl CN H Cl A-355 Cl 3-Methyl-isoxazol-5-yl CN F F A-356 Cl 3-Methyl-isoxazol-5-yl CN F Cl A-357 Cl 3-Methyl-isoxazol-5-yl CN F H A-358 Cl 3-Methyl-isoxazol-5-yl CN Cl F A-359 Cl 3-Methyl-isoxazol-5-yl CN Cl Cl A-360 Cl 3-Methyl-isoxazol-5-yl CN Cl H A-361 CH₃ H Cl H F A-362 CH₃ H Cl H Cl A-363 CH₃ H Cl F F A-364 CH₃ H Cl F Cl A-365 CH₃ H Cl F H A-366 CH₃ H Cl Cl F A-367 CH₃ H Cl Cl Cl A-368 CH₃ H Cl Cl H A-369 CH₃ H F H F A-370 CH₃ H F H Cl A-371 CH₃ H F F F A-372 CH₃ H F F Cl A-373 CH₃ H F F H A-374 CH₃ H F Cl F A-375 CH₃ H F Cl Cl A-376 CH₃ H F Cl H A-377 CH₃ H CF₃ H F A-378 CH₃ H CF₃ H Cl A-379 CH₃ H CF₃ F F A-380 CH₃ H CF₃ F Cl A-381 CH₃ H CF₃ F H A-382 CH₃ H CF₃ Cl F A-383 CH₃ H CF₃ Cl Cl A-384 CH₃ H CF₃ Cl H A-385 CH₃ H SO₂CH₃ H F A-386 CH₃ H SO₂CH₃ H Cl A-387 CH₃ H SO₂CH₃ F F A-388 CH₃ H SO₂CH₃ F Cl A-389 CH₃ H SO₂CH₃ F H A-390 CH₃ H SO₂CH₃ Cl F A-391 CH₃ H SO₂CH₃ Cl Cl A-392 CH₃ H SO₂CH₃ Cl H A-393 CH₃ H CN H F A-394 CH₃ H CN H Cl A-395 CH₃ H CN F F A-396 CH₃ H CN F Cl A-397 CH₃ H CN F H A-398 CH₃ H CN Cl F A-399 CH₃ H CN Cl Cl A-400 CH₃ H CN Cl H A-401 CH₃ SO₂CH₃ Cl H F A-402 CH₃ SO₂CH₃ Cl H Cl A-403 CH₃ SO₂CH₃ Cl F F A-404 CH₃ SO₂CH₃ Cl F Cl A-405 CH₃ SO₂CH₃ Cl F H A-406 CH₃ SO₂CH₃ Cl Cl F A-407 CH₃ SO₂CH₃ Cl Cl Cl A-408 CH₃ SO₂CH₃ Cl Cl H A-409 CH₃ SO₂CH₃ F H F A-410 CH₃ SO₂CH₃ F H Cl A-411 CH₃ SO₂CH₃ F F F A-412 CH₃ SO₂CH₃ F F Cl A-413 CH₃ SO₂CH₃ F F H A-414 CH₃ SO₂CH₃ F Cl F A-415 CH₃ SO₂CH₃ F Cl Cl A-416 CH₃ SO₂CH₃ F Cl H A-417 CH₃ SO₂CH₃ CF₃ H F A-418 CH₃ SO₂CH₃ CF₃ H Cl A-419 CH₃ SO₂CH₃ CF₃ F F A-420 CH₃ SO₂CH₃ CF₃ F Cl A-421 CH₃ SO₂CH₃ CF₃ F H A-422 CH₃ SO₂CH₃ CF₃ Cl F A-423 CH₃ SO₂CH₃ CF₃ Cl Cl A-424 CH₃ SO₂CH₃ CF₃ Cl H A-425 CH₃ SO₂CH₃ SO₂CH₃ H F A-426 CH₃ SO₂CH₃ SO₂CH₃ H Cl A-427 CH₃ SO₂CH₃ SO₂CH₃ F F A-428 CH₃ SO₂CH₃ SO₂CH₃ F Cl A-429 CH₃ SO₂CH₃ SO₂CH₃ F H A-430 CH₃ SO₂CH₃ SO₂CH₃ Cl F A-431 CH₃ SO₂CH₃ SO₂CH₃ Cl Cl A-432 CH₃ SO₂CH₃ SO₂CH₃ Cl H A-433 CH₃ SO₂CH₃ CN H F A-434 CH₃ SO₂CH₃ CN H Cl A-435 CH₃ SO₂CH₃ CN F F A-436 CH₃ SO₂CH₃ CN F Cl A-437 CH₃ SO₂CH₃ CN F H A-438 CH₃ SO₂CH₃ CN Cl F A-439 CH₃ SO₂CH₃ CN Cl Cl A-440 CH₃ SO₂CH₃ CN Cl H A-441 CH₃ CH₂OCH₂CF₃ Cl H F A-442 CH₃ CH₂OCH₂CF₃ Cl H Cl A-443 CH₃ CH₂OCH₂CF₃ Cl F F A-444 CH₃ CH₂OCH₂CF₃ Cl F Cl A-445 CH₃ CH₂OCH₂CF₃ Cl F H A-446 CH₃ CH₂OCH₂CF₃ Cl Cl F A-447 CH₃ CH₂OCH₂CF₃ Cl Cl Cl A-448 CH₃ CH₂OCH₂CF₃ Cl Cl H A-449 CH₃ CH₂OCH₂CF₃ F H F A-450 CH₃ CH₂OCH₂CF₃ F H Cl A-451 CH₃ CH₂OCH₂CF₃ F F F A-452 CH₃ CH₂OCH₂CF₃ F F Cl A-453 CH₃ CH₂OCH₂CF₃ F F H A-454 CH₃ CH₂OCH₂CF₃ F Cl F A-455 CH₃ CH₂OCH₂CF₃ F Cl Cl A-456 CH₃ CH₂OCH₂CF₃ F Cl H A-457 CH₃ CH₂OCH₂CF₃ CF₃ H F A-458 CH₃ CH₂OCH₂CF₃ CF₃ H Cl A-459 CH₃ CH₂OCH₂CF₃ CF₃ F F A-460 CH₃ CH₂OCH₂CF₃ CF₃ F Cl A-461 CH₃ CH₂OCH₂CF₃ CF₃ F H A-462 CH₃ CH₂OCH₂CF₃ CF₃ Cl F A-463 CH₃ CH₂OCH₂CF₃ CF₃ Cl Cl A-464 CH₃ CH₂OCH₂CF₃ CF₃ Cl H A-465 CH₃ CH₂OCH₂CF₃ SO₂CH₃ H F A-466 CH₃ CH₂OCH₂CF₃ SO₂CH₃ H Cl A-467 CH₃ CH₂OCH₂CF₃ SO₂CH₃ F F A-468 CH₃ CH₂OCH₂CF₃ SO₂CH₃ F Cl A-469 CH₃ CH₂OCH₂CF₃ SO₂CH₃ F H A-470 CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl F A-471 CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl Cl A-472 CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl H A-473 CH₃ CH₂OCH₂CF₃ CN H F A-474 CH₃ CH₂OCH₂CF₃ CN H Cl A-475 CH₃ CH₂OCH₂CF₃ CN F F A-476 CH₃ CH₂OCH₂CF₃ CN F Cl A-477 CH₃ CH₂OCH₂CF₃ CN F H A-478 CH₃ CH₂OCH₂CF₃ CN Cl F A-479 CH₃ CH₂OCH₂CF₃ CN Cl Cl A-480 CH₃ CH₂OCH₂CF₃ CN Cl H A-481 CH₃ Isoxazolin-3-yl Cl H F A-482 CH₃ Isoxazolin-3-yl Cl H Cl A-483 CH₃ Isoxazolin-3-yl Cl F F A-484 CH₃ Isoxazolin-3-yl Cl F Cl A-485 CH₃ Isoxazolin-3-yl Cl F H A-486 CH₃ Isoxazolin-3-yl Cl Cl F A-487 CH₃ Isoxazolin-3-yl Cl Cl Cl A-488 CH₃ Isoxazolin-3-yl Cl Cl H A-489 CH₃ Isoxazolin-3-yl F H F A-490 CH₃ Isoxazolin-3-yl F H Cl A-491 CH₃ Isoxazolin-3-yl F F F A-492 CH₃ Isoxazolin-3-yl F F Cl A-493 CH₃ Isoxazolin-3-yl F F H A-494 CH₃ Isoxazolin-3-yl F Cl F A-495 CH₃ Isoxazolin-3-yl F Cl Cl A-496 CH₃ Isoxazolin-3-yl F Cl H A-497 CH₃ Isoxazolin-3-yl CF₃ H F A-498 CH₃ Isoxazolin-3-yl CF₃ H Cl A-499 CH₃ Isoxazolin-3-yl CF₃ F F A-500 CH₃ Isoxazolin-3-yl CF₃ F Cl A-501 CH₃ Isoxazolin-3-yl CF₃ F H A-502 CH₃ Isoxazolin-3-yl CF₃ Cl F A-503 CH₃ Isoxazolin-3-yl CF₃ Cl Cl A-504 CH₃ Isoxazolin-3-yl CF₃ Cl H A-505 CH₃ Isoxazolin-3-yl SO₂CH₃ H F A-506 CH₃ Isoxazolin-3-yl SO₂CH₃ H Cl A-507 CH₃ Isoxazolin-3-yl SO₂CH₃ F F A-508 CH₃ Isoxazolin-3-yl SO₂CH₃ F Cl A-509 CH₃ Isoxazolin-3-yl SO₂CH₃ F H A-510 CH₃ Isoxazolin-3-yl SO₂CH₃ Cl F A-511 CH₃ Isoxazolin-3-yl SO₂CH₃ Cl Cl A-512 CH₃ Isoxazolin-3-yl SO₂CH₃ Cl H A-513 CH₃ Isoxazolin-3-yl CN H F A-514 CH₃ Isoxazolin-3-yl CN H Cl A-515 CH₃ Isoxazolin-3-yl CN F F A-516 CH₃ Isoxazolin-3-yl CN F Cl A-517 CH₃ Isoxazolin-3-yl CN F H A-518 CH₃ Isoxazolin-3-yl CN Cl F A-519 CH₃ Isoxazolin-3-yl CN Cl Cl A-520 CH₃ Isoxazolin-3-yl CN Cl H A-521 CH₃ 5-Methyl-isoxazolin-3-yl Cl H F A-522 CH₃ 5-Methyl-isoxazolin-3-yl Cl H Cl A-523 CH₃ 5-Methyl-isoxazolin-3-yl Cl F F A-524 CH₃ 5-Methyl-isoxazolin-3-yl Cl F Cl A-525 CH₃ 5-Methyl-isoxazolin-3-yl Cl F H A-526 CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl F A-527 CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl Cl A-528 CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl H A-529 CH₃ 5-Methyl-isoxazolin-3-yl F H F A-530 CH₃ 5-Methyl-isoxazolin-3-yl F H Cl A-531 CH₃ 5-Methyl-isoxazolin-3-yl F F F A-532 CH₃ 5-Methyl-isoxazolin-3-yl F F Cl A-533 CH₃ 5-Methyl-isoxazolin-3-yl F F H A-534 CH₃ 5-Methyl-isoxazolin-3-yl F Cl F A-535 CH₃ 5-Methyl-isoxazolin-3-yl F Cl Cl A-536 CH₃ 5-Methyl-isoxazolin-3-yl F Cl H A-537 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ H F A-538 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ H Cl A-539 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F F A-540 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F Cl A-541 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F H A-542 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl F A-543 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl Cl A-544 CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl H A-545 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H F A-546 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H Cl A-547 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F F A-548 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F Cl A-549 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F H A-550 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl F A-551 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl Cl A-552 CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl H A-553 CH₃ 5-Methyl-isoxazolin-3-yl CN H F A-554 CH₃ 5-Methyl-isoxazolin-3-yl CN H Cl A-555 CH₃ 5-Methyl-isoxazolin-3-yl CN F F A-556 CH₃ 5-Methyl-isoxazolin-3-yl CN F Cl A-557 CH₃ 5-Methyl-isoxazolin-3-yl CN F H A-558 CH₃ 5-Methyl-isoxazolin-3-yl CN Cl F A-559 CH₃ 5-Methyl-isoxazolin-3-yl CN Cl Cl A-560 CH₃ 5-Methyl-isoxazolin-3-yl CN Cl H A-561 CH₃ Isoxazol-3-yl Cl H F A-562 CH₃ Isoxazol-3-yl Cl H Cl A-563 CH₃ Isoxazol-3-yl Cl F F A-564 CH₃ Isoxazol-3-yl Cl F Cl A-565 CH₃ Isoxazol-3-yl Cl F H A-566 CH₃ Isoxazol-3-yl Cl Cl F A-567 CH₃ Isoxazol-3-yl Cl Cl Cl A-568 CH₃ Isoxazol-3-yl Cl Cl H A-569 CH₃ Isoxazol-3-yl F H F A-570 CH₃ Isoxazol-3-yl F H Cl A-571 CH₃ Isoxazol-3-yl F F F A-572 CH₃ Isoxazol-3-yl F F Cl A-573 CH₃ Isoxazol-3-yl F F H A-574 CH₃ Isoxazol-3-yl F Cl F A-575 CH₃ Isoxazol-3-yl F Cl Cl A-576 CH₃ Isoxazol-3-yl F Cl H A-577 CH₃ Isoxazol-3-yl CF₃ H F A-578 CH₃ Isoxazol-3-yl CF₃ H Cl A-579 CH₃ Isoxazol-3-yl CF₃ F F A-580 CH₃ Isoxazol-3-yl CF₃ F Cl A-581 CH₃ Isoxazol-3-yl CF₃ F H A-582 CH₃ Isoxazol-3-yl CF₃ Cl F A-583 CH₃ Isoxazol-3-yl CF₃ Cl Cl A-584 CH₃ Isoxazol-3-yl CF₃ Cl H A-585 CH₃ Isoxazol-3-yl SO₂CH₃ H F A-586 CH₃ Isoxazol-3-yl SO₂CH₃ H Cl A-587 CH₃ Isoxazol-3-yl SO₂CH₃ F F A-588 CH₃ Isoxazol-3-yl SO₂CH₃ F Cl A-589 CH₃ Isoxazol-3-yl SO₂CH₃ F H A-590 CH₃ Isoxazol-3-yl SO₂CH₃ Cl F A-591 CH₃ Isoxazol-3-yl SO₂CH₃ Cl Cl A-592 CH₃ Isoxazol-3-yl SO₂CH₃ Cl H A-593 CH₃ Isoxazol-3-yl CN H F A-594 CH₃ Isoxazol-3-yl CN H Cl A-595 CH₃ Isoxazol-3-yl CN F F A-596 CH₃ Isoxazol-3-yl CN F Cl A-597 CH₃ Isoxazol-3-yl CN F H A-598 CH₃ Isoxazol-3-yl CN Cl F A-599 CH₃ Isoxazol-3-yl CN Cl Cl A-600 CH₃ Isoxazol-3-yl CN Cl H A-601 CH₃ 5-Methyl-isoxazol-3-yl Cl H F A-602 CH₃ 5-Methyl-isoxazol-3-yl Cl H Cl A-603 CH₃ 5-Methyl-isoxazol-3-yl Cl F F A-604 CH₃ 5-Methyl-isoxazol-3-yl Cl F Cl A-605 CH₃ 5-Methyl-isoxazol-3-yl Cl F H A-606 CH₃ 5-Methyl-isoxazol-3-yl Cl Cl F A-607 CH₃ 5-Methyl-isoxazol-3-yl Cl Cl Cl A-608 CH₃ 5-Methyl-isoxazol-3-yl Cl Cl H A-609 CH₃ 5-Methyl-isoxazol-3-yl F H F A-610 CH₃ 5-Methyl-isoxazol-3-yl F H Cl A-611 CH₃ 5-Methyl-isoxazol-3-yl F F F A-612 CH₃ 5-Methyl-isoxazol-3-yl F F Cl A-613 CH₃ 5-Methyl-isoxazol-3-yl F F H A-614 CH₃ 5-Methyl-isoxazol-3-yl F Cl F A-615 CH₃ 5-Methyl-isoxazol-3-yl F Cl Cl A-616 CH₃ 5-Methyl-isoxazol-3-yl F Cl H A-617 CH₃ 5-Methyl-isoxazol-3-yl CF₃ H F A-618 CH₃ 5-Methyl-isoxazol-3-yl CF₃ H Cl A-619 CH₃ 5-Methyl-isoxazol-3-yl CF₃ F F A-620 CH₃ 5-Methyl-isoxazol-3-yl CF₃ F Cl A-621 CH₃ 5-Methyl-isoxazol-3-yl CF₃ F H A-622 CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl F A-623 CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl Cl A-624 CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl H A-625 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H F A-626 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H Cl A-627 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F F A-628 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F Cl A-629 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F H A-630 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl F A-631 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl Cl A-632 CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl H A-633 CH₃ 5-Methyl-isoxazol-3-yl CN H F A-634 CH₃ 5-Methyl-isoxazol-3-yl CN H Cl A-635 CH₃ 5-Methyl-isoxazol-3-yl CN F F A-636 CH₃ 5-Methyl-isoxazol-3-yl CN F Cl A-637 CH₃ 5-Methyl-isoxazol-3-yl CN F H A-638 CH₃ 5-Methyl-isoxazol-3-yl CN Cl F A-639 CH₃ 5-Methyl-isoxazol-3-yl CN Cl Cl A-640 CH₃ 5-Methyl-isoxazol-3-yl CN Cl H A-641 CH₃ 3-Methyl-isoxazolin-5-yl Cl H F A-642 CH₃ 3-Methyl-isoxazolin-5-yl Cl H Cl A-643 CH₃ 3-Methyl-isoxazolin-5-yl Cl F F A-644 CH₃ 3-Methyl-isoxazolin-5-yl Cl F Cl A-645 CH₃ 3-Methyl-isoxazolin-5-yl Cl F H A-646 CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl F A-647 CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl Cl A-648 CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl H A-649 CH₃ 3-Methyl-isoxazolin-5-yl F H F A-650 CH₃ 3-Methyl-isoxazolin-5-yl F H Cl A-651 CH₃ 3-Methyl-isoxazolin-5-yl F F F A-652 CH₃ 3-Methyl-isoxazolin-5-yl F F Cl A-653 CH₃ 3-Methyl-isoxazolin-5-yl F F H A-654 CH₃ 3-Methyl-isoxazolin-5-yl F Cl F A-655 CH₃ 3-Methyl-isoxazolin-5-yl F Cl Cl A-656 CH₃ 3-Methyl-isoxazolin-5-yl F Cl H A-657 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ H F A-658 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ H Cl A-659 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F F A-660 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F Cl A-661 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F H A-662 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl F A-663 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl Cl A-664 CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl H A-665 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H F A-666 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H Cl A-667 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F F A-668 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F Cl A-669 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F H A-670 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl F A-671 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl Cl A-672 CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl H A-673 CH₃ 3-Methyl-isoxazolin-5-yl CN H F A-674 CH₃ 3-Methyl-isoxazolin-5-yl CN H Cl A-675 CH₃ 3-Methyl-isoxazolin-5-yl CN F F A-676 CH₃ 3-Methyl-isoxazolin-5-yl CN F Cl A-677 CH₃ 3-Methyl-isoxazolin-5-yl CN F H A-678 CH₃ 3-Methyl-isoxazolin-5-yl CN Cl F A-679 CH₃ 3-Methyl-isoxazolin-5-yl CN Cl Cl A-680 CH₃ 3-Methyl-isoxazolin-5-yl CN Cl H A-681 CH₃ 3-Methyl-isoxazol-5-yl Cl H F A-682 CH₃ 3-Methyl-isoxazol-5-yl Cl H Cl A-683 CH₃ 3-Methyl-isoxazol-5-yl Cl F F A-684 CH₃ 3-Methyl-isoxazol-5-yl Cl F Cl A-685 CH₃ 3-Methyl-isoxazol-5-yl Cl F H A-686 CH₃ 3-Methyl-isoxazol-5-yl Cl Cl F A-687 CH₃ 3-Methyl-isoxazol-5-yl Cl Cl Cl A-688 CH₃ 3-Methyl-isoxazol-5-yl Cl Cl H A-689 CH₃ 3-Methyl-isoxazol-5-yl F H F A-690 CH₃ 3-Methyl-isoxazol-5-yl F H Cl A-691 CH₃ 3-Methyl-isoxazol-5-yl F F F A-692 CH₃ 3-Methyl-isoxazol-5-yl F F Cl A-693 CH₃ 3-Methyl-isoxazol-5-yl F F H A-694 CH₃ 3-Methyl-isoxazol-5-yl F Cl F A-695 CH₃ 3-Methyl-isoxazol-5-yl F Cl Cl A-696 CH₃ 3-Methyl-isoxazol-5-yl F Cl H A-697 CH₃ 3-Methyl-isoxazol-5-yl CF₃ H F A-698 CH₃ 3-Methyl-isoxazol-5-yl CF₃ H Cl A-699 CH₃ 3-Methyl-isoxazol-5-yl CF₃ F F A-700 CH₃ 3-Methyl-isoxazol-5-yl CF₃ F Cl A-701 CH₃ 3-Methyl-isoxazol-5-yl CF₃ F H A-702 CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl F A-703 CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl Cl A-704 CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl H A-705 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H F A-706 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H Cl A-707 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F F A-708 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F Cl A-709 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F H A-710 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl F A-711 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl Cl A-712 CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl H A-713 CH₃ 3-Methyl-isoxazol-5-yl CN H F A-714 CH₃ 3-Methyl-isoxazol-5-yl CN H Cl A-715 CH₃ 3-Methyl-isoxazol-5-yl CN F F A-716 CH₃ 3-Methyl-isoxazol-5-yl CN F Cl A-717 CH₃ 3-Methyl-isoxazol-5-yl CN F H A-718 CH₃ 3-Methyl-isoxazol-5-yl CN Cl F A-719 CH₃ 3-Methyl-isoxazol-5-yl CN Cl Cl A-720 CH₃ 3-Methyl-isoxazol-5-yl CN Cl H A-721 CF₃ H Cl H F A-722 CF₃ H Cl H Cl A-723 CF₃ H Cl F F A-724 CF₃ H Cl F Cl A-725 CF₃ H Cl F H A-726 CF₃ H Cl Cl F A-727 CF₃ H Cl Cl Cl A-728 CF₃ H Cl Cl H A-729 CF₃ H F H F A-730 CF₃ H F H Cl A-731 CF₃ H F F F A-732 CF₃ H F F Cl A-733 CF₃ H F F H A-734 CF₃ H F Cl F A-735 CF₃ H F Cl Cl A-736 CF₃ H F Cl H A-737 CF₃ H CF₃ H F A-738 CF₃ H CF₃ H Cl A-739 CF₃ H CF₃ F F A-740 CF₃ H CF₃ F Cl A-741 CF₃ H CF₃ F H A-742 CF₃ H CF₃ Cl F A-743 CF₃ H CF₃ Cl Cl A-744 CF₃ H CF₃ Cl H A-745 CF₃ H SO₂CH₃ H F A-746 CF₃ H SO₂CH₃ H Cl A-747 CF₃ H SO₂CH₃ F F A-748 CF₃ H SO₂CH₃ F Cl A-749 CF₃ H SO₂CH₃ F H A-750 CF₃ H SO₂CH₃ Cl F A-751 CF₃ H SO₂CH₃ Cl Cl A-752 CF₃ H SO₂CH₃ Cl H A-753 CF₃ H CN H F A-754 CF₃ H CN H Cl A-755 CF₃ H CN F F A-756 CF₃ H CN F Cl A-757 CF₃ H CN F H A-758 CF₃ H CN Cl F A-759 CF₃ H CN Cl Cl A-760 CF₃ H CN Cl H A-761 CF₃ SO₂CH₃ Cl H F A-762 CF₃ SO₂CH₃ Cl H Cl A-763 CF₃ SO₂CH₃ Cl F F A-764 CF₃ SO₂CH₃ Cl F Cl A-765 CF₃ SO₂CH₃ Cl F H A-766 CF₃ SO₂CH₃ Cl Cl F A-767 CF₃ SO₂CH₃ Cl Cl Cl A-768 CF₃ SO₂CH₃ Cl Cl H A-769 CF₃ SO₂CH₃ F H F A-770 CF₃ SO₂CH₃ F H Cl A-771 CF₃ SO₂CH₃ F F F A-772 CF₃ SO₂CH₃ F F Cl A-773 CF₃ SO₂CH₃ F F H A-774 CF₃ SO₂CH₃ F Cl F A-775 CF₃ SO₂CH₃ F Cl Cl A-776 CF₃ SO₂CH₃ F Cl H A-777 CF₃ SO₂CH₃ CF₃ H F A-778 CF₃ SO₂CH₃ CF₃ H Cl A-779 CF₃ SO₂CH₃ CF₃ F F A-780 CF₃ SO₂CH₃ CF₃ F Cl A-781 CF₃ SO₂CH₃ CF₃ F H A-782 CF₃ SO₂CH₃ CF₃ Cl F A-783 CF₃ SO₂CH₃ CF₃ Cl Cl A-784 CF₃ SO₂CH₃ CF₃ Cl H A-785 CF₃ SO₂CH₃ SO₂CH₃ H F A-786 CF₃ SO₂CH₃ SO₂CH₃ H Cl A-787 CF₃ SO₂CH₃ SO₂CH₃ F F A-788 CF₃ SO₂CH₃ SO₂CH₃ F Cl A-789 CF₃ SO₂CH₃ SO₂CH₃ F H A-790 CF₃ SO₂CH₃ SO₂CH₃ Cl F A-791 CF₃ SO₂CH₃ SO₂CH₃ Cl Cl A-792 CF₃ SO₂CH₃ SO₂CH₃ Cl H A-793 CF₃ SO₂CH₃ CN H F A-794 CF₃ SO₂CH₃ CN H Cl A-795 CF₃ SO₂CH₃ CN F F A-796 CF₃ SO₂CH₃ CN F Cl A-797 CF₃ SO₂CH₃ CN F H A-798 CF₃ SO₂CH₃ CN Cl F A-799 CF₃ SO₂CH₃ CN Cl Cl A-800 CF₃ SO₂CH₃ CN Cl H A-801 CF₃ CH₂OCH₂CF₃ Cl H F A-802 CF₃ CH₂OCH₂CF₃ Cl H Cl A-803 CF₃ CH₂OCH₂CF₃ Cl F F A-804 CF₃ CH₂OCH₂CF₃ Cl F Cl A-805 CF₃ CH₂OCH₂CF₃ Cl F H A-806 CF₃ CH₂OCH₂CF₃ Cl Cl F A-807 CF₃ CH₂OCH₂CF₃ Cl Cl Cl A-808 CF₃ CH₂OCH₂CF₃ Cl Cl H A-809 CF₃ CH₂OCH₂CF₃ F H F A-810 CF₃ CH₂OCH₂CF₃ F H Cl A-811 CF₃ CH₂OCH₂CF₃ F F F A-812 CF₃ CH₂OCH₂CF₃ F F Cl A-813 CF₃ CH₂OCH₂CF₃ F F H A-814 CF₃ CH₂OCH₂CF₃ F Cl F A-815 CF₃ CH₂OCH₂CF₃ F Cl Cl A-816 CF₃ CH₂OCH₂CF₃ F Cl H A-817 CF₃ CH₂OCH₂CF₃ CF₃ H F A-818 CF₃ CH₂OCH₂CF₃ CF₃ H Cl A-819 CF₃ CH₂OCH₂CF₃ CF₃ F F A-820 CF₃ CH₂OCH₂CF₃ CF₃ F Cl A-821 CF₃ CH₂OCH₂CF₃ CF₃ F H A-822 CF₃ CH₂OCH₂CF₃ CF₃ Cl F A-823 CF₃ CH₂OCH₂CF₃ CF₃ Cl Cl A-824 CF₃ CH₂OCH₂CF₃ CF₃ Cl H A-825 CF₃ CH₂OCH₂CF₃ SO₂CH₃ H F A-826 CF₃ CH₂OCH₂CF₃ SO₂CH₃ H Cl A-827 CF₃ CH₂OCH₂CF₃ SO₂CH₃ F F A-828 CF₃ CH₂OCH₂CF₃ SO₂CH₃ F Cl A-829 CF₃ CH₂OCH₂CF₃ SO₂CH₃ F H A-830 CF₃ CH₂OCH₂CF₃ SO₂CH₃ Cl F A-831 CF₃ CH₂OCH₂CF₃ SO₂CH₃ Cl Cl A-832 CF₃ CH₂OCH₂CF₃ SO₂CH₃ Cl H A-833 CF₃ CH₂OCH₂CF₃ CN H F A-834 CF₃ CH₂OCH₂CF₃ CN H Cl A-835 CF₃ CH₂OCH₂CF₃ CN F F A-836 CF₃ CH₂OCH₂CF₃ CN F Cl A-837 CF₃ CH₂OCH₂CF₃ CN F H A-838 CF₃ CH₂OCH₂CF₃ CN Cl F A-839 CF₃ CH₂OCH₂CF₃ CN Cl Cl A-840 CF₃ CH₂OCH₂CF₃ CN Cl H A-841 CF₃ Isoxazolin-3-yl Cl H F A-842 CF₃ Isoxazolin-3-yl Cl H Cl A-843 CF₃ Isoxazolin-3-yl Cl F F A-844 CF₃ Isoxazolin-3-yl Cl F Cl A-845 CF₃ Isoxazolin-3-yl Cl F H A-846 CF₃ Isoxazolin-3-yl Cl Cl F A-847 CF₃ Isoxazolin-3-yl Cl Cl Cl A-848 CF₃ Isoxazolin-3-yl Cl Cl H A-849 CF₃ Isoxazolin-3-yl F H F A-850 CF₃ Isoxazolin-3-yl F H Cl A-851 CF₃ Isoxazolin-3-yl F F F A-852 CF₃ Isoxazolin-3-yl F F Cl A-853 CF₃ Isoxazolin-3-yl F F H A-854 CF₃ Isoxazolin-3-yl F Cl F A-855 CF₃ Isoxazolin-3-yl F Cl Cl A-856 CF₃ Isoxazolin-3-yl F Cl H A-857 CF₃ Isoxazolin-3-yl CF₃ H F A-858 CF₃ Isoxazolin-3-yl CF₃ H Cl A-859 CF₃ Isoxazolin-3-yl CF₃ F F A-860 CF₃ Isoxazolin-3-yl CF₃ F Cl A-861 CF₃ Isoxazolin-3-yl CF₃ F H A-862 CF₃ Isoxazolin-3-yl CF₃ Cl F A-863 CF₃ Isoxazolin-3-yl CF₃ Cl Cl A-864 CF₃ Isoxazolin-3-yl CF₃ Cl H A-865 CF₃ Isoxazolin-3-yl SO₂CH₃ H F A-866 CF₃ Isoxazolin-3-yl SO₂CH₃ H Cl A-867 CF₃ Isoxazolin-3-yl SO₂CH₃ F F A-868 CF₃ Isoxazolin-3-yl SO₂CH₃ F Cl A-869 CF₃ Isoxazolin-3-yl SO₂CH₃ F H A-870 CF₃ Isoxazolin-3-yl SO₂CH₃ Cl F A-871 CF₃ Isoxazolin-3-yl SO₂CH₃ Cl Cl A-872 CF₃ Isoxazolin-3-yl SO₂CH₃ Cl H A-873 CF₃ Isoxazolin-3-yl CN H F A-874 CF₃ Isoxazolin-3-yl CN H Cl A-875 CF₃ Isoxazolin-3-yl CN F F A-876 CF₃ Isoxazolin-3-yl CN F Cl A-877 CF₃ Isoxazolin-3-yl CN F H A-878 CF₃ Isoxazolin-3-yl CN Cl F A-879 CF₃ Isoxazolin-3-yl CN Cl Cl A-880 CF₃ Isoxazolin-3-yl CN Cl H A-881 CF₃ 5-Methyl-isoxazolin-3-yl Cl H F A-882 CF₃ 5-Methyl-isoxazolin-3-yl Cl H Cl A-883 CF₃ 5-Methyl-isoxazolin-3-yl Cl F F A-884 CF₃ 5-Methyl-isoxazolin-3-yl Cl F Cl A-885 CF₃ 5-Methyl-isoxazolin-3-yl Cl F H A-886 CF₃ 5-Methyl-isoxazolin-3-yl Cl Cl F A-887 CF₃ 5-Methyl-isoxazolin-3-yl Cl Cl Cl A-888 CF₃ 5-Methyl-isoxazolin-3-yl Cl Cl H A-889 CF₃ 5-Methyl-isoxazolin-3-yl F H F A-890 CF₃ 5-Methyl-isoxazolin-3-yl F H Cl A-891 CF₃ 5-Methyl-isoxazolin-3-yl F F F A-892 CF₃ 5-Methyl-isoxazolin-3-yl F F Cl A-893 CF₃ 5-Methyl-isoxazolin-3-yl F F H A-894 CF₃ 5-Methyl-isoxazolin-3-yl F Cl F A-895 CF₃ 5-Methyl-isoxazolin-3-yl F Cl Cl A-896 CF₃ 5-Methyl-isoxazolin-3-yl F Cl H A-897 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ H F A-898 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ H Cl A-899 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ F F A-900 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ F Cl A-901 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ F H A-902 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl F A-903 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl Cl A-904 CF₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl H A-905 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H F A-906 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H Cl A-907 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F F A-908 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F Cl A-909 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F H A-910 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl F A-911 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl Cl A-912 CF₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl H A-913 CF₃ 5-Methyl-isoxazolin-3-yl CN H F A-914 CF₃ 5-Methyl-isoxazolin-3-yl CN H Cl A-915 CF₃ 5-Methyl-isoxazolin-3-yl CN F F A-916 CF₃ 5-Methyl-isoxazolin-3-yl CN F Cl A-917 CF₃ 5-Methyl-isoxazolin-3-yl CN F H A-918 CF₃ 5-Methyl-isoxazolin-3-yl CN Cl F A-919 CF₃ 5-Methyl-isoxazolin-3-yl CN Cl Cl A-920 CF₃ 5-Methyl-isoxazolin-3-yl CN Cl H A-921 CF₃ Isoxazol-3-yl Cl H F A-922 CF₃ Isoxazol-3-yl Cl H Cl A-923 CF₃ Isoxazol-3-yl Cl F F A-924 CF₃ Isoxazol-3-yl Cl F Cl A-925 CF₃ Isoxazol-3-yl Cl F H A-926 CF₃ Isoxazol-3-yl Cl Cl F A-927 CF₃ Isoxazol-3-yl Cl Cl Cl A-928 CF₃ Isoxazol-3-yl Cl Cl H A-929 CF₃ Isoxazol-3-yl F H F A-930 CF₃ Isoxazol-3-yl F H Cl A-931 CF₃ Isoxazol-3-yl F F F A-932 CF₃ Isoxazol-3-yl F F Cl A-933 CF₃ Isoxazol-3-yl F F H A-934 CF₃ Isoxazol-3-yl F Cl F A-935 CF₃ Isoxazol-3-yl F Cl Cl A-936 CF₃ Isoxazol-3-yl F Cl H A-937 CF₃ Isoxazol-3-yl CF₃ H F A-938 CF₃ Isoxazol-3-yl CF₃ H Cl A-939 CF₃ Isoxazol-3-yl CF₃ F F A-940 CF₃ Isoxazol-3-yl CF₃ F Cl A-941 CF₃ Isoxazol-3-yl CF₃ F H A-942 CF₃ Isoxazol-3-yl CF₃ Cl F A-943 CF₃ Isoxazol-3-yl CF₃ Cl Cl A-944 CF₃ Isoxazol-3-yl CF₃ Cl H A-945 CF₃ Isoxazol-3-yl SO₂CH₃ H F A-946 CF₃ Isoxazol-3-yl SO₂CH₃ H Cl A-947 CF₃ Isoxazol-3-yl SO₂CH₃ F F A-948 CF₃ Isoxazol-3-yl SO₂CH₃ F Cl A-949 CF₃ Isoxazol-3-yl SO₂CH₃ F H A-950 CF₃ Isoxazol-3-yl SO₂CH₃ Cl F A-951 CF₃ Isoxazol-3-yl SO₂CH₃ Cl Cl A-952 CF₃ Isoxazol-3-yl SO₂CH₃ Cl H A-953 CF₃ Isoxazol-3-yl CN H F A-954 CF₃ Isoxazol-3-yl CN H Cl A-955 CF₃ Isoxazol-3-yl CN F F A-956 CF₃ Isoxazol-3-yl CN F Cl A-957 CF₃ Isoxazol-3-yl CN F H A-958 CF₃ Isoxazol-3-yl CN Cl F A-959 CF₃ Isoxazol-3-yl CN Cl Cl A-960 CF₃ Isoxazol-3-yl CN Cl H A-961 CF₃ 5-Methyl-isoxazol-3-yl Cl H F A-962 CF₃ 5-Methyl-isoxazol-3-yl Cl H Cl A-963 CF₃ 5-Methyl-isoxazol-3-yl Cl F F A-964 CF₃ 5-Methyl-isoxazol-3-yl Cl F Cl A-965 CF₃ 5-Methyl-isoxazol-3-yl Cl F H A-966 CF₃ 5-Methyl-isoxazol-3-yl Cl Cl F A-967 CF₃ 5-Methyl-isoxazol-3-yl Cl Cl Cl A-968 CF₃ 5-Methyl-isoxazol-3-yl Cl Cl H A-969 CF₃ 5-Methyl-isoxazol-3-yl F H F A-970 CF₃ 5-Methyl-isoxazol-3-yl F H Cl A-971 CF₃ 5-Methyl-isoxazol-3-yl F F F A-972 CF₃ 5-Methyl-isoxazol-3-yl F F Cl A-973 CF₃ 5-Methyl-isoxazol-3-yl F F H A-974 CF₃ 5-Methyl-isoxazol-3-yl F Cl F A-975 CF₃ 5-Methyl-isoxazol-3-yl F Cl Cl A-976 CF₃ 5-Methyl-isoxazol-3-yl F Cl H A-977 CF₃ 5-Methyl-isoxazol-3-yl CF₃ H F A-978 CF₃ 5-Methyl-isoxazol-3-yl CF₃ H Cl A-979 CF₃ 5-Methyl-isoxazol-3-yl CF₃ F F A-980 CF₃ 5-Methyl-isoxazol-3-yl CF₃ F Cl A-981 CF₃ 5-Methyl-isoxazol-3-yl CF₃ F H A-982 CF₃ 5-Methyl-isoxazol-3-yl CF₃ Cl F A-983 CF₃ 5-Methyl-isoxazol-3-yl CF₃ Cl Cl A-984 CF₃ 5-Methyl-isoxazol-3-yl CF₃ Cl H A-985 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H F A-986 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H Cl A-987 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F F A-988 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F Cl A-989 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F H A-990 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl F A-991 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl Cl A-992 CF₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl H A-993 CF₃ 5-Methyl-isoxazol-3-yl CN H F A-994 CF₃ 5-Methyl-isoxazol-3-yl CN H Cl A-995 CF₃ 5-Methyl-isoxazol-3-yl CN F F A-996 CF₃ 5-Methyl-isoxazol-3-yl CN F Cl A-997 CF₃ 5-Methyl-isoxazol-3-yl CN F H A-998 CF₃ 5-Methyl-isoxazol-3-yl CN Cl F A-999 CF₃ 5-Methyl-isoxazol-3-yl CN Cl Cl A-1000 CF₃ 5-Methyl-isoxazol-3-yl CN Cl H A-1001 CF₃ 3-Methyl-isoxazolin-5-yl Cl H F A-1002 CF₃ 3-Methyl-isoxazolin-5-yl Cl H Cl A-1003 CF₃ 3-Methyl-isoxazolin-5-yl Cl F F A-1004 CF₃ 3-Methyl-isoxazolin-5-yl Cl F Cl A-1005 CF₃ 3-Methyl-isoxazolin-5-yl Cl F H A-1006 CF₃ 3-Methyl-isoxazolin-5-yl Cl Cl F A-1007 CF₃ 3-Methyl-isoxazolin-5-yl Cl Cl Cl A-1008 CF₃ 3-Methyl-isoxazolin-5-yl Cl Cl H A-1009 CF₃ 3-Methyl-isoxazolin-5-yl F H F A-1010 CF₃ 3-Methyl-isoxazolin-5-yl F H Cl A-1011 CF₃ 3-Methyl-isoxazolin-5-yl F F F A-1012 CF₃ 3-Methyl-isoxazolin-5-yl F F Cl A-1013 CF₃ 3-Methyl-isoxazolin-5-yl F F H A-1014 CF₃ 3-Methyl-isoxazolin-5-yl F Cl F A-1015 CF₃ 3-Methyl-isoxazolin-5-yl F Cl Cl A-1016 CF₃ 3-Methyl-isoxazolin-5-yl F Cl H A-1017 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ H F A-1018 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ H Cl A-1019 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ F F A-1020 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ F Cl A-1021 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ F H A-1022 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl F A-1023 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl Cl A-1024 CF₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl H A-1025 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H F A-1026 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H Cl A-1027 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F F A-1028 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F Cl A-1029 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F H A-1030 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl F A-1031 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl Cl A-1032 CF₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl H A-1033 CF₃ 3-Methyl-isoxazolin-5-yl CN H F A-1034 CF₃ 3-Methyl-isoxazolin-5-yl CN H Cl A-1035 CF₃ 3-Methyl-isoxazolin-5-yl CN F F A-1036 CF₃ 3-Methyl-isoxazolin-5-yl CN F Cl A-1037 CF₃ 3-Methyl-isoxazolin-5-yl CN F H A-1038 CF₃ 3-Methyl-isoxazolin-5-yl CN Cl F A-1039 CF₃ 3-Methyl-isoxazolin-5-yl CN Cl Cl A-1040 CF₃ 3-Methyl-isoxazolin-5-yl CN Cl H A-1041 CF₃ 3-Methyl-isoxazol-5-yl Cl H F A-1042 CF₃ 3-Methyl-isoxazol-5-yl Cl H Cl A-1043 CF₃ 3-Methyl-isoxazol-5-yl Cl F F A-1044 CF₃ 3-Methyl-isoxazol-5-yl Cl F Cl A-1045 CF₃ 3-Methyl-isoxazol-5-yl Cl F H A-1046 CF₃ 3-Methyl-isoxazol-5-yl Cl Cl F A-1047 CF₃ 3-Methyl-isoxazol-5-yl Cl Cl Cl A-1048 CF₃ 3-Methyl-isoxazol-5-yl Cl Cl H A-1049 CF₃ 3-Methyl-isoxazol-5-yl F H F A-1050 CF₃ 3-Methyl-isoxazol-5-yl F H Cl A-1051 CF₃ 3-Methyl-isoxazol-5-yl F F F A-1052 CF₃ 3-Methyl-isoxazol-5-yl F F Cl A-1053 CF₃ 3-Methyl-isoxazol-5-yl F F H A-1054 CF₃ 3-Methyl-isoxazol-5-yl F Cl F A-1055 CF₃ 3-Methyl-isoxazol-5-yl F Cl Cl A-1056 CF₃ 3-Methyl-isoxazol-5-yl F Cl H A-1057 CF₃ 3-Methyl-isoxazol-5-yl CF₃ H F A-1058 CF₃ 3-Methyl-isoxazol-5-yl CF₃ H Cl A-1059 CF₃ 3-Methyl-isoxazol-5-yl CF₃ F F A-1060 CF₃ 3-Methyl-isoxazol-5-yl CF₃ F Cl A-1061 CF₃ 3-Methyl-isoxazol-5-yl CF₃ F H A-1062 CF₃ 3-Methyl-isoxazol-5-yl CF₃ Cl F A-1063 CF₃ 3-Methyl-isoxazol-5-yl CF₃ Cl Cl A-1064 CF₃ 3-Methyl-isoxazol-5-yl CF₃ Cl H A-1065 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H F A-1066 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H Cl A-1067 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F F A-1068 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F Cl A-1069 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F H A-1070 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl F A-1071 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl Cl A-1072 CF₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl H A-1073 CF₃ 3-Methyl-isoxazol-5-yl CN H F A-1074 CF₃ 3-Methyl-isoxazol-5-yl CN H Cl A-1075 CF₃ 3-Methyl-isoxazol-5-yl CN F F A-1076 CF₃ 3-Methyl-isoxazol-5-yl CN F Cl A-1077 CF₃ 3-Methyl-isoxazol-5-yl CN F H A-1078 CF₃ 3-Methyl-isoxazol-5-yl CN Cl F A-1079 CF₃ 3-Methyl-isoxazol-5-yl CN Cl Cl A-1080 CF₃ 3-Methyl-isoxazol-5-yl CN Cl H A-1081 SO₂CH₃ H Cl H F A-1082 SO₂CH₃ H Cl H Cl A-1083 SO₂CH₃ H Cl F F A-1084 SO₂CH₃ H Cl F Cl A-1085 SO₂CH₃ H Cl F H A-1086 SO₂CH₃ H Cl Cl F A-1087 SO₂CH₃ H Cl Cl Cl A-1088 SO₂CH₃ H Cl Cl H A-1089 SO₂CH₃ H F H F A-1090 SO₂CH₃ H F H Cl A-1091 SO₂CH₃ H F F F A-1092 SO₂CH₃ H F F Cl A-1093 SO₂CH₃ H F F H A-1094 SO₂CH₃ H F Cl F A-1095 SO₂CH₃ H F Cl Cl A-1096 SO₂CH₃ H F Cl H A-1097 SO₂CH₃ H CF₃ H F A-1098 SO₂CH₃ H CF₃ H Cl A-1099 SO₂CH₃ H CF₃ F F A-1100 SO₂CH₃ H CF₃ F Cl A-1101 SO₂CH₃ H CF₃ F H A-1102 SO₂CH₃ H CF₃ Cl F A-1103 SO₂CH₃ H CF₃ Cl Cl A-1104 SO₂CH₃ H CF₃ Cl H A-1105 SO₂CH₃ H SO₂CH₃ H F A-1106 SO₂CH₃ H SO₂CH₃ H Cl A-1107 SO₂CH₃ H SO₂CH₃ F F A-1108 SO₂CH₃ H SO₂CH₃ F Cl A-1109 SO₂CH₃ H SO₂CH₃ F H A-1110 SO₂CH₃ H SO₂CH₃ Cl F A-1111 SO₂CH₃ H SO₂CH₃ Cl Cl A-1112 SO₂CH₃ H SO₂CH₃ Cl H A-1113 SO₂CH₃ H CN H F A-1114 SO₂CH₃ H CN H Cl A-1115 SO₂CH₃ H CN F F A-1116 SO₂CH₃ H CN F Cl A-1117 SO₂CH₃ H CN F H A-1118 SO₂CH₃ H CN Cl F A-1119 SO₂CH₃ H CN Cl Cl A-1120 SO₂CH₃ H CN Cl H A-1121 SO₂CH₃ SO₂CH₃ Cl H F A-1122 SO₂CH₃ SO₂CH₃ Cl H Cl A-1123 SO₂CH₃ SO₂CH₃ Cl F F A-1124 SO₂CH₃ SO₂CH₃ Cl F Cl A-1125 SO₂CH₃ SO₂CH₃ Cl F H A-1126 SO₂CH₃ SO₂CH₃ Cl Cl F A-1127 SO₂CH₃ SO₂CH₃ Cl Cl Cl A-1128 SO₂CH₃ SO₂CH₃ Cl Cl H A-1129 SO₂CH₃ SO₂CH₃ F H F A-1130 SO₂CH₃ SO₂CH₃ F H Cl A-1131 SO₂CH₃ SO₂CH₃ F F F A-1132 SO₂CH₃ SO₂CH₃ F F Cl A-1133 SO₂CH₃ SO₂CH₃ F F H A-1134 SO₂CH₃ SO₂CH₃ F Cl F A-1135 SO₂CH₃ SO₂CH₃ F Cl Cl A-1136 SO₂CH₃ SO₂CH₃ F Cl H A-1137 SO₂CH₃ SO₂CH₃ CF₃ H F A-1138 SO₂CH₃ SO₂CH₃ CF₃ H Cl A-1139 SO₂CH₃ SO₂CH₃ CF₃ F F A-1140 SO₂CH₃ SO₂CH₃ CF₃ F Cl A-1141 SO₂CH₃ SO₂CH₃ CF₃ F H A-1142 SO₂CH₃ SO₂CH₃ CF₃ Cl F A-1143 SO₂CH₃ SO₂CH₃ CF₃ Cl Cl A-1144 SO₂CH₃ SO₂CH₃ CF₃ Cl H A-1145 SO₂CH₃ SO₂CH₃ SO₂CH₃ H F A-1146 SO₂CH₃ SO₂CH₃ SO₂CH₃ H Cl A-1147 SO₂CH₃ SO₂CH₃ SO₂CH₃ F F A-1148 SO₂CH₃ SO₂CH₃ SO₂CH₃ F Cl A-1149 SO₂CH₃ SO₂CH₃ SO₂CH₃ F H A-1150 SO₂CH₃ SO₂CH₃ SO₂CH₃ Cl F A-1151 SO₂CH₃ SO₂CH₃ SO₂CH₃ Cl Cl A-1152 SO₂CH₃ SO₂CH₃ SO₂CH₃ Cl H A-1153 SO₂CH₃ SO₂CH₃ CN H F A-1154 SO₂CH₃ SO₂CH₃ CN H Cl A-1155 SO₂CH₃ SO₂CH₃ CN F F A-1156 SO₂CH₃ SO₂CH₃ CN F Cl A-1157 SO₂CH₃ SO₂CH₃ CN F H A-1158 SO₂CH₃ SO₂CH₃ CN Cl F A-1159 SO₂CH₃ SO₂CH₃ CN Cl Cl A-1160 SO₂CH₃ SO₂CH₃ CN Cl H A-1161 SO₂CH₃ CH₂OCH₂CF₃ Cl H F A-1162 SO₂CH₃ CH₂OCH₂CF₃ Cl H Cl A-1163 SO₂CH₃ CH₂OCH₂CF₃ Cl F F A-1164 SO₂CH₃ CH₂OCH₂CF₃ Cl F Cl A-1165 SO₂CH₃ CH₂OCH₂CF₃ Cl F H A-1166 SO₂CH₃ CH₂OCH₂CF₃ Cl Cl F A-1167 SO₂CH₃ CH₂OCH₂CF₃ Cl Cl Cl A-1168 SO₂CH₃ CH₂OCH₂CF₃ Cl Cl H A-1169 SO₂CH₃ CH₂OCH₂CF₃ F H F A-1170 SO₂CH₃ CH₂OCH₂CF₃ F H Cl A-1171 SO₂CH₃ CH₂OCH₂CF₃ F F F A-1172 SO₂CH₃ CH₂OCH₂CF₃ F F Cl A-1173 SO₂CH₃ CH₂OCH₂CF₃ F F H A-1174 SO₂CH₃ CH₂OCH₂CF₃ F Cl F A-1175 SO₂CH₃ CH₂OCH₂CF₃ F Cl Cl A-1176 SO₂CH₃ CH₂OCH₂CF₃ F Cl H A-1177 SO₂CH₃ CH₂OCH₂CF₃ CF₃ H F A-1178 SO₂CH₃ CH₂OCH₂CF₃ CF₃ H Cl A-1179 SO₂CH₃ CH₂OCH₂CF₃ CF₃ F F A-1180 SO₂CH₃ CH₂OCH₂CF₃ CF₃ F Cl A-1181 SO₂CH₃ CH₂OCH₂CF₃ CF₃ F H A-1182 SO₂CH₃ CH₂OCH₂CF₃ CF₃ Cl F A-1183 SO₂CH₃ CH₂OCH₂CF₃ CF₃ Cl Cl A-1184 SO₂CH₃ CH₂OCH₂CF₃ CF₃ Cl H A-1185 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ H F A-1186 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ H Cl A-1187 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ F F A-1188 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ F Cl A-1189 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ F H A-1190 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl F A-1191 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl Cl A-1192 SO₂CH₃ CH₂OCH₂CF₃ SO₂CH₃ Cl H A-1193 SO₂CH₃ CH₂OCH₂CF₃ CN H F A-1194 SO₂CH₃ CH₂OCH₂CF₃ CN H Cl A-1195 SO₂CH₃ CH₂OCH₂CF₃ CN F F A-1196 SO₂CH₃ CH₂OCH₂CF₃ CN F Cl A-1197 SO₂CH₃ CH₂OCH₂CF₃ CN F H A-1198 SO₂CH₃ CH₂OCH₂CF₃ CN Cl F A-1199 SO₂CH₃ CH₂OCH₂CF₃ CN Cl Cl A-1200 SO₂CH₃ CH₂OCH₂CF₃ CN Cl H A-1201 SO₂CH₃ Isoxazolin-3-yl Cl H F A-1202 SO₂CH₃ Isoxazolin-3-yl Cl H Cl A-1203 SO₂CH₃ Isoxazolin-3-yl Cl F F A-1204 SO₂CH₃ Isoxazolin-3-yl Cl F Cl A-1205 SO₂CH₃ Isoxazolin-3-yl Cl F H A-1206 SO₂CH₃ Isoxazolin-3-yl Cl Cl F A-1207 SO₂CH₃ Isoxazolin-3-yl Cl Cl Cl A-1208 SO₂CH₃ Isoxazolin-3-yl Cl Cl H A-1209 SO₂CH₃ Isoxazolin-3-yl F H F A-1210 SO₂CH₃ Isoxazolin-3-yl F H Cl A-1211 SO₂CH₃ Isoxazolin-3-yl F F F A-1212 SO₂CH₃ Isoxazolin-3-yl F F Cl A-1213 SO₂CH₃ Isoxazolin-3-yl F F H A-1214 SO₂CH₃ Isoxazolin-3-yl F Cl F A-1215 SO₂CH₃ Isoxazolin-3-yl F Cl Cl A-1216 SO₂CH₃ Isoxazolin-3-yl F Cl H A-1217 SO₂CH₃ Isoxazolin-3-yl CF₃ H F A-1218 SO₂CH₃ Isoxazolin-3-yl CF₃ H Cl A-1219 SO₂CH₃ Isoxazolin-3-yl CF₃ F F A-1220 SO₂CH₃ Isoxazolin-3-yl CF₃ F Cl A-1221 SO₂CH₃ Isoxazolin-3-yl CF₃ F H A-1222 SO₂CH₃ Isoxazolin-3-yl CF₃ Cl F A-1223 SO₂CH₃ Isoxazolin-3-yl CF₃ Cl Cl A-1224 SO₂CH₃ Isoxazolin-3-yl CF₃ Cl H A-1225 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ H F A-1226 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ H Cl A-1227 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ F F A-1228 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ F Cl A-1229 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ F H A-1230 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ Cl F A-1231 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ Cl Cl A-1232 SO₂CH₃ Isoxazolin-3-yl SO₂CH₃ Cl H A-1233 SO₂CH₃ Isoxazolin-3-yl CN H F A-1234 SO₂CH₃ Isoxazolin-3-yl CN H Cl A-1235 SO₂CH₃ Isoxazolin-3-yl CN F F A-1236 SO₂CH₃ Isoxazolin-3-yl CN F Cl A-1237 SO₂CH₃ Isoxazolin-3-yl CN F H A-1238 SO₂CH₃ Isoxazolin-3-yl CN Cl F A-1239 SO₂CH₃ Isoxazolin-3-yl CN Cl Cl A-1240 SO₂CH₃ Isoxazolin-3-yl CN Cl H A-1241 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl H F A-1242 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl H Cl A-1243 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl F F A-1244 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl F Cl A-1245 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl F H A-1246 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl F A-1247 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl Cl A-1248 SO₂CH₃ 5-Methyl-isoxazolin-3-yl Cl Cl H A-1249 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F H F A-1250 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F H Cl A-1251 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F F F A-1252 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F F Cl A-1253 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F F H A-1254 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F Cl F A-1255 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F Cl Cl A-1256 SO₂CH₃ 5-Methyl-isoxazolin-3-yl F Cl H A-1257 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ H F A-1258 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ H Cl A-1259 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F F A-1260 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F Cl A-1261 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ F H A-1262 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl F A-1263 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl Cl A-1264 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CF₃ Cl H A-1265 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H F A-1266 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ H Cl A-1267 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F F A-1268 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F Cl A-1269 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ F H A-1270 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl F A-1271 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl Cl A-1272 SO₂CH₃ 5-Methyl-isoxazolin-3-yl SO₂CH₃ Cl H A-1273 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN H F A-1274 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN H Cl A-1275 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN F F A-1276 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN F Cl A-1277 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN F H A-1278 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN Cl F A-1279 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN Cl Cl A-1280 SO₂CH₃ 5-Methyl-isoxazolin-3-yl CN Cl H A-1281 SO₂CH₃ Isoxazol-3-yl Cl H F A-1282 SO₂CH₃ Isoxazol-3-yl Cl H Cl A-1283 SO₂CH₃ Isoxazol-3-yl Cl F F A-1284 SO₂CH₃ Isoxazol-3-yl Cl F Cl A-1285 SO₂CH₃ Isoxazol-3-yl Cl F H A-1286 SO₂CH₃ Isoxazol-3-yl Cl Cl F A-1287 SO₂CH₃ Isoxazol-3-yl Cl Cl Cl A-1288 SO₂CH₃ Isoxazol-3-yl Cl Cl H A-1289 SO₂CH₃ Isoxazol-3-yl F H F A-1290 SO₂CH₃ Isoxazol-3-yl F H Cl A-1291 SO₂CH₃ Isoxazol-3-yl F F F A-1292 SO₂CH₃ Isoxazol-3-yl F F Cl A-1293 SO₂CH₃ Isoxazol-3-yl F F H A-1294 SO₂CH₃ Isoxazol-3-yl F Cl F A-1295 SO₂CH₃ Isoxazol-3-yl F Cl Cl A-1296 SO₂CH₃ Isoxazol-3-yl F Cl H A-1297 SO₂CH₃ Isoxazol-3-yl CF₃ H F A-1298 SO₂CH₃ Isoxazol-3-yl CF₃ H Cl A-1299 SO₂CH₃ Isoxazol-3-yl CF₃ F F A-1300 SO₂CH₃ Isoxazol-3-yl CF₃ F Cl A-1301 SO₂CH₃ Isoxazol-3-yl CF₃ F H A-1302 SO₂CH₃ Isoxazol-3-yl CF₃ Cl F A-1303 SO₂CH₃ Isoxazol-3-yl CF₃ Cl Cl A-1304 SO₂CH₃ Isoxazol-3-yl CF₃ Cl H A-1305 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ H F A-1306 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ H Cl A-1307 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ F F A-1308 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ F Cl A-1309 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ F H A-1310 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ Cl F A-1311 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ Cl Cl A-1312 SO₂CH₃ Isoxazol-3-yl SO₂CH₃ Cl H A-1313 SO₂CH₃ Isoxazol-3-yl CN H F A-1314 SO₂CH₃ Isoxazol-3-yl CN H Cl A-1315 SO₂CH₃ Isoxazol-3-yl CN F F A-1316 SO₂CH₃ Isoxazol-3-yl CN F Cl A-1317 SO₂CH₃ Isoxazol-3-yl CN F H A-1318 SO₂CH₃ Isoxazol-3-yl CN Cl F A-1319 SO₂CH₃ Isoxazol-3-yl CN Cl Cl A-1320 SO₂CH₃ Isoxazol-3-yl CN Cl H A-1321 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl H F A-1322 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl H Cl A-1323 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl F F A-1324 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl F Cl A-1325 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl F H A-1326 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl Cl F A-1327 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl Cl Cl A-1328 SO₂CH₃ 5-Methyl-isoxazol-3-yl Cl Cl H A-1329 SO₂CH₃ 5-Methyl-isoxazol-3-yl F H F A-1330 SO₂CH₃ 5-Methyl-isoxazol-3-yl F H Cl A-1331 SO₂CH₃ 5-Methyl-isoxazol-3-yl F F F A-1332 SO₂CH₃ 5-Methyl-isoxazol-3-yl F F Cl A-1333 SO₂CH₃ 5-Methyl-isoxazol-3-yl F F H A-1334 SO₂CH₃ 5-Methyl-isoxazol-3-yl F Cl F A-1335 SO₂CH₃ 5-Methyl-isoxazol-3-yl F Cl Cl A-1336 SO₂CH₃ 5-Methyl-isoxazol-3-yl F Cl H A-1337 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ H F A-1338 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ H Cl A-1339 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ F F A-1340 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ F Cl A-1341 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ F H A-1342 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl F A-1343 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl Cl A-1344 SO₂CH₃ 5-Methyl-isoxazol-3-yl CF₃ Cl H A-1345 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H F A-1346 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ H Cl A-1347 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F F A-1348 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F Cl A-1349 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ F H A-1350 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl F A-1351 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl Cl A-1352 SO₂CH₃ 5-Methyl-isoxazol-3-yl SO₂CH₃ Cl H A-1353 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN H F A-1354 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN H Cl A-1355 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN F F A-1356 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN F Cl A-1357 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN F H A-1358 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN Cl F A-1359 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN Cl Cl A-1360 SO₂CH₃ 5-Methyl-isoxazol-3-yl CN Cl H A-1361 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl H F A-1362 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl H Cl A-1363 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl F F A-1364 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl F Cl A-1365 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl F H A-1366 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl F A-1367 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl Cl A-1368 SO₂CH₃ 3-Methyl-isoxazolin-5-yl Cl Cl H A-1369 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F H F A-1370 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F H Cl A-1371 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F F F A-1372 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F F Cl A-1373 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F F H A-1374 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F Cl F A-1375 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F Cl Cl A-1376 SO₂CH₃ 3-Methyl-isoxazolin-5-yl F Cl H A-1377 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ H F A-1378 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ H Cl A-1379 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F F A-1380 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F Cl A-1381 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ F H A-1382 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl F A-1383 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl Cl A-1384 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CF₃ Cl H A-1385 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H F A-1386 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ H Cl A-1387 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F F A-1388 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F Cl A-1389 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ F H A-1390 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl F A-1391 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl Cl A-1392 SO₂CH₃ 3-Methyl-isoxazolin-5-yl SO₂CH₃ Cl H A-1393 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN H F A-1394 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN H Cl A-1395 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN F F A-1396 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN F Cl A-1397 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN F H A-1398 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN Cl F A-1399 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN Cl Cl A-1400 SO₂CH₃ 3-Methyl-isoxazolin-5-yl CN Cl H A-1401 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl H F A-1402 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl H Cl A-1403 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl F F A-1404 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl F Cl A-1405 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl F H A-1406 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl Cl F A-1407 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl Cl Cl A-1408 SO₂CH₃ 3-Methyl-isoxazol-5-yl Cl Cl H A-1409 SO₂CH₃ 3-Methyl-isoxazol-5-yl F H F A-1410 SO₂CH₃ 3-Methyl-isoxazol-5-yl F H Cl A-1411 SO₂CH₃ 3-Methyl-isoxazol-5-yl F F F A-1412 SO₂CH₃ 3-Methyl-isoxazol-5-yl F F Cl A-1413 SO₂CH₃ 3-Methyl-isoxazol-5-yl F F H A-1414 SO₂CH₃ 3-Methyl-isoxazol-5-yl F Cl F A-1415 SO₂CH₃ 3-Methyl-isoxazol-5-yl F Cl Cl A-1416 SO₂CH₃ 3-Methyl-isoxazol-5-yl F Cl H A-1417 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ H F A-1418 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ H Cl A-1419 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ F F A-1420 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ F Cl A-1421 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ F H A-1422 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl F A-1423 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl Cl A-1424 SO₂CH₃ 3-Methyl-isoxazol-5-yl CF₃ Cl H A-1425 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H F A-1426 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ H Cl A-1427 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F F A-1428 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F Cl A-1429 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ F H A-1430 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl F A-1431 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl Cl A-1432 SO₂CH₃ 3-Methyl-isoxazol-5-yl SO₂CH₃ Cl H A-1433 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN H F A-1434 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN H Cl A-1435 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN F F A-1436 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN F Cl A-1437 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN F H A-1438 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN Cl F A-1439 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN Cl Cl A-1440 SO₂CH₃ 3-Methyl-isoxazol-5-yl CN Cl H A-1441 Cl Cl H H F A-1442 Cl SMe Cl H F

The HPPD-inhibiting herbicides useful for the present invention are often best applied in conjunction with one or more other HPPD- and/or HST targeting herbicides to obtain control of a wider variety of undesirable vegetation. When used in conjunction with other HPPD- and/or HST targeting herbicides, the presently claimed compounds can be formulated with the other herbicide or herbicides, tank mixed with the other herbicide or herbicides, or applied sequentially with the other herbicide or herbicides.

Some of the herbicides that are useful in conjunction with the HPPD-inhibiting herbicides of the present invention include benzobicyclon, mesotrione, sulcotrione, tefuryltrione, tembotrione, 4-hydroxy-3-[[2-(2-methoxyethoxy)methyl]-6-(trifluoromethyl)-3-pyridinyl]carbonyl]-bicyclo[3.2.1]-oct-3-en-2-one (bicyclopyrone), ketospiradox or the free acid thereof, benzofenap, pyrasulfotole, pyrazolynate, pyrazoxyfen, topramezone, [2-chloro-3-(2-methoxyethoxy)-4-(methylsulfonyl)phenyl](I-ethyl-5-hydroxy-1H-pyrazol-4-yl)-methanone, (2,3-dihydro-3,3,4-trimethyl-1,1-dioxidobenzo[b]thien-5-yl)(5-hydroxy-1-methyl-1H-pyrazol-4-yl)-methanone, isoxachlortole, isoxaflutole, α-(cyclopropylcarbonyl)-2-(methylsulfonyl)-β-oxo-4-chloro-benzenepropanenitrile, and α-(cyclopropylcarbonyl)-2-(methyisulfonyl)-β-oxo-4-(trifluoromethyl)-benzenepropanenitrile.

In a preferred embodiment the additional herbicide is topramezone.

In a particularly preferred embodiment the additional herbicide is

-   (1-Ethyl-5-prop-2-ynyloxy-1H-pyrazol-4-yl)-[4-methanesulfonyl-2-methyl-3-(3-methyl-4,5-dihydro-isoxazol-5-yl)-phenyl]-methanon

or

-   (1-Ethyl-5-hydroxy-1H-pyrazol-4-yl)-[4-methanesulfonyl-2-methyl-3-(3-methyl-4,5-dihydro-isoxazol-5-yl)-phenyl]-methanon

The above described compounds are described in great detail in WO2011067184 which is entirely incorporated herein by reference.

The herbicidal compounds useful for the present invention may further be used in conjunction with additional herbicides to which the crop plant is naturally tolerant, or to which it is resistant via expression of one or more additional transgenes as mentioned supra. Some of the herbicides that can be employed in conjunction with the compounds of the present invention include sulfonamides such as metosulam, flumetsulam, cloransulam-methyl, diclosulam, penoxsulam and florasulam, sulfonylureas such as chlorimuron, tribenuron, sulfometuron, nicosulfuron, chlorsulfuron, amidosulfuron, triasulfuron, prosulfuron, tritosulfuron, thifensulfuron, sulfosulfuron and metsulfuron, imidazolinones such as imazaquin, imazapic, ima-zethapyr, imzapyr, imazamethabenz and imazamox, phenoxyalkanoic acids such as 2,4-D, MCPA, dichlorprop and mecoprop, pyridinyloxyacetic acids such as triclopyr and fluroxypyr, carboxylic acids such as clopyralid, picloram, aminopyralid and dicamba, dinitroanilines such as trifluralin, benefin, benfluralin and pendimethalin, chloroacetanilides such as alachlor, acetochlor and metolachlor, semicarbazones (auxin transport inhibitors) such as chlorflurenol and diflufenzopyr, aryloxyphenoxypropionates such as fluazifop, haloxyfop, diclofop, clodinafop and fenoxaprop and other common herbicides including glyphosate, glufosinate, acifluorfen, bentazon, clomazone, fumiclorac, fluometuron, fomesafen, lactofen, linuron, isoproturon, simazine, norflurazon, paraquat, diuron, diflufenican, picolinafen, cinidon, sethoxydim, tralkoxydim, quinmerac, isoxaben, bromoxynil, metribuzin and mesotrione.

The HPPD-inhibiting herbicides employed for the present invention can, further, be used in conjunction with glyphosate and glufosinate on glyphosate-tolerant or glufosinate-tolerant crops.

Unless already included in the disclosure above, the HPPD-inhibiting herbicides of the present invention can, further, be used in conjunction with compounds:

a) from the group of Lipid Biosynthesis Inhibitors:

Alloxydim, Alloxydim-natrium, Butroxydim, Clethodim, Clodinafop, Clodinafop-propargyl, Cycloxydim, Cyhalofop, Cyhalofop-butyl, Diclofop, Diclofop-methyl, Fenoxaprop, Fenoxaprop-ethyl, Fenoxaprop-P, Fenoxaprop-P-ethyl, Fluazifop, Fluazifop-butyl, Fluazifop-P, Fluazifop-P-butyl, Haloxyfop, Haloxyfop-methyl, Haloxyfop-P, Haloxyfop-P-methyl, Metamifop, Pinoxaden, Profoxydim, Propaquizafop, Quizalofop, Quizalofop-ethyl, Quizalofoptefuryl, Quizalofop-P, Quizalofop-P-ethyl, Quizalofop-P-tefuryl, Sethoxydim, Tepraloxydim, Tralkoxydim, Benfuresat, Butylat, Cycloat, Dalapon, Dimepiperat, EPTC, Esprocarb, Ethofumesat, Flupropanat, Molinat, Orbencarb, Pebulat, Prosulfocarb, TCA, Thiobencarb, Tiocarbazil, Triallat and Vemolat;

b) from the group of ALS-Inhibitors:

Amidosulfuron, Azimsulfuron, Bensulfuron, Bensulfuron-methyl, Bispyribac, Bispyribacnatrium, Chlorimuron, Chlorimuron-ethyl, Chlorsulfuron, Cinosulfuron, Cloransulam, Cloransulam-methyl, Cyclosulfamuron, Diclosulam, Ethametsulfuron, Ethametsulfuron-methyl, Ethoxysulfuron, Flazasulfuron, Florasulam, Flucarbazon, Flucarbazon-natnum, Flucetosulfuron, Flumetsulam, Flupyrsulfuron, Flupyrsulfuron-methyl-natrium, Foramsulfuron, Halosulfuron, Halosulfuron-methyl, Imazamethabenz, Imazamethabenz-methyl, Imazamox, Imazapic, Imazapyr, Imazaquin, Imazethapyr, Imazosulfuron, Iodosulfuron, Iodosulfuronmethyl-natrium, Mesosulfuron, Metosulam, Metsulfuron, Metsulfuron-methyl, Nicosulfuron, Orthosulfamuron, Oxasulfuron, Penoxsulam, Primisulfuron, Primisulfuron-methyl, Propoxycarbazon, Propoxycarbazon-natrium, Prosulfuron, Pyrazosulfuron, Pyrazosulfuronethyl, Pyribenzoxim, Pyrimisulfan, Pyriftalid, Pyriminobac, Pyriminobac-methyl, Pyrithiobac, Pyrithiobac-natrium, Pyroxsulam, Rimsulfuron, Sulfometuron, Sulfometuron-methyl, Sulfosulfuron, Thiencarbazon, Thiencarbazon-methyl, Thifensulfuron, Thifensulfuron-methyl, Triasulfuron, Tribenuron, Tribenuron-methyl, Trifloxysulfuron, Triflusulfuron, Triflusulfuronmethyl and Tritosulfuron;

c) from the group of Photosynthese-Inhibitors:

Ametryn, Amicarbazon, Atrazin, Bentazon, Bentazon-natrium, Bromacil, Bromofenoxim, Bromoxynil and its salts and esters, Chlorobromuron, Chloridazon, Chlorotoluron, Chloroxuron, Cyanazin, Desmedipham, Desmetryn, Dimefuron, Dimethametryn, Diquat, Diquat-dibromid, Diuron, Fluometuron, Hexazinon, loxynil and its salts and esters, Isoproturon, Isouron, Karbutilat, Lenacil, Linuron, Metamitron, Methabenzthiazuron, Metobenzuron, Metoxuron, Metribuzin, Monolinuron, Neburon, Paraquat, Paraquat-dichlorid, Paraquat-dimetilsulfat, Pentanochlor, Phenmedipham, Phenmedipham-ethyl, Prometon, Prometryn, Propanil, Propazin, Pyridafol, Pyridat, Siduron, Simazin, Simetryn, Tebuthiuron, Terbacil, Terbumeton, Terbuthylazin, Terbutryn, Thidiazuron and Trietazin;

d) from the group of Protoporphyrinogen-IX-Oxidase-Inhibitors:

Acifluorfen, Acifluorfen-natrium, Azafenidin, Bencarbazon, Benzfendizon, Benzoxazinone (as described in WO2010/145992), Bifenox, Butafenacil, Carfentrazon, Carfentrazon-ethyl, Chlomethoxyfen, Cinidon-ethyl, Fluazolat, Flufenpyr, Flufenpyr-ethyl, Flumiclorac, Flumiclorac-pentyl, Flumioxazin, Fluoroglycofen, Fluoroglycofen-ethyl, Fluthiacet, Fluthiacet-methyl, Fomesafen, Halosafen, Lactofen, Oxadiargyl, Oxadiazon, Oxyfluorfen, Pentoxazon, Profluazol, Pyraclonil, Pyraflufen, Pyraflufen-ethyl, Saflufenacil, Sulfentrazon, Thidiazimin, 2-Chlor-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluormethyl)-1(2H)-pyrimidinyl]-4-fluor-N-[(isopropyl)methylsulfamoyl]benzamid (H-1; CAS 372137-35-4), [3-[2-Chlor-4-fluor-5-(1-methyl-6-trifluormethyl-2,4-dioxo-1,2,3,4,-tetrahydropyrimidin-3-yl)phenoxy]-2-pyridyloxy]acetic acidethylester (H-2; CAS 353292-31-6), N-Ethyl-3-(2,6-dichlor-4-trifluormethylphenoxy)-5-methyl-1H-pyrazol-1-carboxamid (H-3; CAS 452098-92-9), N-Tetrahydrofurfuryl-3-(2,6-dichlor-4-trifluormethylphenoxy)-5-methyl-1H-pyrazol-1-carboxamid (H-4; CAS 915396-43-9), N-Ethyl-3-(2-chlor-6-fluor-4-trifluormethylphenoxy)-5-methyl-1H-pyrazol-1-carboxamid (H-5; CAS 452099-05-7) and N-Tetrahydrofurfuryl-3-(2-chlor-6-fluor-4-trifluormethylphenoxy)-5-methyl-1H-pyrazol-1-carboxamid (H-6; CAS 45100-03-7);

e) from the group of Bleacher-Herbicides:

Aclonifen, Amitrol, Beflubutamid, Benzobicyclon, Benzofenap, Clomazon, Diflufenican, Fluridon, Flurochloridon, Flurtamon, Isoxaflutol, Mesotrion, Norflurazon, Picolinafen, Pyrasulfutol, Pyrazolynat, Pyrazoxyfen, Sulcotrion, Tefuryltrion, Tembotrion, Topramezon, 4-Hydroxy-3-[[2-[(2-methoxyethoxy)methyl]-6-(trifluormethyl)-3-pyridyl]carbonyl]bicyclo[3.2.1]oct-3-en-2-one (H-7; CAS 352010-68-5) and 4-(3-Trifluormethyl-phenoxy)-2-(4-trifluormethylphenyl)pyrimidin (H-8; CAS 180608-33-7);

f) from the group of EPSP-Synthase-Inhibitors:

Glyphosat, Glyphosat-isopropylammonium and Glyphosat-trimesium (Sulfosat);

g) from the group of Glutamin-Synthase-Inhibitors:

Bilanaphos (Bialaphos), Bilanaphos-natrium, Glufosinat and Glufosinat-ammonium;

h) from the group of DHP-Synthase-Inhibitors: Asulam;

i) from the group of Mitose-Inhibitors:

Amiprophos, Amiprophos-methyl, Benfluralin, Butamiphos, Butralin, Carbetamid, Chlorpropham, Chlorthal, Chlorthal-dimethyl, Dinitramin, Dithiopyr, Ethalfluralin, Fluchloralin, Oryzalin, Pendimethalin, Prodiamin, Propham, Propyzamid, Tebutam, Thiazopyr and Trifluralin;

j) from the group of VLCFA-Inhibitors:

Acetochlor, Alachlor, Anilofos, Butachlor, Cafenstrol, Dimethachlor, Dimethanamid, Dimethenamid-P, Diphenamid, Fentrazamid, Flufenacet, Mefenacet, Metazachlor, Metolachlor, Metolachlor-S, Naproanilid, Napropamid, Pethoxamid, Piperophos, Pretilachlor, Propachlor, Propisochlor, Pyroxasulfon (KIH-485) and Thenylchlor; Compounds of the formula 2:

Particularly preferred Compounds of the formula 2 are: 3-[5-(2,2-Difluor-ethoxy)-1-methyl-3-trifluormethyl-1H-pyrazol-4-ylmethansulfonyl]-4-fluor-5,5-dimethyl-4,5-dihydro-isoxazol (2-1); 3-{[5-(2,2-Difluor-ethoxy)-1-methyl-3-trifluormethyl-1H-pyrazol-4-yl]-fluor-methansulfonyl}-5,5-dimethyl-4,5-dihydro-isoxazol (2-2); 4-(4-Fluor-5,5-dimethyl-4,5-dihydro-isoxazol-3-sulfonylmethyl)-2-methyl-5-trifluormethyl-2H-[1,2,3]triazol (2-3); 4-[(5,5-Dimethyl-4,5-dihydro-isoxazol-3-sulfonyl)-fluor-methyl]-2-methyl-5-trifluormethyl-2H-[1,2,3]triazol (2-4); 4-(5,5-Dimethyl-4,5-dihydro-isoxazol-3-sulfonylmethyl)-2-methyl-5-trifluormethyl-2H-[,2,3]triazol (2-5); 3-{[5-(2,2-Difluor-ethoxy)-1-methyl-3-trifluormethyl-1H-pyrazol-4-yl]-difluor-methansulfonyl}-5,5-dimethyl-4,5-dihydro-isoxazol (2-6); 4-[(5,5-Dimethyl-4,5-dihydro-isoxazol-3-sulfonyl)-difluor-methyl]-2-methyl-5-trifluormethyl-2H-[1,2,3]triazol (2-7); 3-{[5-(2,2-Difluor-ethoxy)-1-methyl-3-trifluormethyl-1H-pyrazol-4-yl]-difluor-methansulfonyl}-4-fluor-5,5-dimethyl-4,5-dihydro-isoxazol (2-8); 4-[Difluor-(4-fluor-5,5-dimethyl-4,5-dihydro-isoxazol-3-sulfonyl)-methyl]-2-methyl-5-trifluormethyl-2H-[1,2,3]triazol (2-9);

k) from the group of Cellulose-Biosynthese-Inhibitors:

Chlorthiamid, Dichlobenil, Flupoxam and Isoxaben;

l) from the group of Uncoupling-Herbicides:

Dinoseb, Dinoterb and DNOC and its salts;

m) from the group of Auxin-Herbicides:

2,4-D and its salts and esters, 2,4-DB and its salts and esters, Aminopyralid and its salts wie Aminopyralid-tris(2-hydroxypropyl)ammonium and its esters, Benazolin, Benazolin-ethyl, Chloramben and its salts and esters, Clomeprop, Clopyralid and its salts and esters, Dicamba and its salts and esters, Dichlorprop and its salts and esters, Dichlorprop-P and its salts and esters, Fluroxypyr, Fluroxypyr-butometyl, Fluroxypyr-meptyl, MCPA and its salts and esters, MCPA-thioethyl, MCPB and its salts and esters, Mecoprop and its salts and esters, Mecoprop-P and its salts and esters, Picloram and its salts and esters, Quinclorac, Quinmerac, TBA (2,3,6) and its salts and esters, Triclopyr and its salts and esters, and 5,6-Dichlor-2-cyclopropyl-4-pyrimidincarbonic acid (H-9; CAS 858956-08-8) and its salts and esters;

n) from the group of Auxin-Transport-Inhibitors: Diflufenzopyr, Diflufenzopyr-natrium, Naptalam and Naptalam-natrium;

o) from the group of other Herbicides: Bromobutid, Chlorflurenol, Chlorflurenol-methyl, Cinmethylin, Cumyluron, Dalapon, Dazomet, Difenzoquat, Difenzoquat-metilsulfate, Dimethipin, DSMA, Dymron, Endothal and its salts, Etobenzanid, Flamprop, Flamprop-isopropyl, Flamprop-methyl Flamprop-M-isopropyl, Flamprop-M-methyl, Flurenol, Flurenol-butyl, Flurprimidol, Fosamin, Fosamine-ammonium, Indanofan, Maleinic acid-hydrazid, Mefluidid, Metam, Methylazid, Methylbromid, Methyl-dymron, Methyljodid. MSMA, oleic acid, Oxaziclomefon, Pelargonic acid, Pyributicarb, Quinoclamin, Triazifiam, Tridiphan and 6-Chlor-3-(2-cyclopropyl-6-methylphenoxy)-4-pyridazinol (H-10; CAS 499223-49-3) and its salts and esters.

Examples for preferred Safeners C are Benoxacor, Cloquintocet, Cyometrinil, Cyprosulfamid, Dichlormid, Dicyclonon, Dietholate, Fenchlorazol, Fenclorim, Flurazol, Fluxofenim, Furilazol, Isoxadifen, Mefenpyr, Mephenat, Naphthalic acid anhydrid, Oxabetrinil, 4-(Dichloracetyl)-1-oxa-4-azaspiro[4.5]decan (H-11; MON4660, CAS 71526-07-3) and 2,2,5-Trimethyl-3-(dichloracetyl)-1,3-oxazolidin (H-12; R-29148, CAS 52836-31-4).

The compounds of groups a) to o) and the Safeners C are known Herbicides and Safeners, see e.g. The Compendium of Pesticide Common Names (http://www.alanwood.net/pesticides/); B. Hock, C. Fedtke, R. R. Schmidt, Herbicides, Georg Thieme Verlag, Stuttgart 1995. Other herbicidal effectors are known from WO 96/26202, WO 97/41116, WO 97/41117, WO 97/41118, WO 01/83459 and WO 2008/074991 as well as from W. Kramer et al. (ed.) “Modern Crop Protection Compounds”, Vol. 1, Wiley VCH, 2007 and the literature cited therein.

It is generally preferred to use the compounds of the invention in combination with herbicides that are selective for the crop being treated and which complement the spectrum of weeds controlled by these compounds at the application rate employed. It is further generally preferred to apply the compounds of the invention and other complementary herbicides at the same time, either as a combination formulation or as a tank mix.

The term “mut-HPPD nucleic acid” refers to an HPPD nucleic acid having a sequence that is mutated from a wild-type HPPD nucleic acid and that confers increased “HPPD-inhibiting herbicide” tolerance to a plant in which it is expressed. Furthermore, the term “mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD)” refers to the replacement of an amino acid of the wild-type primary sequences SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, a variant, a derivative, a homologue, an orthologue, or paralogue thereof, with another amino acid. The expression “mutated amino acid” will be used below to designate the amino acid which is replaced by another amino acid, thereby designating the site of the mutation in the primary sequence of the protein.

The term “mut-HST nucleic acid” refers to an HST nucleic acid having a sequence that is mutated from a wild-type HST nucleic acid and that confers increased “HPPD-inhibiting herbicide” tolerance to a plant in which it is expressed. Furthermore, the term “mutated homogentisate solanesyl transferase (mut-HST)” refers to the replacement of an amino acid of the wild-type primary sequences SEQ ID NO: 48 or 50 with another amino acid. The expression “mutated amino acid” will be used below to designate the amino acid which is replaced by another amino acid, thereby designating the site of the mutation in the primary sequence of the protein.

Several HPPDs and their primary sequences have been described in the state of the art, in particular the HPPDs of bacteria such as Pseudomonas (Ruetschi et al., Eur. J. Biochem., 205, 459-466, 1992, WO96/38567), of plants such as Arabidopsis (WO96/38567, Genebank AF047834) or of carrot (WO96/38567, Genebank 87257), of Coccicoides (Genebank COITRP), HPPDs of Brassica, cotton, Synechocystis, and tomato (U.S. Pat. No. 7,297,541), of mammals such as the mouse or the pig. Furthermore, artificial HPPD sequences have been described, for example in U.S. Pat. Nos. 6,768,044; 6,268,549;

In a preferred embodiment, the nucleotide sequence of (i) comprises the sequence of SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69 or a variant or derivative thereof.

In a particularly preferred embodiment, the mut-HPPD nucleic acid useful for the present invention comprises a mutated nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO: 52, or a variant or derivative thereof.

In another preferred embodiment, the nucleotide sequence of (ii) comprises the sequence of SEQ ID NO: 47 or 49, or a variant or derivative thereof.

Furthermore, it will be understood by the person skilled in the art that the nucleotide sequences of (i) or (ii) encompasses homologues, paralogues and and orthologues of SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, and respectively SEQ ID NO: 47 or 49, as defined hereinafter.

The term “variant” with respect to a sequence (e.g., a polypeptide or nucleic acid sequence such as—for example—a transcription regulating nucleotide sequence of the invention) is intended to mean substantially similar sequences. For nucleotide sequences comprising an open reading frame, variants include those sequences that, because of the degeneracy of the genetic code, encode the identical amino acid sequence of the native protein. Naturally occurring allelic variants such as these can be identified with the use of well-known molecular biology techniques, as, for example, with polymerase chain reaction (PCR) and hybridization techniques. Variant nucleotide sequences also include synthetically derived nucleotide sequences, such as those generated, for example, by using site-directed mutagenesis and for open reading frames, encode the native protein, as well as those that encode a polypeptide having amino acid substitutions relative to the native protein. Generally, nucleotide sequence variants of the invention will have at least 30, 40, 50, 60, to 70%, e.g., preferably 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, to 79%, generally at least 80%, e.g., 81%-84%, at least 85%, e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, to 98% and 99% nucleotide “sequence identity” to the nucleotide sequence of SEQ ID NO:1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, 47, or 49. By “variant” polypeptide is intended a polypeptide derived from the protein of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, by deletion (so-called truncation) or addition of one or more amino acids to the N-terminal and/or C-terminal end of the native protein; deletion or addition of one or more amino acids at one or more sites in the native protein; or substitution of one or more amino acids at one or more sites in the native protein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Methods for such manipulations are generally known in the art.

In a preferred embodiment, variants of the polynucleotides useful for the present invention will have at least 30, 40, 50, 60, to 70%, e.g., preferably 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, to 79%, generally at least 80%, e.g., 81%-84%, at least 85%, e.g., 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, to 98% and 99% nucleotide “sequence identity” to the nucleotide sequence of SEQ ID NO:1, or SEQ ID NO: 52.

It is recognized that the polynucleotide molecules and polypeptides of the invention encompass polynucleotide molecules and polypeptides comprising a nucleotide or an amino acid sequence that is sufficiently identical to nucleotide sequences set forth in SEQ ID Nos: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, 47, or 49, or to the amino acid sequences set forth in SEQ ID Nos: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 48, or 50. The term “sufficiently identical” is used herein to refer to a first amino acid or nucleotide sequence that contains a sufficient or minimum number of identical or equivalent (e.g., with a similar side chain) amino acid residues or nucleotides to a second amino acid or nucleotide sequence such that the first and second amino acid or nucleotide sequences have a common structural domain and/or common functional activity.

“Sequence identity” refers to the extent to which two optimally aligned DNA or amino acid sequences are invariant throughout a window of alignment of components, e.g., nucleotides or amino acids. An “identity fraction” for aligned segments of a test sequence and a reference sequence is the number of identical components that are shared by the two aligned sequences divided by the total number of components in reference sequence segment, i.e., the entire reference sequence or a smaller defined part of the reference sequence. “Percent identity” is the identity fraction times 100. Optimal alignment of sequences for aligning a comparison window are well known to those skilled in the art and may be conducted by tools such as the local homology algorithm of Smith and Waterman, the homology alignment algorithm of Needleman and Wunsch, the search for similarity method of Pearson and Lipman, and preferably by computerized implementations of these algorithms such as GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG. Wisconsin Package. (Accelrys Inc. Burlington, Mass.)

The terms “polynucleotide(s)”, “nucleic acid sequence(s)”, “nucleotide sequence(s)”, “nucleic acid(s)”, “nucleic acid molecule” are used interchangeably herein and refer to nucleotides, either ribonucleotides or deoxyribonucleotides or a combination of both, in a polymeric unbranched form of any length.

“Derivatives” of a protein encompass peptides, oligopeptides, polypeptides, proteins and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified protein in question and having similar biological and functional activity as the unmodified protein from which they are derived.

“Homologues” of a protein encompass peptides, oligopeptides, polypeptides, proteins and enzymes having amino acid substitutions, deletions and/or insertions relative to the unmodified protein in question and having similar biological and functional activity as the unmodified protein from which they are derived.

A deletion refers to removal of one or more amino acids from a protein.

An insertion refers to one or more amino acid residues being introduced into a predetermined site in a protein. Insertions may comprise N-terminal and/or C-terminal fusions as well as intra-sequence insertions of single or multiple amino acids. Generally, insertions within the amino acid sequence will be smaller than N- or C-terminal fusions, of the order of about 1 to 10 residues. Examples of N- or C-terminal fusion proteins or peptides include the binding domain or activation domain of a transcriptional activator as used in the yeast two-hybrid system, phage coat proteins, (histidine)-6-tag, glutathione S-transferase-tag, protein A, maltose-binding protein, dihydrofolate reductase, Tag⋅100 epitope, c-myc epitope, FLAG®-epitope, lacZ, CMP (calmodulin-binding peptide), HA epitope, protein C epitope and VSV epitope.

A substitution refers to replacement of amino acids of the protein with other amino acids having similar properties (such as similar hydrophobicity, hydrophilicity, antigenicity, propensity to form or break α-helical structures or β-sheet structures). Amino acid substitutions are typically of single residues, but may be clustered depending upon functional constraints placed upon the polypeptide and may range from 1 to 10 amino acids; insertions will usually be of the order of about 1 to 10 amino acid residues. The amino acid substitutions are preferably conservative amino acid substitutions. Conservative substitution tables are well known in the art (see for example Creighton (1984) Proteins. W.H. Freeman and Company (Eds).

TABLE 3 Examples of conserved amino acid substitutions Conservative Residue Conservative Substitutions Residue Substitutions Ala Ser Leu Ile; Val Arg Lys Lys Arg; Gln Asn Gln; His Met Leu; Ile Asp Glu Phe Met; Leu; Tyr Gln Asn Ser Thr; Gly Cys Ser Thr Ser; Val Glu Asp Trp Tyr Gly Pro Tyr Trp; Phe His Asn; Gln Val Ile; Leu Ile Leu, Val

Amino acid substitutions, deletions and/or insertions may readily be made using peptide synthetic techniques well known in the art, such as solid phase peptide synthesis and the like, or by recombinant DNA manipulation. Methods for the manipulation of DNA sequences to produce substitution, insertion or deletion variants of a protein are well known in the art. For example, techniques for making substitution mutations at predetermined sites in DNA are well known to those skilled in the art and include M13 mutagenesis, T7-Gen in vitro mutagenesis (USB, Cleveland, Ohio), QuikChange Site Directed mutagenesis (Stratagene, San Diego, Calif.), PCR-mediated site-directed mutagenesis or other site-directed mutagenesis protocols.

“Derivatives” further include peptides, oligopeptides, polypeptides which may, compared to the amino acid sequence of the naturally-occurring form of the protein, such as the protein of interest, comprise substitutions of amino acids with non-naturally occurring amino acid residues, or additions of non-naturally occurring amino acid residues. “Derivatives” of a protein also encompass peptides, oligopeptides, polypeptides which comprise naturally occurring altered (glycosylated, acylated, prenylated, phosphorylated, myristoylated, sulphated etc.) or non-naturally altered amino acid residues compared to the amino acid sequence of a naturally-occurring form of the polypeptide. A derivative may also comprise one or more non-amino acid substituents or additions compared to the amino acid sequence from which it is derived, for example a reporter molecule or other ligand, covalently or non-covalently bound to the amino acid sequence, such as a reporter molecule which is bound to facilitate its detection, and non-naturally occurring amino acid residues relative to the amino acid sequence of a naturally-occurring protein. Furthermore, “derivatives” also include fusions of the naturally-occurring form of the protein with tagging peptides such as FLAG, HIS6 or thioredoxin (for a review of tagging peptides, see Terpe, Appl. Microbiol. Biotechnol. 60, 523-533, 2003).

“Orthologues” and “paralogues” encompass evolutionary concepts used to describe the ancestral relationships of genes. Paralogues are genes within the same species that have originated through duplication of an ancestral gene; orthologues are genes from different organisms that have originated through speculation, and are also derived from a common ancestral gene. A non-limiting list of examples of such orthologues is shown in Table 1.

It is well-known in the art that paralogues and orthologues may share distinct domains harboring suitable amino acid residues at given sites, such as binding pockets for particular substrates or binding motifs for interaction with other proteins.

The term “domain” refers to a set of amino acids conserved at specific positions along an alignment of sequences of evolutionarily related proteins. While amino acids at other positions can vary between homologues, amino acids that are highly conserved at specific positions indicate amino acids that are likely essential in the structure, stability or function of a protein. Identified by their high degree of conservation in aligned sequences of a family of protein homologues, they can be used as identifiers to determine if any polypeptide in question belongs to a previously identified polypeptide family.

The term “motif” or “consensus sequence” refers to a short conserved region in the sequence of evolutionarily related proteins. Motifs are frequently highly conserved parts of domains, but may also include only part of the domain, or be located outside of conserved domain (if all of the amino acids of the motif fall outside of a defined domain).

Specialist databases exist for the identification of domains, for example, SMART (Schultz et al. (1998) Proc. Natl. Acad. Sci. USA 95, 5857-5864; Letunic et al. (2002) Nucleic Acids Res 30, 242-244), InterPro (Mulder et al., (2003) Nucl. Acids. Res. 31, 315-318), Prosite (Bucher and Bairoch (1994), A generalized profile syntax for biomolecular sequences motifs and its function in automatic sequence interpretation. (In) ISMB-94; Proceedings 2nd Inter-national Conference on Intelligent Systems for Molecular Biology. Altman R., Brutlag D., Karp P., Lathrop R., Searls D., Eds., pp 53-61, AAAI Press, Menlo Park; Hulo et al., Nucl. Acids. Res. 32:D134-D137, (2004)), or Pfam (Bateman et al., Nucleic Acids Research 30(1): 276-280 (2002)). A set of tools for in silico analysis of protein sequences is available on the ExPASy proteomics server (Swiss Institute of Bioinformatics (Gasteiger et al., ExPASy: the proteomics server for in-depth protein knowledge and analysis, Nucleic Acids Res. 31:3784-3788(2003)). Domains or motifs may also be identified using routine techniques, such as by sequence alignment.

Methods for the alignment of sequences for comparison are well known in the art, such methods include GAP, BESTFIT, BLAST, FASTA and TFASTA. GAP uses the algorithm of Needleman and Wunsch ((1970) J Mol Biol 48: 443-453) to find the global (i.e. spanning the complete sequences) alignment of two sequences that maximizes the number of matches and minimizes the number of gaps. The BLAST algorithm (Altschul et al. (1990) J Mol Biol 215: 403-10) calculates percent sequence identity and performs a statistical analysis of the similarity between the two sequences. The software for performing BLAST analysis is publicly available through the National Centre for Biotechnology Information (NCBI). Homologues may readily be identified using, for example, the ClustalW multiple sequence alignment algorithm (version 1.83), with the default pairwise alignment parameters, and a scoring method in percentage. Global percentages of similarity and identity may also be determined using one of the methods available in the MatGAT software package (Campanella et al., BMC Bioinformatics. 2003 Jul. 10; 4:29. MatGAT: an application that generates similarity/identity matrices using protein or DNA sequences.). Minor manual editing may be performed to optimise alignment between conserved motifs, as would be apparent to a person skilled in the art. Furthermore, instead of using full-length sequences for the identification of homologues, specific domains may also be used. The sequence identity values may be determined over the entire nucleic acid or amino acid sequence or over selected domains or conserved motif(s), using the programs mentioned above using the default parameters. For local alignments, the Smith-Waterman algorithm is particularly useful (Smith T F, Waterman M S (1981) J. Mol. Biol 147(1); 195-7).

The inventors of the present invention have surprisingly found that by substituting one or more of the key amino acid residues the herbicide tolerance or resistance could be remarkably increased as compared to the activity of the wild type HPPD enzymes with SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67. Preferred substitutions of mut-HPPD are those that increase the herbicide tolerance of the plant, but leave the biological activity of the dioxygenase activity substantially unaffected.

Accordingly, in another object of the present invention the key amino acid residues of a HPPD enzyme comprising SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, a variant, derivative, othologue, paralogue or homologue thereof, is substituted by any other amino acid.

In one embodiment, the key amino acid residues of a HPPD enzyme, a variant, derivative, othologue, paralogue or homologue thereof, is substituted by a conserved amino acid as depicted in Table 3 above.

It will be understood by the person skilled in the art that amino acids located in a close proximity to the positions of amino acids mentioned below may also be substituted. Thus, in another embodiment the mut HPPD useful for the present invention comprises a sequence of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or a variant, derivative, orthologue, paralogue or homologue thereof, wherein an amino acid ±3, ±2 or ±1 amino acid positions from a key amino acid is substituted by any other amino acid.

Based on techniques well-known in the art, a highly characteristic sequence pattern can be developed, by means of which further of mut-HPPD candidates with the desired activity may be searched.

Searching for further mut-HPPD candidates by applying a suitable sequence pattern would also be encompassed by the present invention. It will be understood by a skilled reader that the present sequence pattern is not limited by the exact distances between two adjacent amino acid residues of said pattern. Each of the distances between two neighbours in the above patterns may, for example, vary independently of each other by up to ±10, ±5, ±3, ±2 or ±1 amino acid positions without substantially affecting the desired activity.

In line with said above functional and spatial analysis of individual amino acid residues based on the crystallographic data as obtained according to the present invention, unique partial amino acid sequences characteristic of potentially useful mut-HPPD candidates of the invention may be identified.

In a particularly preferred embodiment, the mut-HPPD refers to a variant or derivative of SEQ ID NO: 2 wherein the substitutions are selected from the following Table 4a.

TABLE 4a (Sequence ID No: 2): single amino acid substitutions Key amino acid position Substituents Val212 Ile, Leu Val213 Thr, Ala Asn215 Ala, His Ala236 Leu, Ser, Arg Phe238 Val, Ala Leu250 Val, Met Ser252 Thr Pro265 Ala Asn267 Tyr, Gln Gln278 His, Asn, Ser Ile279 Thr Arg309 Lys, Ala Leu320 Asn, Gln, His, Tyr, Pro321 Ala, Arg, Gly, Asn Leu334 Glu, Cys Leu353 Met, Tyr, Ala, Ser Phe366 Ile, Leu, Tyr Gly371 Ile, Phe Thr375 Pro Phe377 Ala, Leu, Ser Gly403 Arg Phe404 Leu, Pro Lys406 Thr Gly407 Cys, His Phe409 Ile, His Glu411 Thr Leu412 Met, Phe, Trp, Ala, Ser Ile416 Val, Phe Ser410 Gly Val254 Ala

It is to be understood that any amino acid besides the ones mentioned in the above tables could be used as a substitutent. Assays to test for the functionality of such mutants are readily available in the art, and respectively, described in the Example section of the present invention.

In a preferred embodiment, the amino acid sequence of a mut-HPPD differs from an amino acid sequence of a wildtype HPPD at one or more of the following positions corresponding to positions: 212, 213, 215, 236, 238, 250, 252, 254, 265, 267, 278, 279, 309, 320, 321, 334, 353, 366, 371, 375, 377, 403, 404, 406, 407, 409, 411, 410, 412 or 416 of SEQ ID NO:2.

Examples of differences at these amino acid positions include, but are not limited to, one or more of the following:

the amino acid corresponding to or at position 236 is other than alanine;

the amino acid corresponding to or at position 411 is other than glutamic acid;

the amino acid corresponding to or at position 320 is other than leucine;

the amino acid corresponding to or at position 403 is other than glycine;

the amino acid corresponding to or at position 334 is other than leucine;

the amino acid corresponding to or at position 353 is other than leucine;

the amino acid corresponding to or at position 321 is other than proline;

the amino acid corresponding to or at position 212 is other than valine;

the amino acid corresponding to or at position 407 is other than glycine;

the amino acid corresponding to or at position 377 is other than phenylalanine;

the amino acid corresponding to or at position 412 is other than leucine;

the amino acid corresponding to or at position 278 is other than glutamine;

the amino acid corresponding to or at position 406 is other than lysine;

the amino acid corresponding to or at position 404 is other than phenylalanine;

the amino acid corresponding to or at position 409 is other than phenylalanine;

the amino acid corresponding to or at position 416 is other than isoleucine;

the amino acid corresponding to or at position 250 is other than leucine;

the amino acid corresponding to or at position 267 is other than asparagine;

the amino acid corresponding to or at position 252 is other than serine;

the amino acid corresponding to or at position 265 is other than proline;

the amino acid corresponding to or at position 371 is other than glycine;

the amino acid corresponding to or at position 375 is other than threonine;

the amino acid corresponding to or at position 309 is other than arginine;

the amino acid corresponding to or at position 279 is other than isoleucine;

the amino acid corresponding to or at position 366 is other than phenylalanine;

the amino acid corresponding to or at position 238 is other than phenylalanine;

the amino acid corresponding to or at position 213 is other than valine;

the amino acid corresponding to or at position 215 is other than asparagine;

the amino acid corresponding to or at position 410 is other than serine;

the amino acid corresponding to or at position 254 is other than valine.

In some embodiments, the mut HPPD enzyme comprises a polypeptide of SEQ ID NO:2, a variant, derivative, homologue or orthologue thereof, having one or more substitutions at the following positions:

the amino acid corresponding to or at position 236 is leucine, serine or arginine;

the amino acid corresponding to or at position 411 is threonine;

the amino acid corresponding to or at position 320 is asparagine, glutamine, histidine or tyrosine;

the amino acid corresponding to or at position 403 is arginine;

the amino acid corresponding to or at position 334 is glutamic acid or cysteine;

the amino acid corresponding to or at position 353 is methionine, tyrosine, alanine, or serine;

the amino acid corresponding to or at position 321 is alanine, arginine, glycine or asparagine;

the amino acid corresponding to or at position 212 is isoleucine or leucine;

the amino acid corresponding to or at position 407 is cysteine or histidine;

the amino acid corresponding to or at position 377 is alanine, leucine or serine;

the amino acid corresponding to or at position 412 is methionine, phenylalanine, tryptophan, alanine or serine;

the amino acid corresponding to or at position 278 is histidine, asparagine or serine;

the amino acid corresponding to or at position 406 is threonine;

the amino acid corresponding to or at position 404 is leucine or proline;

the amino acid corresponding to or at position 409 is isoleucine or histidine;

the amino acid corresponding to or at position 416 is valine or phenylalanine;

the amino acid corresponding to or at position 250 is valine or methionine;

the amino acid corresponding to or at position 267 is tyrosine or glutamine;

the amino acid corresponding to or at position 252 is threonine;

the amino acid corresponding to or at position 265 is alanine;

the amino acid corresponding to or at position 371 is isoleucine or phenylalanine;

the amino acid corresponding to or at position 375 is proline;

the amino acid corresponding to or at position 309 is lysine or alanine;

the amino acid corresponding to or at position 279 is threonine;

the amino acid corresponding to or at position 366 is isoleucine, leucine or tyrosine;

the amino acid corresponding to or at position 238 is valine or alanine;

the amino acid corresponding to or at position 213 is threonine or alanine;

the amino acid corresponding to or at position 215 is alanine or histidine;

the amino acid corresponding to or at position 410 is glycine;

the amino acid corresponding to or at position 254 is alanine.

Furthermore, the inventors of the present invention have surprisingly found that by substituting at least two of the key amino acid residues of SEQ ID NO: 2 with specific residues, the herbicide tolerance or resistance could be remarkably increased as compared to the activity of the wild type HPPD enzymes or HPPD enzymes in which only one amino acid residue had been substituted. Therefore, in another preferred embodiment the present invention the variant or derivative of the mut-HPPD refers to a polypeptide of SEQ ID NO: 2, wherein two, three, four or five key amino acids are substituted by another amino acid residue. Particularly preferred double, triple, quadruple, or quintuple mutations are described in Table 4b.

TABLE 4b (with reference to Sequence ID No: 2): combined amino acid substitutions Combination No Key amino acid position and and its substitutents 1 A236L, E411T 2 L320H, P321A 3 L320H, P321R 4 L320N, P321A 5 L320N, P321R 6 L320Q, P321A 7 L320Q, P321R 8 L320Y, P321A 9 L320Y, P321R 10 L353M, P321R 11 L353M, P321R, A236L 12 L353M, P321R, A236L, E411T 13 L353M, P321R, E411T 14 L353M, P321R, L320H 15 L353M, P321R, L320N 16 L353M, P321R, L320Q 17 L353M, P321R, L320Y 18 L353M, P321R, V212I 19 L353M, P321R, V212I, L334E 20 L353M, P321R, V212L, L334E 21 L353M, P321R, V212L, L334E, A236L 22 L353M, P321R, V212L, L334E, A236L, E411T 23 L353M, P321R, V212L, L334E, E411T 24 L353M, P321R, V212L, L334E, L320H 25 L353M, P321R, V212L, L334E, L320N 26 L353M, P321R, V212L, L334E, L320Q 27 L353M, P321R, V212L, L334E, L320Y 28 L353M, V212I

In a particularly preferred embodiment, the mut HPPD enzyme comprising a polypeptide of SEQ ID NO: 2, a variant, derivative, homologue, paralogue or orthologue thereof, useful for the present invention comprises one or more of the following: the amino acid corresponding to or at position 320 is histidine, asparagine or glutamine; the amino acid position 334 is glutamic acid; the amino acid position 353 is methionine; the amino acid corresponding to or at position 321 alanine or arginine; the amino acid corresponding to or at position 212 is isoleucine.

In an especially particularly preferred embodiment, the mut HPPD refers to a polypeptide comprising SEQ ID NO: 2, wherein the leucine corresponding to or at position 320 is substituted by a histidine, and the proline corresponding to or at position 321 is substituted by an alanine.

In another especially particularly preferred embodiment, the mut HPPD refers to a polypeptide comprising SEQ ID NO: 2, wherein Leucine corresponding to or at position 353 is substituted by a Methionine, the Proline corresponding to or at position 321 is substituted by an Arginine, and the Leucine corresponding to or at position 320 is substituted by an Asparagine.

In another especially particularly preferred embodiment, the mut HPPD refers to a polypeptide comprising SEQ ID NO: 2, wherein the Leucine corresponding to or at position 353 is substituted by a Methionine, the Proline corresponding to or at position 321 is substituted by an Arginine, and the Leucine corresponding to or at position 320 is substituted by a glutamine.

In another preferred embodiment, the mut-HPPD refers to a variant or derivative of SEQ ID NO: 53 wherein the substitutions are selected from the following Table 4c.

TABLE 4c (Sequence ID No: 53): single amino acid substitutions Key amino Preferred acid position Substituents substituents Val228 Thr, Ala Thr, Ala Asn230 Ala, His Ala, His Ala251 Ser, Arg Ser, Arg Phe253 Val, Ala Val, Ala Leu265 Val, Met Val, Met Ser267 Thr Thr Pro280 Ala Ala Asn282 Tyr, Gln Tyr, Gln Lys291 Arg, Ala Arg Gln293 Ala, Leu, Ile, Val, His, Asn, Ser His, Asn, Ser Ile294 Thr Thr Arg324 Lys, Ala Lys, Ala Met335 Ala, Trp, Phe, Leu, Ile, Val, Asn, Gln, Gln, Asn, His, His, Tyr, Ser, Thr, Cys Tyr Pro336 Ala, Arg, Gly, Asn Ala, Gly Ser337 Ala, Pro, Thr Pro, Thr Pro339 Deletion Deletion Pro340 Gly Gly Glu363 Gln Gln Leu368 Met, Tyr, Met Phe381 Ile, Leu, Tyr Ile, Leu Leu385 Ala, Val, Gln, Asp Val, Asp Gly386 Ile, Phe Ile, Phe Thr390 Pro Pro Phe392 Ala, Leu, Ser Ala Ile393 Ala, Leu, Phe, Val Leu Phe419 Leu, Pro Leu, Pro Lys421 Thr Thr Gly422 His, Met, Phe, Cys His, Cys Phe424 Ile, His Ile, His Leu427 Phe, Trp, Ala, Ser, Met Phe Ile431 Val, Phe Val, Phe Ser425 Gly Gly Val269 Ala Ala

It is to be understood that any amino acid besides the ones mentioned in the above tables could be used as a substitutent. Assays to test for the functionality of such mutants are readily available in the art, and respectively, described in the Example section of the present invention.

In another preferred embodiment, the mut-HPPD amino acid sequence differs from a wildtype amino acid sequence of an HPPD at one or more positions corresponding to or at the following positions of SEQ ID NO:53:

228, 230, 251, 253, 265, 267, 280, 282, 291, 293, 294, 324, 335, 336, 337, 339, 340, 363, 368, 381, 385, 386, 390, 392, 393, 419, 421, 422, 424, 427, 431, 425, 269.

Examples of differences at these amino acid positions include, but are not limited to, one or more of the following:

the amino acid corresponding to or at position 228 is other than valine;

the amino acid corresponding to or at position 230 is other than asparagine;

the amino acid corresponding to or at position 251 is other than alanine;

the amino acid corresponding to or at position 253 is other than phenylalanine;

the amino acid corresponding to or at position 265 is other than leucine;

the amino acid corresponding to or at position 267 is other than serine;

the amino acid corresponding to or at position 280 is other than proline;

the amino acid corresponding to or at position 282 is other than asparagine;

the amino acid corresponding to or at position 291 is other than lysine;

the amino acid corresponding to or at position 293 is other than glutamine;

the amino acid corresponding to or at position 294 is other than isoleucine;

the amino acid corresponding to or at position 324 is other than arginine;

the amino acid corresponding to or at position 335 is other than methionine;

the amino acid corresponding to or at position 336 is other than proline;

the amino acid corresponding to or at position 337 is other than serine;

the amino acid corresponding to or at position 339 is other than proline;

the amino acid corresponding to or at position 340 is other than proline;

the amino acid corresponding to or at position 363 is other than glutamic acid;

the amino acid corresponding to or at position 368 is other than leucine;

the amino acid corresponding to or at position 381 is other than phenylalanine;

the amino acid corresponding to or at position 385 is other than leucine;

the amino acid corresponding to or at position 386 is other than glycine;

the amino acid corresponding to or at position 390 is other than threonine;

the amino acid corresponding to or at position 392 is other than phenylalanine;

the amino acid corresponding to or at position 393 is other than an isoleucine;

the amino acid corresponding to or at position 419 is other than phenylalanine;

the amino acid corresponding to or at position 421 is other than lysine;

the amino acid corresponding to or at position 422 is other than glycine;

the amino acid corresponding to or at position 424 is other than phenylalanine;

the amino acid corresponding to or at position 427 is other than leucine;

the amino acid corresponding to or at position 431 is other than isoleucine;

the amino acid corresponding to or at position 425 is other than serine;

the amino acid corresponding to or at position 269 is other than valine.

In some embodiments, the mut-HPPD enzyme comprises one or more substitutions at positions corresponding to the following positions of SEQ ID NO: 53:

the amino acid corresponding to or at position 228 is Thr, or Ala;

the amino acid corresponding to or at position 230 is Ala, or His;

the amino acid corresponding to or at position 251 is Ser, or Arg;

the amino acid corresponding to or at position 253 is Val, or Ala;

the amino acid corresponding to or at position 265 is Val, or Met;

the amino acid corresponding to or at position 267 is threonine;

the amino acid corresponding to or at position 280 is Ala;

the amino acid corresponding to or at position 282 is Tyr, or Gln;

the amino acid corresponding to or at position 291 is Arg, or Ala;

the amino acid corresponding to or at position 293 is alanine, leucine, isoleucine, valine, histidine, asparagine or serine, preferably histidine, asparagine or serine;

the amino acid corresponding to or at position 294 is threonine;

the amino acid corresponding to or at position 324 is Lys, or Ala;

the amino acid corresponding to or at position 335 is alanine, tryptophane, phenylalanine, leucine, isoleucine, valine, asparagine, glutamine, histidine, tyrosine, serine, threonine or cysteine, preferably Gln, Asn, His, or Tyr;

the amino acid corresponding to or at position 336 is alanine, arginine, Gly, or Asn, preferably alanine or glycine;

the amino acid corresponding to or at position 337 is alanine, threonine or proline, preferably threonine or proline;

the amino acid corresponding to or at position 339 is deleted;

the amino acid corresponding to or at position 340 is glycine;

the amino acid corresponding to or at position 363 is glutamine;

the amino acid corresponding to or at position 368 is methionine or tyrosine, preferably methionine;

the amino acid corresponding to or at position 381 is Ile, Leu, or Tyr, preferably Isoleucine or leucine;

the amino acid corresponding to or at position 385 is valine, alanine, Gln, or Asp, preferably valine or aspartic acid;

the amino acid corresponding to or at position 386 is Ile, or Phe;

the amino acid corresponding to or at position 390 is Pro;

the amino acid corresponding to or at position 392 is alanine, leucine or serine, preferably alanine;

the amino acid corresponding to or at position 393 is Ala, Leu, Phe, Val, preferably leucine;

the amino acid corresponding to or at position 419 is Leu or Pro;

the amino acid corresponding to or at position 421 is threonine;

the amino acid corresponding to or at position 422 is histidine, methionine, phenylalanine, or cysteine, preferably histidine or cysteine;

the amino acid corresponding to or at position 424 is Ile or His;

the amino acid corresponding to or at position 427 is phenylalanine, tryptophan, Ala, Ser, or Met, preferably phenylalanine;

the amino acid corresponding to or at position 431 is Val or Phe;

the amino acid corresponding to or at position 425 is glycine;

the amino acid corresponding to or at position 269 is alanine.

Furthermore, the inventors of the present invention have found that by substituting at least two of the key amino acid residues of SEQ ID NO: 53 with specific residues, the herbicide tolerance or resistance could be remarkably increased as compared to the activity of the wild type HPPD enzymes or HPPD enzymes in which only one amino acid residue had been substituted. Therefore, in another preferred embodiment the present invention the variant or derivative of the mut-HPPD refers to a polypeptide of SEQ ID NO: 53, a homologue, orthologue, or paralogue thereof, wherein two, three, four or five key amino acids are substituted by another amino acid residue. Particularly preferred double, triple, quadruple, or quintuple mutations are described in Table 4d.

TABLE 4d (reference to Sequence ID No: 53): combined amino acid substitutions Combination Key amino acid Preferred No position Substituents substituents 1 Pro336 Ala, Arg Ala Glu363 Gln Gln 2 Pro336 Ala, Arg Ala Glu363 Gln Gln Leu385 Ala, Val Val 3 Pro336 Ala, Arg Ala Glu363 Gln Gln Leu385 Ala, Val Val Ile393 Ala, Leu Leu 4 Leu385 Ala, Val Val Ile393 Ala, Leu Leu 5 Met335 Ala, Trp, Phe, Leu, Ile, Gln, Asn, His, Val, Asn, Gln, His, Tyr, Ser, Thr, Cys Tyr Pro336 Ala, Arg, Gly Ala, Gly 6 Met335 Ala, Trp, Phe, Leu, Ile, Gln, Asn, His, Val, Asn, Gln, His, Tyr, Ser, Thr, Cys Tyr Pro336 Ala, Arg, Gly Ala, Gly Glu363 Gln Gln 7 Met335 Ala, Trp, Phe, Leu, Ile, Gln, Asn, His, Val, Asn, Gln, His, Tyr, Ser, Thr, Cys Tyr, Leu Pro336 Ala, Arg, Gly Ala, Arg, Gly Ser337 Ala, Pro, Thr Pro, Thr Pro339 Deletion Deletion Pro340 Gly Gly

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, or Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, Val.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala, Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala, Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 385 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 393 of SEQ ID NO:53 is Leu.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, Trp, Phe, Leu, Ile, Val, Asn, Gin, His, Tyr, Ser, Thr, Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, Arg, Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, Trp, Phe, Leu, Ile, Val, Asn, Gin, His, Tyr, Ser, Thr, Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, Arg, Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 363 of SEQ ID NO:53 is Gln.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, Trp, Phe, Leu, Ile, Val, Asn, Gin, His, Tyr, Ser, Thr, Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, Arg, Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, Pro, Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Trp, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Phe, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Leu, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ile, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Val, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Asn, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Gln, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is His, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Tyr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Ser, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Arg, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Ala, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Pro, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another preferred embodiment, the mut-HPPD comprises a sequence of SEQ ID NO: 53 a variant, derivative, orthologue, paralogue or homologue thereof, in which:

the amino acid corresponding to or at position 335 of SEQ ID NO:53 is Cys, and the amino acid corresponding to or at position 336 of SEQ ID NO:53 is Gly, and the amino acid corresponding to or at position 337 of SEQ ID NO:53 is Thr, and the amino acid corresponding to or at position 339 of SEQ ID NO:53 is deleted, and the amino acid corresponding to or at position 340 of SEQ ID NO:53 is Gly.

In another embodiment, the variant or derivative of the HPPD enzyme of SEQ ID NO: 67 comprises one or more of the following substitutions:

the alanine corresponding to or at position 8 is substituted by threonine;

the glycine corresponding to or at position 68 is substituted by alanine;

the valine at position 261 is substituted by alanine;

the methionine corresponding to or at position 301 is substituted by isoleucine;

the methionine corresponding to or at position 327 is substituted by leucine;

the alanine corresponding to or at position 328 is substituted by proline;

the threonine corresponding to or at position 331 is substituted by proline;

the arginine corresponding to or at position 341 is substituted by glutamic acid;

the lysine corresponding to or at position 352 is substituted by asparagine;

the leucine corresponding to or at position 360 is substituted by methionine;

The leucine corresponding to or at position 383 is substituted by phenylalanine;

The glycine corresponding to or at position 414 is substituted by aspartic acid.

In another embodiment, the variant or derivative of the HPPD enzyme of SEQ ID NO: 67 comprises one or more of the following substitutions:

the alanine corresponding to or at position 8 is substituted by threonine;

the histidine corresponding to or at position 44 is substituted by glutamine;

the glycine at position 68 is substituted by alanine;

the alanine corresponding to or at position 71 is substituted by valine;

the phenylalanine at position 98 is substituted by leucine;

the phenylalanine corresponding to or at position 233 is substituted by methionine;

the alanine corresponding to or at position 253 is substituted by threonine;

the valine corresponding to or at position 261 is substituted by alanine;

the methionine corresponding to or at position 301 is substituted by isoleucine;

the glutamine corresponding to or at position 316 is substituted by arginine;

the methionine corresponding to or at position 327 is substituted by leucine;

the alanine corresponding to or at position 328 is substituted by proline;

the threonine corresponding to or at position 331 is substituted by proline;

the arginine corresponding to or at position 341 is substituted by cysteine;

the lysine corresponding to or at position 352 is substituted by asparagine;

the leucine corresponding to or at position 360 is substituted by methionine;

the leucine corresponding to or at position 383 is substituted by phenylalanine;

the serine corresponding to or at position 417 is substituted by glycine.

In a further preferred embodiment, the amino acid sequence differs from an amino acid sequence of an HPPD of SEQ ID NO: 57 corresponding to or at position 418. Preferably, the amino acid corresponding to or at position 418 is other than alanine. More preferably, the amino acid corresponding to or at position 418 is threonine.

In a further preferred embodiment, the amino acid sequence differs from an amino acid sequence of an HPPD of SEQ ID NO: 57 corresponding to or at position 237. Preferably, the amino acid corresponding to or at position 237 is other than serine. More preferably, the amino acid corresponding to or at position 237 is leucine.

The corresponding positions, i.e. preferred sites to be substituted are listed in the following-Table 4 e)

TABLE 4e SEQ- Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos ID 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 53 A227 V228 N230 A251 F253 L265 S267 V269 P280 N282 K291 Q293 I294 R324 M335 P336 S337 P339 P340 2 V212 V213 N215 A236 F238 L250 S252 V254 P265 N267 R276 Q278 I279 R309 L320 P321 P322 L324 P325 5 A270 V271 N273 A294 F296 L308 S310 V312 P323 N325 K333 Q335 I336 R366 M378 K379 R380 S382 E383 8 A227 V228 N230 A251 F253 L265 S267 V269 P280 N282 K291 Q293 I294 R324 M335 P336 R337 S339 P340 11 T192 V193 N195 A216 F218 L230 S232 V234 P245 N247 K255 Q257 I258 R288 M300 K301 R302 S304 D305 14 V152 V153 N155 Q178 F180 L189 S191 A193 N204 N206 N212 Q214 I215 R245 L252 S253 V254 N256 S257 17 G160 V161 N163 R186 F188 L197 S199 V201 P212 N214 N220 Q222 I223 K253 L260 D261 I262 P264 S265 20 V145 V146 N148 Q171 F173 L182 S184 A186 N197 N199 S205 Q207 I208 R238 L245 K246 I247 T249 G250 22 V218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 R315 M326 A327 P328 Q330 A331 24 V218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 R315 M326 A327 P328 Q330 A331 26 I218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 Q315 M326 A327 P328 A330 P331 28 I218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 Q315 M326 A327 P328 A330 P331 30 V212 V213 N215 A236 F238 L250 S252 V254 P265 N267 R276 Q278 I279 Q309 M320 A321 P322 Q324 P325 32 V212 V213 N215 A236 F238 L250 S252 V254 P265 N267 R276 Q278 I279 Q309 M320 A321 P322 Q324 P325 34 V218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 R315 M326 A327 P328 Q330 A331 36 V144 V145 N147 Y170 Y172 L181 S183 V185 A196 N198 A204 Q206 I207 R237 L244 Q245 V246 P248 Q249 38 V184 V185 N187 W210 A212 L224 S226 V228 P239 N241 K249 Q251 I252 R282 L289 E290 V291 P293 K294 40 I176 V177 N179 I202 F204 L216 S218 V220 P230 N232 K240 Q242 I243 E273 L280 K281 T282 G284 S285 42 M194 V195 N197 I220 F222 L234 S236 V238 P249 N251 K259 Q261 I262 R292 L299 Y300 V301 D303 T304 44 A207 V208 N210 A233 F235 L247 S249 V251 P262 N264 K272 Q274 I275 R305 L312 N313 T314 D316 A317 46 A207 V208 N210 A233 F235 L247 S249 V251 P262 N264 K272 Q274 I275 R305 L312 N313 T314 D316 A317 55 A213 V214 N216 S237 F239 L251 S253 V255 P266 N268 K277 Q279 I280 R310 M321 P322 R323 N325 A326 57 A213 V214 N216 S237 F239 L251 S253 V255 P266 N268 K277 Q279 I280 R310 M321 P322 R323 N325 A326 58 A214 V215 N217 A238 F240 L252 S254 V256 P267 N269 K278 Q280 I281 R311 M322 P323 K324 P326 P327 59 V224 V225 N227 A248 F250 L262 S264 V266 P277 N279 R288 Q290 I291 R321 L332 A333 P334 P336 P337 60 V214 V215 N217 A238 F240 L252 S254 V256 P267 N269 R278 Q280 I281 R311 L322 P323 P324 C326 R327 61 I219 V220 N222 A243 F245 L257 S259 V261 P272 N274 R283 Q285 I286 Q316 M327 A328 P329 T331 S332 62 A226 V227 N229 A250 F252 L264 S266 V268 P279 N281 K290 Q292 I293 R323 M334 P335 S336 P338 P339 63 T223 V224 N226 A247 F249 L261 S263 V265 P276 N278 K287 Q289 I290 R320 M331 P332 S333 P335 P336 64 L163 T164 N166 R189 F191 L200 S202 A204 P215 N217 A224 Q226 I227 K257 M264 T265 A266 P268 D269 65 L163 T164 N166 R189 F191 L200 S202 A204 P215 N217 A224 Q226 I227 K257 M264 T265 A266 P268 D269 66 V218 V219 N221 A242 F244 L256 S258 V260 P271 N273 R282 Q284 I285 R315 M326 A327 P328 Q330 A331 67 I219 V220 N222 A243 F245 L257 S259 V261 P272 N274 R283 Q285 I286 Q316 M327 A328 P329 T331 S332 SEQ- Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos Pos ID 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 53 R349 E363 L368 F381 L385 G386 T390 F392 I393 G418 F419 K421 G422 F424 S425 E426 L427 I431 2 L334 Q348 L353 F366 V370 G371 T375 F377 L378 G403 F404 K406 G407 F409 S410 E411 L412 I416 5 R392 E406 L411 F424 V428 G429 T433 F435 F436 G467 F468 K470 G471 F473 R474 E475 L476 I480 8 R349 E363 L368 F381 L385 G386 T390 F392 F393 G423 F424 K426 G427 F429 S430 E431 L432 I436 11 R314 E328 L333 F346 L350 G351 T355 F357 L358 G396 F397 Q399 G400 F402 R403 E404 L405 I409 14 R267 E283 L288 F304 I308 F309 T313 F315 F316 G327 F328 Q330 G331 F333 Q334 A335 L336 I340 17 E275 E287 L292 F308 I312 F313 T317 F319 F320 G331 F332 Q334 R335 F337 L338 A339 L340 M344 20 Y260 Q272 L277 F293 C297 Y298 T302 F304 W305 G316 F317 Q319 G320 F322 Q323 A324 L325 V329 22 L340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 E417 L418 I422 24 L340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 E417 L418 I422 26 R340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 Q417 L418 I422 28 R340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 Q417 L418 I422 30 I334 Q348 L353 F366 V370 G371 T375 F377 L378 G403 F404 K406 G407 F409 S410 E411 L412 I416 32 I334 Q348 L353 F366 V370 G371 T375 F377 L378 G403 F404 K406 G407 F409 S410 E411 L412 I416 34 I340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 E417 L418 I422 36 G259 V276 L281 F301 L305 F306 T310 F312 F313 G324 F325 E327 A328 F330 Q331 A332 L333 L337 38 R302 E318 L323 F336 V340 E341 T345 F347 Y348 G358 F359 I361 G362 F364 K365 A366 L367 L371 40 R293 E305 L310 F323 V327 T328 T332 F334 F335 S345 F346 N348 G349 F351 K352 A353 L354 I358 42 R312 K324 L329 F342 I346 V347 T351 F353 F354 S364 F365 V367 G368 F370 K371 A372 L373 I377 44 R327 Q339 L344 F357 L361 G362 T366 F368 F369 G379 F380 A382 G383 F385 Q386 A387 L388 I392 46 R327 Q339 L344 F357 L361 G362 T366 F368 F369 G379 F380 A382 G383 F385 Q386 A387 L388 I392 55 R335 E349 L354 F367 L371 G372 T376 F378 I379 G410 F411 K413 G414 F416 G417 A418 L419 I423 57 R335 E349 L354 F367 L371 G372 T376 F378 I379 G410 F411 K413 G414 F416 G417 A418 L419 I423 58 R336 D350 L355 F368 V372 G373 S377 F379 V380 G406 F407 K409 G410 F412 S413 E414 L415 I419 59 R346 Q360 L365 F378 V382 G383 T387 F389 L390 G415 F416 K418 G419 F421 S422 E423 L424 I428 60 I336 Q350 L355 F368 V372 G373 T377 F379 L380 G405 F406 K408 G409 F411 S412 E413 L414 I418 61 R341 Q355 L360 F373 V377 G378 T382 F384 L385 G410 F411 K413 G414 F416 S417 Q418 L419 I423 62 R348 E362 L367 F380 V384 G385 T389 F391 I392 G417 F418 K420 G421 F423 S424 E425 L426 I430 63 R345 E359 L364 F377 L381 G382 T386 F388 I389 G414 F415 K417 G418 F420 S421 E422 L423 I427 64 R278 Q290 L295 F312 L316 M317 — F321 F322 G332 F333 E335 G336 F338 K339 A340 L341 I345 65 R278 Q290 L295 F312 L316 M317 — F321 F322 G332 F333 E335 G336 F338 K339 A340 L341 I345 66 I340 Q354 L359 F372 V376 G377 T381 F383 L384 G409 F410 K412 G413 F415 S416 E417 L418 I422 67 R341 Q355 L360 F373 V377 G378 T382 F384 L385 G410 F411 K413 G414 F416 S417 Q418 L419 I423

It will be within the knowledge of the skilled artisan to identify conserved regions and motifs shared between the homologues, orthologues and paralogues of of SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, and respectively SEQ ID NO: 48 or 50, such as those depicted in Table 1. Having identified such conserved regions that may represent suitable binding motifs, amino acids corresponding to the amino acids listed in Table 4a and 4b, 4c, and 4d can be chosen to be substituted by any other amino acid, preferably by conserved amino acids as shown in table 3, and more preferably by the amino acids of tables 4a and 4b, 4c, and 4d.

In addition, the present invention refers to a method for identifying a HPPD-inhibiting herbicide by using a mut-HPPD encoded by a nucleic acid which comprises the nucleotide sequence of SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, or a variant or derivative thereof, and/or by using a mut-HST encoded by a nucleic acid which comprises the nucleotide sequence of SEQ ID NO: 47 or 49, or a variant or derivative thereof.

Said method comprises the steps of:

-   a) generating a transgenic cell or plant comprising a nucleic acid     encoding a mut-HPPD, wherein the mut-HPPD is expressed; -   b) applying a HPPD-inhibiting herbicide to the transgenic cell or     plant of a) and to a control cell or plant of the same variety; -   c) determining the growth or the viability of the transgenic cell or     plant and the control cell or plant after application of said     HPPD-inhibiting herbicide, and -   d) selecting “HPPD-inhibiting herbicides” which confer reduced     growth to the control cell or plant as compared to the growth of the     transgenic cell or plant.

By “control cell” or “similar, wild-type, plant, plant tissue, plant cell or host cell” is intended a plant, plant tissue, plant cell, or host cell, respectively, that lacks the herbicide-resistance characteristics and/or particular polynucleotide of the invention that are disclosed herein. The use of the term “wild-type” is not, therefore, intended to imply that a plant, plant tissue, plant cell, or other host cell lacks recombinant DNA in its genome, and/or does not possess herbicide-resistant characteristics that are different from those disclosed herein.

Another object refers to a method of identifying a nucleotide sequence encoding a mut-HPPD which is resistant or tolerant to a HPPD-inhibiting herbicide, the method comprising:

-   a) generating a library of mut-HPPD-encoding nucleic acids, -   b) screening a population of the resulting mut-HPPD-encoding nucleic     acids by expressing each of said nucleic acids in a cell or plant     and treating said cell or plant with a HPPD-inhibiting herbicide, -   c) comparing the HPPD-inhibiting herbicide-tolerance levels provided     by said population of mut-HPPD encoding nucleic acids with the     HPPD-inhibiting herbicide-tolerance level provided by a control     HPPD-encoding nucleic acid, -   d) selecting at least one mut-HPPD-encoding nucleic acid that     provides a significantly increased level of tolerance to a     HPPD-inhibiting herbicide as compared to that provided by the     control HPPD-encoding nucleic acid.

In a preferred embodiment, the mut-HPPD-encoding nucleic acid selected in step d) provides at least 2-fold as much resistance or tolerance of a cell or plant to a HPPD-inhibiting herbicide as compared to that provided by the control HPPD-encoding nucleic acid.

In a further preferred embodiment, the mut-HPPD-encoding nucleic acid selected in step d) provides at least 2-fold, at least 5-fold, at least 10-fold, at least 20-fold, at least 50-fold, at least 100-fold, at least 500-fold, as much resistance or tolerance of a cell or plant to a HPPD-inhibiting herbicide as compared to that provided by the control HPPD-encoding nucleic acid.

The resistance or tolerance can be determined by generating a transgenic plant or host cell, preferably a plant cell, comprising a nucleic acid sequence of the library of step a) and comparing said transgenic plant with a control plant or host cell, preferably a plant cell.

Another object refers to a method of identifying a plant or algae containing a nucleic acid comprising a nucleotide sequence encoding a mut-HPPD or mut-HST which is resistant or tolerant to a HPPD-inhibiting herbicide, the method comprising:

-   a) identifying an effective amount of a HPPD-inhibiting herbicide in     a culture of plant cells or green algae that leads to death of said     cells. -   b) treating said plant cells or green algae with a mutagenizing     agent, -   c) contacting said mutagenized cells population with an effective     amount of HPPD-inhibiting herbicide, identified in a), -   d) selecting at least one cell surviving these test conditions, -   e) PCR-amplification and sequencing of HPPD and/or HST genes from     cells selected in d) and comparing such sequences to wild-type HPPD     or HST gene sequences, respectively.

In a preferred embodiment, said mutagenizing agent is ethylmethanesulfonate (EMS).

Many methods well known to the skilled artisan are available for obtaining suitable candidate nucleic acids for identifying a nucleotide sequence encoding a mut-HPPD from a variety of different potential source organisms including microbes, plants, fungi, algae, mixed cultures etc. as well as environmental sources of DNA such as soil. These methods include inter alia the preparation of cDNA or genomic DNA libraries, the use of suitably degenerate oligonucleotide primers, the use of probes based upon known sequences or complementation assays (for example, for growth upon tyrosine) as well as the use of mutagenesis and shuffling in order to provide recombined or shuffled mut-HPPD-encoding sequences. Nucleic acids comprising candidate and control HPPD encoding sequences can be expressed in yeast, in a bacterial host strain, in an alga or in a higher plant such as tobacco or Arabidopsis and the relative levels of inherent tolerance of the HPPD encoding sequences screened according to a visible indicator phenotype of the transformed strain or plant in the presence of different concentrations of the selected HPPD-inhibiting herbicide. Dose responses and relative shifts in dose responses associated with these indicator phenotypes (formation of brown color, growth inhibition, herbicidal effect etc) are conveniently expressed in terms, for example, of GR50 (concentration for 50% reduction of growth) or MIC (minimum inhibitory concentration) values where increases in values correspond to increases in inherent tolerance of the expressed HPPD. For example, in a relatively rapid assay system based upon transformation of a bacterium such as E. coli, each mut-HPPD encoding sequence may be expressed, for example, as a DNA sequence under expression control of a controllable promoter such as the lacZ promoter and taking suitable account, for example by the use of synthetic DNA, of such issues as codon usage in order to obtain as comparable a level of expression as possible of different HPPD sequences. Such strains expressing nucleic acids comprising alternative candidate HPPD sequences may be plated out on different concentrations of the selected HPPD-inhibiting herbicide in, optionally, a tyrosine supplemented medium and the relative levels of inherent tolerance of the expressed HPPD enzymes estimated on the basis of the extent and MIC for inhibition of the formation of the brown, ochronotic pigment.

In another embodiment, candidate nucleic acids are transformed into plant material to generate a transgenic plant, regenerated into morphologically normal fertile plants which are then measured for differential tolerance to selected HPPD-inhibiting—herbicides. Many suitable methods for transformation using suitable selection markers such as kanamycin, binary vectors such as from Agrobacterium and plant regeneration as, for example, from tobacco leaf discs are well known in the art. Optionally, a control population of plants is likewise transformed with a nuclaic acid expressing the control HPPD. Alternatively, an untransformed dicot plant such as Arabidopsis or Tobacco can be used as a control since this, in any case, expresses its own endogenous HPPD. The average, and distribution, of herbicide tolerance levels of a range of primary plant transformation events or their progeny to HPPD-inhibiting herbicides, for example the benzamides selected from Table 2 are evaluated in the normal manner based upon plant damage, meristematic bleaching symptoms etc. at a range of different concentrations of herbicides. These data can be expressed in terms of, for example, GR50 values derived from dose/response curves having “dose” plotted on the x-axis and “percentage kill”, “herbicidal effect”, “numbers of emerging green plants” etc. plotted on the y-axis where increased GR50 values correspond to increased levels of inherent tolerance of the expressed HPPD. Herbicides can suitably be applied pre-emergence or post-emergence.

Another object refers to an isolated nucleic acid encoding a mut-HPPD, wherein the nucleic acid is identifiable by a method as defined above.

In another embodiment, the invention refers to a plant cell transformed by a wild-type or a mut-HPPD nucleic acid according to the present invention or or a plant cell which has been mutated to obtain a plant expressing a wild-type or a mut-HPPD nucleic acid, wherein expression of the nucleic acid in the plant cell results in increased resistance or tolerance to a HPPD-inhibiting herbicide as compared to a wild type variety of the plant cell.

The term “expression/expressing” or “gene expression” means the transcription of a specific gene or specific genes or specific genetic construct. The term “expression” or “gene expression” in particular means the transcription of a gene or genes or genetic construct into structural RNA (rRNA, tRNA) or mRNA with or without subsequent translation of the latter into a protein. The process includes transcription of DNA and processing of the resulting mRNA product.

To obtain the desired effect, i.e. plants that are tolerant or resistant to the HPPD-inhibiting herbicide of the present invention, it will be understood that the at least one nucleic acid is “over-expressed” by methods and means known to the person skilled in the art.

The term “increased expression” or “overexpression” as used herein means any form of expression that is additional to the original wild-type expression level. Methods for increasing expression of genes or gene products are well documented in the art and include, for example, overexpression driven by appropriate promoters, the use of transcription enhancers or translation enhancers. Isolated nucleic acids which serve as promoter or enhancer elements may be introduced in an appropriate position (typically upstream) of a non-heterologous form of a polynucleotide so as to upregulate expression of a nucleic acid encoding the polypeptide of interest. For example, endogenous promoters may be altered in vivo by mutation, deletion, and/or substitution (see, Kmiec, U.S. Pat. No. 5,565,350; Zarling et al., WO9322443), or isolated promoters may be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene.

If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3′-end of a polynucleotide coding region. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA. The 3′ end sequence to be added may be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or less preferably from any other eukaryotic gene.

An intron sequence may also be added to the 5′ untranslated region (UTR) or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold (Buchman and Berg (1988) Mol. Cell biol. 8: 4395-4405; Callis et al. (1987) Genes Dev 1:1183-1200). Such intron enhancement of gene expression is typically greatest when placed near the 5′ end of the transcription unit. Use of the maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. For general information see: The Maize Handbook, Chapter 116, Freeling and Walbot, Eds., Springer, N.Y. (1994)

The term “introduction” or “transformation” as referred to herein encompasses the transfer of an exogenous polynucleotide into a host cell, irrespective of the method used for transfer. Plant tissue capable of subsequent clonal propagation, whether by organogenesis or embryogenesis, may be transformed with a genetic construct of the present invention and a whole plant regenerated there from. The particular tissue chosen will vary depending on the clonal propagation systems available for, and best suited to, the particular species being transformed. Exemplary tissue targets include leaf disks, pollen, embryos, cotyledons, hypocotyls, megagametophytes, callus tissue, existing meristematic tissue (e.g., apical meristem, axillary buds, and root meristems), and induced meristem tissue (e.g., cotyledon meristem and hypocotyl meristem). The polynucleotide may be transiently or stably introduced into a host cell and may be maintained non-integrated, for example, as a plasmid. Alternatively, it may be integrated into the host genome. The resulting transformed plant cell may then be used to regenerate a transformed plant in a manner known to persons skilled in the art.

The transfer of foreign genes into the genome of a plant is called transformation. Transformation of plant species is now a fairly routine technique. Advantageously, any of several transformation methods may be used to introduce the gene of interest into a suitable ancestor cell. The methods described for the transformation and regeneration of plants from plant tissues or plant cells may be utilized for transient or for stable transformation. Transformation methods include the use of liposomes, electroporation, chemicals that increase free DNA uptake, injection of the DNA directly into the plant, particle gun bombardment, transformation using viruses or pollen and microprojection. Methods may be selected from the calcium/polyethylene glycol method for protoplasts (Krens, F. A. et al., (1982) Nature 296, 72-74; Negrutiu I et al. (1987) Plant Mol Biol 8: 363-373); electroporation of protoplasts (Shillito R. D. et al. (1985) Bio/Technol 3, 1099-1102); microinjection into plant material (Crossway A et al., (1986) Mol. Gen Genet 202: 179-185); DNA or RNA-coated particle bombardment (Klein T M et al., (1987) Nature 327: 70) infection with (non-integrative) viruses and the like. Transgenic plants, including transgenic crop plants, are preferably produced via Agrobacterium-mediated transformation. An advantageous transformation method is the transformation in planta. To this end, it is possible, for example, to allow the agrobacteria to act on plant seeds or to inoculate the plant meristem with agrobacteria. It has proved particularly expedient in accordance with the invention to allow a suspension of transformed agrobacteria to act on the intact plant or at least on the flower primordia. The plant is subsequently grown on until the seeds of the treated plant are obtained (Clough and Bent, Plant J. (1998) 16, 735-743). Methods for Agrobacterium-mediated transformation of rice include well known methods for rice transformation, such as those described in any of the following: European patent application EP 1198985 A1, Aldemita and Hodges (Planta 199: 612-617, 1996); Chan et al. (Plant Mol Biol 22 (3): 491-506, 1993), Hiei et al. (Plant J 6 (2): 271-282, 1994), which disclosures are incorporated by reference herein as if fully set forth. In the case of corn transformation, the preferred method is as described in either Ishida et al. (Nat. Biotechnol 14(6): 745-50, 1996) or Frame et al. (Plant Physiol 129(1): 13-22, 2002), which disclosures are incorporated by reference herein as if fully set forth. Said methods are further described by way of example in B. Jenes et al., Techniques for Gene Transfer, in: Transgenic Plants, Vol. 1, Engineering and Utilization, eds. S. D. Kung and R. Wu, Academic Press (1993) 128-143 and in Potrykus Annu. Rev. Plant Physiol. Plant Molec. Biol. 42 (1991) 205-225). The nucleic acids or the construct to be expressed is preferably cloned into a vector, which is suitable for transforming Agrobacterium tumefaciens, for example pBin19 (Bevan et al., Nucl. Acids Res. 12 (1984) 8711). Agrobacteria transformed by such a vector can then be used in known manner for the transformation of plants, such as plants used as a model, like Arabidopsis (Arabidopsis thaliana is within the scope of the present invention not considered as a crop plant), or crop plants such as, by way of example, tobacco plants, for example by immersing bruised leaves or chopped leaves in an agrobacterial solution and then culturing them in suitable media. The transformation of plants by means of Agrobacterium tumefaciens is described, for example, by Hbfgen and Willmitzer in Nucl. Acid Res. (1988) 16, 9877 or is known inter alia from F. F. White, Vectors for Gene Transfer in Higher Plants; in Transgenic Plants, Vol. 1, Engineering and Utilization, eds. S. D. Kung and R. Wu, Academic Press, 1993, pp. 15-38.

In addition to the transformation of somatic cells, which then have to be regenerated into intact plants, it is also possible to transform the cells of plant meristems and in particular those cells which develop into gametes. In this case, the transformed gametes follow the natural plant development, giving rise to transgenic plants. Thus, for example, seeds of Arabidopsis are treated with agrobacteria and seeds are obtained from the developing plants of which a certain proportion is transformed and thus transgenic [Feldman, K A and Marks M D (1987). Mol Gen Genet 208:274-289; Feldmann K (1992). In: C Koncz, N-H Chua and J Shell, eds, Methods in Arabidopsis Research. Word Scientific, Singapore, pp. 274-289]. Alternative methods are based on the repeated removal of the inflorescences and incubation of the excision site in the center of the rosette with transformed agrobacteria, whereby transformed seeds can likewise be obtained at a later point in time (Chang (1994). Plant J. 5: 551-558; Katavic (1994). Mol Gen Genet, 245: 363-370). However, an especially effective method is the vacuum infiltration method with its modifications such as the “floral dip” method. In the case of vacuum infiltration of Arabidopsis, intact plants under reduced pressure are treated with an agrobacterial suspension [Bechthold, N (1993). C R Acad Sci Paris Life Sci, 316: 1194-1199], while in the case of the “floral dip” method the developing floral tissue is incubated briefly with a surfactant-treated agrobacterial suspension [Clough, S J and Bent A F (1998) The Plant J. 16, 735-743]. A certain proportion of transgenic seeds is harvested in both cases, and these seeds can be distinguished from non-transgenic seeds by growing under the above-described selective conditions. In addition the stable transformation of plastids is of advantages because plastids are inherited maternally in most crops reducing or eliminating the risk of transgene flow through pollen. The transformation of the chloroplast genome is generally achieved by a process which has been schematically displayed in Klaus et al., 2004 [Nature Biotechnology 22 (2), 225-229]. Briefly the sequences to be transformed are cloned together with a selectable marker gene between flanking sequences homologous to the chloroplast genome. These homologous flanking sequences direct site specific integration into the plastome. Plastidal transformation has been described for many different plant species and an overview is given in Bock (2001) Transgenic plastids in basic research and plant biotechnology. J Mol Biol. 2001 Sep. 21; 312 (3):425-38 or Maliga, P (2003) Progress towards commercialization of plastid transformation technology. Trends Biotechnol. 21, 20-28. Further biotechnological progress has recently been reported in form of marker free plastid transformants, which can be produced by a transient co-integrated maker gene (Klaus et al., 2004, Nature Biotechnology 22(2), 225-229). The genetically modified plant cells can be regenerated via all methods with which the skilled worker is familiar. Suitable methods can be found in the abovementioned publications by S. D. Kung and R. Wu, Potrykus or Höfgen and Willmitzer.

Generally after transformation, plant cells or cell groupings are selected for the presence of one or more markers which are encoded by plant-expressible genes co-transferred with the gene of interest, following which the transformed material is regenerated into a whole plant. To select transformed plants, the plant material obtained in the transformation is, as a rule, subjected to selective conditions so that transformed plants can be distinguished from untransformed plants. For example, the seeds obtained in the above-described manner can be planted and, after an initial growing period, subjected to a suitable selection by spraying. A further possibility consists in growing the seeds, if appropriate after sterilization, on agar plates using a suitable selection agent so that only the transformed seeds can grow into plants. Alternatively, the transformed plants are screened for the presence of a selectable marker such as the ones described above.

Following DNA transfer and regeneration, putatively transformed plants may also be evaluated, for instance using Southern analysis, for the presence of the gene of interest, copy number and/or genomic organisation. Alternatively or additionally, expression levels of the newly introduced DNA may be monitored using Northern and/or Western analysis, both techniques being well known to persons having ordinary skill in the art.

The generated transformed plants may be propagated by a variety of means, such as by clonal propagation or classical breeding techniques. For example, a first generation (or T1) transformed plant may be selfed and homozygous second-generation (or T2) transformants selected, and the T2 plants may then further be propagated through classical breeding techniques. The generated transformed organisms may take a variety of forms. For example, they may be chimeras of transformed cells and non-transformed cells; clonal transformants (e.g., all cells transformed to contain the expression cassette); grafts of transformed and untransformed tissues (e.g., in plants, a transformed rootstock grafted to an untransformed scion).

Preferably, the wild-type or mut-HPPD nucleic acid (a) or wild-type or mut-HST nucleic acid (b) comprises a polynucleotide sequence selected from the group consisting of: a) a polynucleotide as shown in SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, or a variant or derivative thereof; b) a polynucleotide as shown in SEQ ID NO: 47 or 49, or a variant or derivative thereof; c) a polynucleotide encoding a polypeptide as shown in SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or a variant or derivative thereof; d) a polynucleotide comprising at least 60 consecutive nucleotides of any of a) through c); and e) a polynucleotide complementary to the polynucleotide of any of a) through d).

Preferably, the expression of the nucleic acid in the plant results in the plants increased resistance to HPPD-inhibiting herbicide as compared to a wild type variety of the plant.

In another embodiment, the invention refers to a plant, preferably a transgenic plant, comprising a plant cell according to the present invention, wherein expression of the nucleic acid in the plant results in the plants increased resistance to HPPD-inhibiting herbicide as compared to a wild type variety of the plant.

The plants described herein can be either transgenic crop plants or non-transgenic plants.

For the purposes of the invention, “transgenic”, “transgene” or “recombinant” means with regard to, for example, a nucleic acid sequence, an expression cassette, gene construct or a vector comprising the nucleic acid sequence or an organism transformed with the nucleic acid sequences, expression cassettes or vectors according to the invention, all those constructions brought about by recombinant methods in which either

-   (a) the nucleic acid sequences encoding proteins useful in the     methods of the invention,

or

-   (b) genetic control sequence(s) which is operably linked with the     nucleic acid sequence according to the invention, for example a     promoter, or -   (c) a) and b)

are not located in their natural genetic environment or have been modified by recombinant methods, it being possible for the modification to take the form of, for example, a substitution, addition, deletion, inversion or insertion of one or more nucleotide residues. The natural genetic environment is understood as meaning the natural genomic or chromosomal locus in the original plant or the presence in a genomic library. In the case of a genomic library, the natural genetic environment of the nucleic acid sequence is preferably retained, at least in part. The environment flanks the nucleic acid sequence at least on one side and has a sequence length of at least 50 bp, preferably at least 500 bp, especially preferably at least 1000 bp, most preferably at least 5000 bp. A naturally occurring expression cassette—for example the naturally occurring combination of the natural promoter of the nucleic acid sequences with the corresponding nucleic acid sequence encoding a polypeptide useful in the methods of the present invention, as defined above—becomes a transgenic expression cassette when this expression cassette is modified by non-natural, synthetic (“artificial”) methods such as, for example, mutagenic treatment. Suitable methods are described, for example, in U.S. Pat. No. 5,565,350 or WO 00/15815.

A transgenic plant for the purposes of the invention is thus understood as meaning, as above, that the nucleic acids used in the method of the invention are not at their natural locus in the genome of said plant, it being possible for the nucleic acids to be expressed homologously or heterologously. However, as mentioned, transgenic also means that, while the nucleic acids according to the invention or used in the inventive method are at their natural position in the genome of a plant, the sequence has been modified with regard to the natural sequence, and/or that the regulatory sequences of the natural sequences have been modified. Transgenic is preferably understood as meaning the expression of the nucleic acids according to the invention at an unnatural locus in the genome, i.e. homologous or, preferably, heterologous expression of the nucleic acids takes place. Preferred transgenic plants are mentioned herein. Furthermore, the term “transgenic” refers to any plant, plant cell, callus, plant tissue, or plant part, that contains all or part of at least one recombinant polynucleotide. In many cases, all or part of the recombinant polynucleotide is stably integrated into a chromosome or stable extra-chromosomal element, so that it is passed on to successive generations. For the purposes of the invention, the term “recombinant polynucleotide” refers to a polynucleotide that has been altered, rearranged, or modified by genetic engineering. Examples include any cloned polynucleotide, or polynucleotides, that are linked or joined to heterologous sequences. The term “recombinant” does not refer to alterations of polynucleotides that result from naturally occurring events, such as spontaneous mutations, or from non-spontaneous mutagenesis followed by selective breeding.

Plants containing mutations arising due to non-spontaneous mutagenesis and selective breeding are referred to herein as non-transgenic plants and are included in the present invention. In embodiments wherein the plant is transgenic and comprises multiple mut-HPPD nucleic acids, the nucleic acids can be derived from different genomes or from the same genome. Alternatively, in embodiments wherein the plant is non-transgenic and comprises multiple mut-HPPD nucleic acids, the nucleic acids are located on different genomes or on the same genome.

In certain embodiments, the present invention involves herbidicide-resistant plants that are produced by mutation breeding. Such plants comprise a polynucleotide encoding a mut-HPPD and/or a mut-HST and are tolerant to one or more “HPPD-inhibiting herbicides”. Such methods can involve, for example, exposing the plants or seeds to a mutagen, particularly a chemical mutagen such as, for example, ethyl methanesulfonate (EMS) and selecting for plants that have enhanced tolerance to at least one or more HPPD-inhibiting herbicide.

However, the present invention is not limited to herbicide-tolerant plants that are produced by a mutagenesis method involving the chemical mutagen EMS. Any mutagenesis method known in the art may be used to produce the herbicide-resistant plants of the present invention. Such mutagenesis methods can involve, for example, the use of any one or more of the following mutagens: radiation, such as X-rays, Gamma rays (e.g., cobalt 60 or cesium 137), neutrons, (e.g., product of nuclear fission by uranium 235 in an atomic reactor), Beta radiation (e.g., emitted from radioisotopes such as phosphorus 32 or carbon 14), and ultra-violet radiation (preferably from 250 to 290 nm), and chemical mutagens such as base analogues (e.g., 5-bromo-uracil), related compounds (e.g., 8-ethoxy caffeine), antibiotics (e.g., streptonigrin), alkylating agents (e.g., sulfur mustards, nitrogen mustards, epoxides, ethylenamines, sulfates, sulfonates, sulfones, lactones), azide, hydroxylamine, nitrous acid, or acridines. Herbicide-resistant plants can also be produced by using tissue culture methods to select for plant cells comprising herbicide-resistance mutations and then regenerating herbicide-resistant plants therefrom. See, for example, U.S. Pat. Nos. 5,773,702 and 5,859,348, both of which are herein incorporated in their entirety by reference. Further details of mutation breeding can be found in “Principals of Cultivar Development” Fehr, 1993 Macmillan Publishing Company the disclosure of which is incorporated herein by reference

In addition to the definition above, the term “plant” is intended to encompass crop plants at any stage of maturity or development, as well as any tissues or organs (plant parts) taken or derived from any such plant unless otherwise clearly indicated by context. Plant parts include, but are not limited to, stems, roots, flowers, ovules, stamens, leaves, embryos, meristematic regions, callus tissue, anther cultures, gametophytes, sporophytes, pollen, microspores, protoplasts, and the like.

The plant of the present invention comprises at least one mut-HPPD nucleic acid or over-expressed wild-type HPPD nucleic acid, and has increased tolerance to a HPPD-inhibiting herbicide as compared to a wild-type variety of the plant. It is possible for the plants of the present invention to have multiple wild-type or mut-HPPD nucleic acids from different genomes since these plants can contain more than one genome. For example, a plant contains two genomes, usually referred to as the A and B genomes. Because HPPD is a required metabolic enzyme, it is assumed that each genome has at least one gene coding for the HPPD enzyme (i.e. at least one HPPD gene). As used herein, the term “HPPD gene locus” refers to the position of an HPPD gene on a genome, and the terms “HPPD gene” and “HPPD nucleic acid” refer to a nucleic acid encoding the HPPD enzyme. The HPPD nucleic acid on each genome differs in its nucleotide sequence from an HPPD nucleic acid on another genome. One of skill in the art can determine the genome of origin of each HPPD nucleic acid through genetic crossing and/or either sequencing methods or exonuclease digestion methods known to those of skill in the art.

The present invention includes plants comprising one, two, three, or more mut-HPPD alleles, wherein the plant has increased tolerance to a HPPD-inhibiting herbicide as compared to a wild-type variety of the plant. The mut-HPPD alleles can comprise a nucleotide sequence selected from the group consisting of a polynucleotide as defined in SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, or a variant or derivative thereof, a polynucleotide encoding a polypeptide as defined in SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or a variant or derivative, homologue, orthologue, paralogue thereof, a polynucleotide comprising at least 60 consecutive nucleotides of any of the aforementioned polynucleotides; and a polynucleotide complementary to any of the aforementioned polynucleotides.

“Alleles” or “allelic variants” are alternative forms of a given gene, located at the same chromosomal position. Allelic variants encompass Single Nucleotide Polymorphisms (SNPs), as well as Small Insertion/Deletion Polymorphisms (INDELs). The size of INDELs is usually less than 100 bp. SNPs and INDELs form the largest set of sequence variants in naturally occurring polymorphic strains of most organisms

The term “variety” refers to a group of plants within a species defined by the sharing of a common set of characteristics or traits accepted by those skilled in the art as sufficient to distinguish one cultivar or variety from another cultivar or variety. There is no implication in either term that all plants of any given cultivar or variety will be genetically identical at either the whole gene or molecular level or that any given plant will be homozygous at all loci. A cultivar or variety is considered “true breeding” for a particular trait if, when the true-breeding cultivar or variety is self-pollinated, all of the progeny contain the trait. The terms “breeding line” or “line” refer to a group of plants within a cultivar defined by the sharing of a common set of characteristics or traits accepted by those skilled in the art as sufficient to distinguish one breeding line or line from another breeding line or line. There is no implication in either term that all plants of any given breeding line or line will be genetically identical at either the whole gene or molecular level or that any given plant will be homozygous at all loci. A breeding line or line is considered “true breeding” for a particular trait if, when the true-breeding line or breeding line is self-pollinated, all of the progeny contain the trait. In the present invention, the trait arises from a mutation in a HPPD gene of the plant or seed.

In some embodiments, traditional plant breeding is employed whereby the HPPD-inhibiting herbicides-tolerant trait is introduced in the progeny plant resulting therefrom. In one embodiment, the present invention provides a method for producing a HPPD-inhibiting herbicides-tolerant progeny plant, the method comprising: crossing a parent plant with a HPPD-inhibiting herbicides-tolerant plant to introduce the HPPD-inhibiting herbicides-tolerance characteristics of the HPPD-inhibiting herbicides-tolerant plant into the germplasm of the progeny plant, wherein the progeny plant has increased tolerance to the HPPD-inhibiting herbicides relative to the parent plant. In other embodiments, the method further comprises the step of introgressing the HPPD-inhibiting herbicides-tolerance characteristics through traditional plant breeding techniques to obtain a descendent plant having the HPPD-inhibiting herbicides-tolerance characteristics.

The herbicide-resistant plants of the invention that comprise polynucleotides encoding mut-HPPD and/or mut-HST polypeptides also find use in methods for increasing the herbicide-resistance of a plant through conventional plant breeding involving sexual reproduction. The methods comprise crossing a first plant that is a herbicide-resistant plant of the invention to a second plant that may or may not be resistant to the same herbicide or herbicides as the first plant or may be resistant to different herbicide or herbicides than the first plant. The second plant can be any plant that is capable of producing viable progeny plants (i.e., seeds) when crossed with the first plant. Typically, but not necessarily, the first and second plants are of the same species. The methods can optionally involve selecting for progeny plants that comprise the mut-HPPD and/or mut-HST polypeptides of the first plant and the herbicide resistance characteristics of the second plant. The progeny plants produced by this method of the present invention have increased resistance to a herbicide when compared to either the first or second plant or both. When the first and second plants are resistant to different herbicides, the progeny plants will have the combined herbicide tolerance characteristics of the first and second plants. The methods of the invention can further involve one or more generations of backcrossing the progeny plants of the first cross to a plant of the same line or genotype as either the first or second plant. Alternatively, the progeny of the first cross or any subsequent cross can be crossed to a third plant that is of a different line or genotype than either the first or second plant. The present invention also provides plants, plant organs, plant tissues, plant cells, seeds, and non-human host cells that are transformed with the at least one polynucleotide molecule, expression cassette, or transformation vector of the invention. Such transformed plants, plant organs, plant tissues, plant cells, seeds, and non-human host cells have enhanced tolerance or resistance to at least one herbicide, at levels of the herbicide that kill or inhibit the growth of an untransformed plant, plant tissue, plant cell, or non-human host cell, respectively. Preferably, the transformed plants, plant tissues, plant cells, and seeds of the invention are Arabidopsis thaliana and crop plants.

In other aspects, plants of the invention include those plants which, in addition to being HPPD-inhibiting herbicides-tolerant, have been subjected to further genetic modifications by breeding, mutagenesis or genetic engineering, e.g. have been rendered tolerant to applications of specific other classes of herbicides, such as AHAS inhibitors; auxinic herbicides; bleaching herbicides such as hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors or phytoene desaturase (PDS) inhibitors; EPSPS inhibitors such as glyphosate; glutamine synthetase (GS) inhibitors such as glufosinate; lipid biosynthesis inhibitors such as acetyl CoA carboxylase (ACCase) inhibitors; or oxynil {i.e. bromoxynil or ioxynil) herbicides as a result of conventional methods of breeding or genetic engineering, Thus, HPPD-inhibiting herbicides-tolerant plants of the invention can be made resistant to multiple classes of herbicides through multiple genetic modifications, such as resistance to both glyphosate and glufosinate or to both glyphosate and a herbicide from another class such as HPPD inhibitors, AHAS inhibitors, or ACCase inhibitors. These herbicide resistance technologies are, for example, described in Pest Management Science (at volume, year, page): 61, 2005, 246; 61, 2005, 258; 61, 2005, 277; 61, 2005, 269; 61, 2005, 286; 64, 2008, 326; 64, 2008, 332; Weed Science 57, 2009, 108; Australian Journal of Agricultural Research 58, 2007, 708; Science 316, 2007, 1185; and references quoted therein. For example, HPPD-inhibiting herbicides-tolerant plants of the invention, in some embodiments, may be tolerant to ACCase inhibitors, such as “dims” {e.g., cycloxydim, sethoxydim, clethodim, or tepraloxydim), “fops” {e.g., clodinafop, diclofop, fluazifop, haloxyfop, or quizalofop), and “dens” (such as pinoxaden); to auxinic herbicides, such as dicamba; to EPSPS inhibitors, such as glyphosate; to other HPPD inhibitors; and to GS inhibitors, such as glufosinate.

In addition to these classes of inhibitors, HPPD-inhibiting herbicides-tolerant plants of the invention may also be tolerant to herbicides having other modes of action, for example, chlorophyll/carotenoid pigment inhibitors, cell membrane disrupters, photosynthesis inhibitors, cell division inhibitors, root inhibitors, shoot inhibitors, and combinations thereof.

Such tolerance traits may be expressed, e.g.: as mutant or wildtype HPPD proteins, as mutant AHASL proteins, mutant ACCase proteins, mutant EPSPS proteins, or mutant glutamine synthetase proteins; or as mutant native, inbred, or transgenic aryloxyalkanoate dioxygenase (AAD or DHT), haloarylnitrilase (BXN), 2,2-dichloropropionic acid dehalogenase (DEH), glyphosate-N-acetyltransferase (GAT), glyphosate decarboxylase (GDC), glyphosate oxidoreductase (GOX), glutathione-S-transferase (GST), phosphinothricin acetyltransferase (PAT or bar), or CYP450s proteins having an herbicide-degrading activity. HPPD-inhibiting herbicides-tolerant plants hereof can also be stacked with other traits including, but not limited to, pesticidal traits such as Bt Cry and other proteins having pesticidal activity toward coleopteran, lepidopteran, nematode, or other pests; nutrition or nutraceutical traits such as modified oil content or oil profile traits, high protein or high amino acid concentration traits, and other trait types known in the art.

Furthermore, in other embodiments, HPPD-inhibiting herbicides-tolerant plants are also covered which are, by the use of recombinant DNA techniques and/or by breeding and/or otherwise selected for such characteristics, rendered able to synthesize one or more insecticidal proteins, especially those known from the bacterial genus Bacillus, particularly from Bacillus thuringiensis, such as [delta]-endotoxins, e.g. CryIA(b), CryIA(c), CryIF, CryIF(a2), CryIIA(b), CryIIIA, CryIIIB(bl) or Cry9c; vegetative insecticidal proteins (VIP), e.g. VIP1, VIP2, VIP3 or VIP3A; insecticidal proteins of bacteria colonizing nematodes, e.g. Photorhabdus spp. or Xenorhabdus spp.; toxins produced by animals, such as scorpion toxins, arachnid toxins, wasp toxins, or other insect-specific neurotoxins; toxins produced by fungi, such streptomycete toxins; plant lectins, such as pea or barley lectins; agglutinins; proteinase inhibitors, such as trypsin inhibitors, serine protease inhibitors, patatin, cystatin or papain inhibitors; ribosome-inactivating proteins (RIP), such as ricin, maize-RIP, abrin, luffin, saporin or bryodin; steroid metabolism enzymes, such as 3-hydroxy-steroid oxidase, ecdysteroid-IDP-glycosyl-transferase, cholesterol oxidases, ecdysone inhibitors or HMG-CoA-reductase; ion channel blockers, such as blockers of sodium or calcium channels; juvenile hormone esterase; diuretic hormone receptors (helicokinin receptors); stilben synthase, bibenzyl synthase, chitinases or glucanases. In the context of the present invention these insecticidal proteins or toxins are to be understood expressly also as pre-toxins, hybrid proteins, truncated or otherwise modified proteins. Hybrid proteins are characterized by a new combination of protein domains, (see, e.g. WO 02/015701). Further examples of such toxins or genetically modified plants capable of synthesizing such toxins are disclosed, e.g., in EP-A 374 753, WO 93/007278, WO 95/34656, EP-A 427 529, EP-A 451 878, WO 03/18810 und WO 03/52073. The methods for producing such genetically modified plants are generally known to the person skilled in the art and are described, e.g. in the publications mentioned above. These insecticidal proteins contained in the genetically modified plants impart to the plants producing these proteins tolerance to harmful pests from all taxonomic groups of arthropods, especially to beetles (Coeloptera), two-winged insects (Diptera), and moths (Lepidoptera) and to nematodes (Nematoda).

In some embodiments, expression of one or more protein toxins (e.g., insecticidal proteins) in the HPPD-inhibiting herbicides-tolerant plants is effective for controlling organisms that include, for example, members of the classes and orders: Coleoptera such as the American bean weevil Acanthoscelides obtectus; the leaf beetle Agelastica alni; click beetles (Agriotes lineatus, Agriotes obscurus, Agriotes bicolor); the grain beetle Ahasverus advena; the summer schafer Amphimallon solstitialis; the furniture beetle Anobium punctatum; Anthonomus spp. (weevils); the Pygmy mangold beetle Atomaria linearis; carpet beetles (Anthrenus spp., Attagenus spp.); the cowpea weevil Callosobruchus maculates; the fried fruit beetle Carpophilus hemipterus; the cabbage seedpod weevil Ceutorhynchus assimilis; the rape winter stem weevil Ceutorhynchus picitarsis; the wireworms Conoderus vespertinus and Conoderus falli; the banana weevil Cosmopolites sordidus; the New Zealand grass grub Costelytra zealandica; the June beetle Cotinis nitida; the sunflower stem weevil

Cylindrocopturus adspersus; the larder beetle Dermestes lardarius; the corn rootworms Diabrotica virgifera, Diabrotica virgifera virgifera, and Diabrotica barberi; the Mexican bean beetle Epilachna vaivestis; the old house borer Hylotropes bajulus; the luceme weevil Hypera postica; the shiny spider beetle Gibbium psylloides; the cigarette beetle Lasioderma serricome; the Colorado potato beetle Leptinotarsa decemlineata; Lyctus beetles {Lyctus spp., the pollen beetle Meligethes aeneus; the common cockshafer Melolontha melolontha; the American spider beetle Mezium americanum; the golden spider beetle Niptus hololeuc s; the grain beetles Oryzaephilus surinamensis and Oryzaephilus Mercator; the black vine weevil Otiorhynchus sulcatus; the mustard beetle Phaedon cochleariae, the crucifer flea beetle Phyllotreta cruciferae; the striped flea beetle Phyllotreta striolata; the cabbage steam flea beetle Psylliodes chrysocephala; Ptinus spp. (spider beetles); the lesser grain borer Rhizopertha dominica; the pea and been weevil Sitona lineatus; the rice and granary beetles Sitophilus oryzae and Sitophilus granaries; the red sunflower seed weevil Smicronyx fulvus; the drugstore beetle Stegobium paniceum; the yellow mealworm beetle Tenebrio molitor, the flour beetles Tribolium castaneum and Tribolium confusum; warehouse and cabinet beetles {Trogoderma spp.); the sunflower beetle Zygogramma exclamationis; Dermaptera (earwigs) such as the European earwig Forficula auricularia and the striped earwig Labidura riparia; Dictyoptera such as the oriental cockroach Blatta orientalis; the greenhouse millipede Oxidus gracilis; the beet fly Pegomyia betae; the frit fly Oscinella frit; fruitflies (Dacus spp., Drosophila spp.); Isoptera (termites) including species from the familes Hodotermitidae, Kalotermitidae, Mastotermitidae, Rhinotermitidae, Serritermitidae, Termitidae, Termopsidae; the tarnished plant bug Lygus lineolaris; the black bean aphid Aphis fabae; the cotton or melon aphid Aphis gossypii; the green apple aphid Aphis pomi; the citrus spiny whitefly Aleurocanthus spiniferus; the sweet potato whitefly Bemesia tabaci; the cabbage aphid Brevicoryne brassicae; the pear psylla Cacopsylla pyricola; the currant aphid Cryptomyzus ribis; the grape phylloxera Daktulosphaira vitifoliae; the citrus psylla Diaphorina citri; the potato leafhopper Empoasca fabae; the bean leafhopper Empoasca Solana; the vine leafhopper Empoasca vitis; the woolly aphid Eriosoma lanigerum; the European fruit scale Eulecanium comi; the mealy plum aphid Hyalopterus arundinis; the small brown planthopper Laodelphax striatellus; the potato aphid Macrosiphum euphorbiae; the green peach aphid Myzus persicae; the green rice leafhopper Nephotettix cinticeps; the brown planthopper Nilaparvata lugens; the hop aphid Phorodon humuli; the bird-cherry aphid Rhopalosiphum padi; the grain aphid Sitobion avenae; Lepidoptera such as Adoxophyes orana (summer fruit tortrix moth); Archips podana (fruit tree tortrix moth); Bucculatrix pyrivorella (pear leafminer); Bucculatrix thurberiella (cotton leaf perforator); Bupalus piniarius (pine looper); Carpocapsa pomonella (codling moth); Chilo suppressalis (striped rice borer); Choristoneura fumiferana (eastern spruce budworm); Cochylis hospes (banded sunflower moth); Diatraea grandiosella (southwestern corn borer); Eupoecilia ambiguella (European grape berry moth); Helicoverpa armigera (cotton bollworm); Helicoverpa zea (cotton bollworm); Heliothis virescens (tobacco budworm), Homeosoma electellum (sunflower moth); Homona magnanima (oriental tea tree tortrix moth); Lithocolletis blancardella (spotted tentiform leafminer); Lymantria dispar (gypsy moth); Malacosoma neustria (tent caterpillar); Mamestra brassicae (cabbage armyworm); Mamestra configurata (Bertha armyworm); Operophtera brumata (winter moth); Ostrinia nubilalis (European corn borer), Panolis flammea (pine beauty moth), Phyllocnistis citrella (citrus leafminer); Pieris brassicae (cabbage white butterfly); Rachiplusia ni (soybean looper); Spodoptera exigua (beet armywonn); Spodoptera littoralis (cotton leafworm); Sylepta derogata (cotton leaf roller); Trichoplusia ni (cabbage looper); Orthoptera such as the common cricket Acheta domesticus, tree locusts (Anacridium spp.), the migratory locust Locusta migratoria, the twostriped grasshopper Melanoplus bivittatus, the differential grasshopper Melanoplus differ entialis, the redlegged grasshopper Melanoplus femurrubrum, the migratory grasshopper Melanoplus sanguinipes, the northern mole cricket Neocurtilla hexadectyla, the red locust Nomadacris septemfasciata, the shortwinged mole cricket Scapteriscus abbreviatus, the southem mole cricket Scapteriscus borellii, the tawny mole cricket Scapteriscus vicinus, and the desert locust Schistocerca gregaria; Symphyla such as the garden symphylan Scutigerella immaculata; Thysanoptera such as the tobacco thrips Frankliniella fusca, the flower thrips Frankliniella intonsa, the western flower thrips Frankliniella occidentalism the cotton bud thrips Frankliniella schultzei, the banded greenhouse thrips Hercinothrips femoralis, the soybean thrips Neohydatothrips variabilis, Kelly's citrus thrips Pezothrips kellyanus, the avocado thrips Scirtothrips perseae, the melon thrips Thrips palmi, and the onion thrips Thrips tabaci; and the like, and combinations comprising one or more of the foregoing organisms.

In some embodiments, expression of one or more protein toxins (e.g., insecticidal proteins) in the HPPD-inhibiting herbicides-tolerant plants is effective for controlling flea beetles, i.e. members of the flea beetle tribe of family Chrysomelidae, preferably against Phyllotreta spp., such as Phyllotreta cruciferae and/or Phyllotreta triolata. In other embodiments, expression of one or more protein toxins {e.g., insecticidal proteins) in the HPPD-inhibiting herbicides-tolerant plants is effective for controlling cabbage seedpod weevil, the Bertha armyworm, Lygus bugs, or the diamondback moth.

It is to be understood that the plant of the present invention can comprise a wild type HPPD nucleic acid in addition to a mut-HPPD nucleic acid. It is contemplated that the HPPD-inhibiting herbicide tolerant lines may contain a mutation in only one of multiple HPPD iso-enzymes. Therefore, the present invention includes a plant comprising one or more mut-HPPD nucleic acids in addition to one or more wild type HPPD nucleic acids.

In another embodiment, the invention refers to a seed produced by a transgenic plant comprising a plant cell of the present invention, wherein the seed is true breeding for an increased resistance to a HPPD-inhibiting herbicide as compared to a wild type variety of the seed.

In another embodiment, the invention refers to a method of producing a transgenic plant cell with an increased resistance to a HPPD-inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a nucleic acid encoding a wildtype or a mut-HPPD as defined SUPRA.

In another embodiment, the invention refers to a method of producing a transgenic plant comprising, (a) transforming a plant cell with an expression cassette comprising a nucleic acid encoding a wildtype or a mut-HPPD, and (b) generating a plant with an increased resistance to HPPD-inhibiting herbicide from the plant cell.

Consequently, HPPD nucleic acids encoding a wildtype or a mut-HPPD useful for the invention are provided in expression cassettes for expression in the plant of interest. The cassette will include regulatory sequences operably linked to a HPPD nucleic acid sequence encoding a wildtype or a mut-HPPD of the invention. The term “regulatory element” as used herein refers to a polynucleotide that is capable of regulating the transcription of an operably linked polynucleotide. It includes, but not limited to, promoters, enhancers, introns, 5′ UTRs, and 3′ UTRs. By “operably linked” is intended a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence. Generally, operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame. The cassette may additionally contain at least one additional gene to be cotransformed into the organism. Alternatively, the additional gene(s) can be provided on multiple expression cassettes.

Such an expression cassette is provided with a plurality of restriction sites for insertion of the HPPD nucleic acid sequence to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

The expression cassette will include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region (i.e., a promoter), a mut-HPPD nucleic acid sequence of the invention, and a transcriptional and translational termination region (i.e., termination region) functional in plants. The promoter may be native or analogous, or foreign or heterologous, to the plant host and/or to the HPPD nucleic acid sequence of the invention. Additionally, the promoter may be the natural sequence or alternatively a synthetic sequence. Where the promoter is “foreign” or “heterologous” to the plant host, it is intended that the promoter is not found in the native plant into which the promoter is introduced. Where the promoter is “foreign” or “heterologous” to the HPPD nucleic acid sequence of the invention, it is intended that the promoter is not the native or naturally occurring promoter for the operably linked HPPD nucleic acid sequence of the invention. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

While it may be preferable to express the HPPD nucleic acids of the invention using heterologous promoters, the native promoter sequences may be used. Such constructs would change expression levels of the HPPD protein in the plant or plant cell. Thus, the phenotype of the plant or plant cell is altered.

The termination region may be native with the transcriptional initiation region, may be native with the operably linked HPPD sequence of interest, may be native with the plant host, or may be derived from another source (i.e., foreign or heterologous to the promoter, the HPPD nucleic acid sequence of interest, the plant host, or any combination thereof). Convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262: 141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5: 141-149; Mogen et al. (1990) Plant Cell 2: 1261-1272; Munroe et al. (1990) Gene 91: 151-158; Ballas t al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al. (1987) Nucleic Acid Res. 15:9627-9639. Where appropriate, the gene(s) may be optimized for increased expression in the transformed plant. That is, the genes can be synthesized using plant-preferred codons for improved expression. See, for example, Campbell and Gowri (1990) Plant Physiol. 92: 1-11 for a discussion of host-preferred codon usage. Methods are available in the art for synthesizing plant-preferred genes. See, for example, U.S. Pat. Nos. 5,380,831, and 5,436,391, and Murray et al. (1989) Nucleic Acids Res. 17:477-498, herein incorporated by reference.

Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures. Nucleotide sequences for enhancing gene expression can also be used in the plant expression vectors. These include the introns of the maize AdhI, intronI gene (Callis et al. Genes and Development 1: 1183-1200, 1987), and leader sequences, (W-sequence) from the Tobacco Mosaic virus (TMV), Maize Chlorotic Mottle Virus and Alfalfa Mosaic Virus (Gallie et al. Nucleic Acid Res. 15:8693-8711, 1987 and Skuzeski et al. Plant Mol. Biol. 15:65-79, 1990). The first intron from the shrunken-1 locus of maize, has been shown to increase expression of genes in chimeric gene constructs. U.S. Pat. Nos. 5,424,412 and 5,593,874 disclose the use of specific introns in gene expression constructs, and Gallie et al. (Plant Physiol. 106:929-939, 1994) also have shown that introns are useful for regulating gene expression on a tissue specific basis. To further enhance or to optimize mut-HPPD gene expression, the plant expression vectors of the invention may also contain DNA sequences containing matrix attachment regions (MARs). Plant cells transformed with such modified expression systems, then, may exhibit overexpression or constitutive expression of a nucleotide sequence of the invention.

The expression cassettes may additionally contain 5′ leader sequences in the expression cassette construct. Such leader sequences can act to enhance translation. Translation leaders are known in the art and include: picomavirus leaders, for example, EMCV leader (Encephalomyocarditis 5′ noncoding region) (Elroy-Stein et al. (1989) Proc. Natl. Acad. ScL USA 86:6126-6130); potyvirus leaders, for example, TEV leader (Tobacco Etch Virus) (Gallie et al. (1995) Gene 165(2):233-238), MDMV leader (Maize Dwarf Mosaic Virus) (Virology 154:9-20), and human immunoglobulin heavy-chain binding protein (BiP) (Macejak et al. (1991) Nature 353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus (AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss, New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel et al. (1991) Virology 81:382-385). See also, Della-Cioppa et al. (1987) Plant Physiol. 84:965-968. Other methods known to enhance translation can also be utilized, for example, introns, and the like.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and trans versions, may be involved.

A number of promoters can be used in the practice of the invention. The promoters can be selected based on the desired outcome. The nucleic acids can be combined with constitutive, tissue-preferred, or other promoters for expression in plants. Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in WO 99/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2: 163-171); ubiquitin (Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) Plant Mol. Biol. 18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730); ALS promoter (U.S. Pat. No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.

Tissue-preferred promoters can be utilized to target enhanced HPPD expression within a particular plant tissue. Such tissue-preferred promoters include, but are not limited to, leaf-preferred promoters, root-preferred promoters, seed-preferred promoters, and stem-preferred promoters. Tissue-preferred promoters include Yamamoto et al. (1997) Plant J. 12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803; Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2): 157-168; Rinehart et al. (1996) Plant Physiol. 112(3): 1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20: 181-196; Orozco et al. (1993) Plant Mol Biol. 23(6): 1129-1138; Matsuoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. Such promoters can be modified, if necessary, for weak expression. In one embodiment, the nucleic acids of interest are targeted to the chloroplast for expression. In this manner, where the nucleic acid of interest is not directly inserted into the chloroplast, the expression cassette will additionally contain a chloroplast-targeting sequence comprising a nucleotide sequence that encodes a chloroplast transit peptide to direct the gene product of interest to the chloroplasts. Such transit peptides are known in the art. With respect to chloroplast-targeting sequences, “operably linked” means that the nucleic acid sequence encoding a transit peptide (i.e., the chloroplast-targeting sequence) is linked to the HPPD nucleic acid of the invention such that the two sequences are contiguous and in the same reading frame. See, for example, Von Heijne et al. (1991) Plant Mol. Biol. Rep. 9: 104-126; Clark et al. (1989) J. Biol. Chem. 264:17544-17550; Della-Cioppa et al. (1987) Plant Physiol. 84:965-968; Romer et al. (1993) Biochem. Biophys. Res. Commun. 196:1414-1421; and Shah et al. (1986) Science 233:478-481. Any chloroplast transit peptide known in the art can be fused to the amino acid sequence of a mature HPPD protein of the invention by operably linking a choloroplast-targeting sequence to the 5′-end of a nucleotide sequence encoding a mature mut-HPPD protein of the invention. Chloroplast targeting sequences are known in the art and include the chloroplast small subunit of ribulose-1,5-bisphosphate carboxylase (Rubisco) (de Castro Silva Filho et al. (1996) Plant Mol. Biol. 30:769-780; Schnell et al. (1991) J. Biol. Chem. 266(5):3335-3342); 5-(enolpyruvyl)shikimate-3-phosphate synthase (EPSPS) (Archer et al. (1990) J. Bioenerg. Biomemb. 22(6):789-810); tryptophan synthase (Zhao et al. (1995) J. Biol. Chem. 270(11):6081-6087); plastocyanin (Lawrence et al. (1997) J. Biol. Chem. 272(33):20357-20363); chorismate synthase (Schmidt et al. (1993) J. Biol. Chem. 268(36):27447-27457); and the light harvesting chlorophyll a/b binding protein (LHBP) (Lamppa et al. (1988) J. Biol. Chem. 263: 14996-14999). See also Von Heijne et al. (1991) Plant Mol. Biol. Rep. 9: 104-126; Clark et al. (1989) J. Biol. Chem. 264:17544-17550; Della-Cioppa et al. (1987) Plant Physiol. 84:965-968; Romer et al. (1993) Biochem. Biophys. Res. Commun. 196: 1414-1421; and Shah et al. (1986) Science 233:478-481.

Methods for transformation of chloroplasts are known in the art. See, for example, Svab et al. (1990) Proc. Natl. Acad. ScL USA 87:8526-8530; Svab and Maliga (1993) Proc. Natl. Acad. Sci. USA 90:913-917; Svab and Maliga (1993) EMBO J. 12:601-606. The method relies on particle gun delivery of DNA containing a selectable marker and targeting of the DNA to the plastid genome through homologous recombination. Additionally, plastid transformation can be accomplished by transactivation of a silent plastid-borne transgene by tissue-preferred expression of a nuclear-encoded and plastid-directed RNA polymerase. Such a system has been reported in McBride et al. (1994) Proc. Natl. Acad. Sci. USA 91:7301-7305. The nucleic acids of interest to be targeted to the chloroplast may be optimized for expression in the chloroplast to account for differences in codon usage between the plant nucleus and this organelle. In this manner, the nucleic acids of interest may be synthesized using chloroplast-preferred codons. See, for example, U.S. Pat. No. 5,380,831, herein incorporated by reference.

In a preferred embodiment, the HPPD nucleic acid encoding a wildtype or a mut-HPPD (a) or the HST nucleic acid (b) comprises a polynucleotide sequence selected from the group consisting of: a) a polynucleotide as shown in SEQ ID NO: 1, 51, 3, 4, 6, 7, 9, 10, 12, 13, 15, 16, 18, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 52, 54, 56, 68, 69, or a variant or derivative thereof; b) a polynucleotide as shown in SEQ ID NO: 47 or 49, or a variant or derivative thereof; c) a polynucleotide encoding a polypeptide as shown in SEQ ID NO: 2, 5, 8, 11, 14, 17, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 53, 55, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, or a variant or derivative thereof; d) a polynucleotide comprising at least 60 consecutive nucleotides of any of a) through c); and e) a polynucleotide complementary to the polynucleotide of any of a) through d) Preferably, the expression cassette further comprises a transcription initiation regulatory region and a translation initiation regulatory region that are functional in the plant.

While the polynucleotides of the invention find use as selectable marker genes for plant transformation, the expression cassettes of the invention can include another selectable marker gene for the selection of transformed cells. Selectable marker genes, including those of the present invention, are utilized for the selection of transformed cells or tissues. Marker genes include, but are not limited to, genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). See generally, Yarranton (1992) Curr. Opin. Biotech. 3:506-511; Christophers on et al (1992) Proc. Natl. Acad. ScL USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; Reznikoff (1992) Mol Microbiol 6:2419-2422; Barkley et al (1980) in The Operon, pp. 177-220; Hu et al (1987) Cell 48:555-566; Brown et al (1987) Cell 49:603-612; Figge et al (1988) Cell 52:713-722; Deuschle et al (1989) Proc. Natl Acad. AcL USA 86:5400-5404; Fuerst et al (1989) Proc. Natl Acad. ScL USA 86:2549-2553; Deuschle et al (1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al (1993) Proc. Natl Acad. ScL USA 90: 1917-1921; Labow et al (1990) Mol Cell Biol 10:3343-3356; Zambretti et al (1992) Proc. Natl Acad. ScL USA 89:3952-3956; Bairnm et al (1991) Proc. Natl Acad. ScL USA 88:5072-5076; Wyborski et al (1991) Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol Struc. Biol 10: 143-162; Degenkolb et al (1991) Antimicrob. Agents Chemother. 35: 1591-1595; Kleinschnidt et al (1988) Biochemistry 27: 1094-1104; Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al (1992) Proc. Natl Acad. ScL USA 89:5547-5551; Oliva et al (1992) Antimicrob. Agents Chemother. 36:913-919; Hlavka et al (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al (1988) Nature 334:721-724. Such disclosures are herein incorporated by reference. The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

The invention further provides an isolated recombinant expression vector comprising the expression cassette containing a HPPD nucleic acid as described above, wherein expression of the vector in a host cell results in increased tolerance to a HPPD-inhibiting herbicide as compared to a wild type variety of the host cell. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid,” which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses, and adeno-associated viruses), which serve equivalent functions.

The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, which is operably linked to the nucleic acid sequence to be expressed. Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cells and those that direct expression of the nucleotide sequence only in certain host cells or under certain conditions. It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of polypeptide desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce polypeptides or peptides, including fusion polypeptides or peptides, encoded by nucleic acids as described herein (e.g., mut-HPPD polypeptides, fusion polypeptides, etc.).

In a preferred embodiment of the present invention, the HPPD polypeptides are expressed in plants and plants cells such as unicellular plant cells (such as algae) (See Falciatore et al., 1999, Marine Biotechnology 1(3):239-251 and references therein) and plant cells from higher plants (e.g., the spermatophytes, such as crop plants). A HPPD polynucleotide may be “introduced” into a plant cell by any means, including transfection, transformation or transduction, electroporation, particle bombardment, agroinfection, biolistics, and the like.

Suitable methods for transforming or transfecting host cells including plant cells can be found in Sambrook et al. (Molecular Cloning: A Laboratory Manual. 2nd, ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) and other laboratory manuals such as Methods in Molecular Biology, 1995, Vol. 44, Agrobacterium protocols, ed: Gartland and Davey, Humana Press, Totowa, N.J. As increased tolerance to HPPD-inhibiting herbicides is a general trait wished to be inherited into a wide variety of plants like maize, wheat, rye, oat, triticale, rice, barley, soybean, pea-nut, cotton, rapeseed and canola, manihot, pepper, sunflower and tagetes, solanaceous plants like potato, tobacco, eggplant, and tomato, Vicia species, pea, alfalfa, bushy plants (coffee, cacao, tea), Salix species, trees (oil palm, coconut), perennial grasses, and forage crops, these crop plants are also preferred target plants for a genetic engineering as one further embodiment of the present invention. In a preferred embodiment, the plant is a crop plant. Forage crops include, but are not limited to, Wheatgrass, Canarygrass, Bromegrass, Wildrye Grass, Bluegrass, Orchardgrass, Alfalfa, Salfoin, Birdsfoot Trefoil, Alsike Clover, Red Clover, and Sweet Clover.

In one embodiment of the present invention, transfection of a mut-HPPD polynucleotide into a plant is achieved by Agrobacterium mediated gene transfer. One transformation method known to those of skill in the art is the dipping of a flowering plant into an Agrobacteria solution, wherein the Agrobacteria contains the mut-HPPD nucleic acid, followed by breeding of the transformed gametes. Agrobacterium mediated plant transformation can be performed using for example the GV3101(pMP90) (Koncz and Schell, 1986, Mol. Gen. Genet. 204:383-396) or LBA4404 (Clontech) Agrobacterium tumefaciens strain. Transformation can be performed by standard transformation and regeneration techniques (Deblaere et al., 1994, Nucl. Acids. Res. 13:4777-4788; Gelvin, Stanton B. and Schilperoort, Robert A, Plant Molecular Biology Manual, 2nd Ed.—Dordrecht: Kluwer Academic Publ., 1995.—in Sect., Ringbuc Zentrale Signatur: BT11-P ISBN 0-7923-2731-4; Glick, Bernard R. and Thompson, John E., Methods in Plant Molecular Biology and Biotechnology, Boca Raton: CRC Press, 1993 360 S., ISBN 0-8493-5164-2). For example, rapeseed can be transformed via cotyledon or hypocotyl transformation (Moloney et al., 1989, Plant Cell Report 8:238-242; De Block et al., 1989, Plant Physiol. 91:694-701). Use of antibiotics for Agrobacterium and plant selection depends on the binary vector and the Agrobacterium strain used for transformation. Rapeseed selection is normally performed using kanamycin as selectable plant marker. Agrobacterium mediated gene transfer to flax can be performed using, for example, a technique described by Mlynarova et al., 1994, Plant Cell Report 13:282-285. Additionally, transformation of soybean can be performed using for example a technique described in European Patent No. 0424 047, U.S. Pat. No. 5,322,783, European Patent No. 0397 687, U.S. Pat. No. 5,376,543, or U.S. Pat. No. 5,169,770. Transformation of maize can be achieved by particle bombardment, polyethylene glycol mediated DNA uptake, or via the silicon carbide fiber technique. (See, for example, Freeling and Walbot “The maize handbook” Springer Verlag: New York (1993) ISBN 3-540-97826-7). A specific example of maize transformation is found in U.S. Pat. No. 5,990,387, and a specific example of wheat transformation can be found in PCT Application No. WO 93/07256.

According to the present invention, the introduced HPPD polynucleotide may be maintained in the plant cell stably if it is incorporated into a non-chromosomal autonomous replicon or integrated into the plant chromosomes. Alternatively, the introduced mut-HPPD polynucleotide may be present on an extra-chromosomal non-replicating vector and be transiently expressed or transiently active. In one embodiment, a homologous recombinant microorganism can be created wherein the mut-HPPD polynucleotide is integrated into a chromosome, a vector is prepared which contains at least a portion of an HPPD gene into which a deletion, addition, or substitution has been introduced to thereby alter, e.g., functionally disrupt, the endogenous HPPD gene and to create a mut-HPPD gene. To create a point mutation via homologous recombination, DNA-RNA hybrids can be used in a technique known as chimeraplasty (Cole-Strauss et al., 1999, Nucleic Acids Research 27(5):1323-1330 and Kmiec, 1999, Gene therapy American Scientist 87(3):240-247). Other homologous recombination procedures in Triticum species are also well known in the art and are contemplated for use herein.

In the homologous recombination vector, the wildtype or mut-HPPD gene can be flanked at its 5′ and 3′ ends by an additional nucleic acid molecule of the HPPD gene to allow for homologous recombination to occur between the exogenous wildtype or mut-HPPD gene carried by the vector and an endogenous HPPD gene, in a microorganism or plant. The additional flanking HPPD nucleic acid molecule is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several hundreds of base pairs up to kilobases of flanking DNA (both at the 5′ and 3′ ends) are included in the vector (see e.g., Thomas, K. R., and Capecchi, M. R., 1987, Cell 51:503 for a description of homologous recombination vectors or Strepp et al., 1998, PNAS, 95(8):4368-4373 for cDNA based recombination in Physcomitrella patens). However, since the mut-HPPD gene normally differs from the HPPD gene at very few amino acids, a flanking sequence is not always necessary. The homologous recombination vector is introduced into a microorganism or plant cell (e.g., via polyethylene glycol mediated DNA), and cells in which the introduced mut-HPPD gene has homologously recombined with the endogenous HPPD gene are selected using art-known techniques.

In another embodiment, recombinant microorganisms can be produced that contain selected systems that allow for regulated expression of the introduced gene. For example, inclusion of a mut-HPPD gene on a vector placing it under control of the lac operon permits expression of the mut-HPPD gene only in the presence of IPTG. Such regulatory systems are well known in the art.

Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but they also apply to the progeny or potential progeny of such a cell.

Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein. A host cell can be any prokaryotic or eukaryotic cell. For example, a mut-HPPD polynucleotide can be expressed in bacterial cells such as C. glutamicum, insect cells, fungal cells, or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells), algae, ciliates, plant cells, fungi or other microorganisms like C. glutamicum. Other suitable host cells are known to those skilled in the art.

A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) a mut-HPPD polynucleotide. Accordingly, the invention further provides methods for producing mut-HPPD polypeptides using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding a mut-HPPD polypeptide has been introduced, or into which genome has been introduced a gene encoding a wild-type or mut-HPPD polypeptide) in a suitable medium until mut-HPPD polypeptide is produced. In another embodiment, the method further comprises isolating mut-HPPD polypeptides from the medium or the host cell. Another aspect of the invention pertains to isolated mut-HPPD polypeptides, and biologically active portions thereof. An “isolated” or “purified” polypeptide or biologically active portion thereof is free of some of the cellular material when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of mut-HPPD polypeptide in which the polypeptide is separated from some of the cellular components of the cells in which it is naturally or recombinantly produced. In one embodiment, the language “substantially free of cellular material” includes preparations of a mut-HPPD polypeptide having less than about 30% (by dry weight) of non-mut-HPPD material (also referred to herein as a “contaminating polypeptide”), more preferably less than about 20% of non-mut-HPPD material, still more preferably less than about 10% of non-mut-HPPD material, and most preferably less than about 5% non-mut-HPPD material.

When the mut-HPPD polypeptide, or biologically active portion thereof, is recombinantly produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the polypeptide preparation. The language “substantially free of chemical precursors or other chemicals” includes preparations of mut-HPPD polypeptide in which the polypeptide is separated from chemical precursors or other chemicals that are involved in the synthesis of the polypeptide. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of a mut-HPPD polypeptide having less than about 30% (by dry weight) of chemical precursors or non-mut-HPPD chemicals, more preferably less than about 20% chemical precursors or non-mut-HPPD chemicals, still more preferably less than about 10% chemical precursors or non-mut-HPPD chemicals, and most preferably less than about 5% chemical precursors or non-mut-HPPD chemicals. In preferred embodiments, isolated polypeptides, or biologically active portions thereof, lack contaminating polypeptides from the same organism from which the mut-HPPD polypeptide is derived. Typically, such polypeptides are produced by recombinant expression of, for example, a mut-HPPD polypeptide in plants other than, or in microorganisms such as C. glutamicum, ciliates, algae, or fungi.

As described above, the present invention teaches compositions and methods for increasing the HPPD-inhibiting herbicide, particularly benzamide tolerance of a crop plant or seed as compared to a wild-type variety of the plant or seed. In a preferred embodiment, the HPPD-inhibiting herbicide, particularly benzamide tolerance of a crop plant or seed is increased such that the plant or seed can withstand a HPPD-inhibiting herbicide, particularly benzamide application of preferably approximately 1-1000 g ai ha⁻¹, more preferably 10-500 g ai ha⁻¹, still more preferably 20-200 g ai ha⁻¹ and most preferably 40-100 g ai ha⁻¹. As used herein, to “withstand” a HPPD-inhibiting herbicide, particularly benzamide application means that the plant is either not killed or not injured by such application.

Furthermore, the present invention provides methods that involve the use of at least one HPPD-inhibiting herbicide, particularly benzamide as depicted in Table 2.

In these methods, the HPPD-inhibiting herbicide, particularly benzamide can be applied by any method known in the art including, but not limited to, seed treatment, soil treatment, and foliar treatment. Prior to application, the HPPD-inhibiting herbicide, particularly benzamide can be converted into the customary formulations, for example solutions, emulsions, suspensions, dusts, powders, pastes and granules. The use form depends on the particular intended purpose; in each case, it should ensure a fine and even distribution of the compound according to the invention.

By providing plants having increased tolerance to HPPD-inhibiting herbicide, particularly benzamide, a wide variety of formulations can be employed for protecting plants from weeds, so as to enhance plant growth and reduce competition for nutrients. A HPPD-inhibiting herbicide, particularly benzamide, can be used by itself for pre-emergence, post-emergence, pre-planting, and at-planting control of weeds in areas surrounding the crop plants described herein, or a HPPD-inhibiting herbicide formulation can be used that contains other additives. The HPPD-inhibiting herbicide, particularly benzamide, can also be used as a seed treatment. Additives found in a HPPD-inhibiting herbicide formulation include other herbicides, detergents, adjuvants, spreading agents, sticking agents, stabilizing agents, or the like. The HPPD-inhibiting herbicide formulation can be a wet or dry preparation and can include, but is not limited to, flowable powders, emulsifiable concentrates, and liquid concentrates. The HPPD-inhibiting herbicide and herbicide formulations can be applied in accordance with conventional methods, for example, by spraying, irrigation, dusting, or the like.

Suitable formulations are described in detail in PCT/EP2009/063387 and PCT/EP2009/063386, which are incorporated herein by reference.

It should also be understood that the foregoing relates to preferred embodiments of the present invention and that numerous changes may be made therein without departing from the scope of the invention. The invention is further illustrated by the following examples, which are not to be construed in any way as imposing limitations upon the scope thereof. On the contrary, it is to be clearly understood that resort may be had to various other embodiments, modifications, and equivalents thereof, which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the present invention and/or the scope of the appended claims.

EXAMPLES Example 1: Cloning of HPPD Encoding Genes

(A) Cloning of Arabidopsis thaliana HPPD

The partial Arabidopsis thaliana AtHPPD coding sequence (SEQ ID No: 52) is amplified by standard PCR techniques from Arabidopsis thaliana cDNA using primers HuJ101 and HuJ102 (Table 5).

TABLE 5 PCR primers for AtHPPD amplification (SEQ ID NO: 70, 71) Primer name Primer sequence (5′ → 3′) HuJ101 GGCCACCAAAACGCCG HuJ102 TCATCCCACTAACTGTTTGGCTTC

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-AtHPPD is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged AtHPPD is confirmed by DNA sequencing.

(B) Cloning of Chlamydomonas reinhardtii HPPD1

The C. reinhardtii HPPD1 (CrHPPD1) coding sequence (SEQ ID No: 54) is codon-optimized for expression in E. coli and provided as a synthetic gene (Entelechon, Regensburg, Germany). The partial synthetic gene is amplified by standard PCR techniques using primers Ta1-1 and Ta1-2 (Table 6).

TABLE 6 PCR primers for CrHPPD1 amplification (SEQ ID NO: 72, 73) Primer name Primer sequence (5′ → 3′) Ta1-1 GGCGCTGGCGGTGCGTCCACTAC Ta1-2 TCAAACGTTCAGGGTACGCTCGTAGTCTTCGATG

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-CrHPPD1 is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged CrHPPD1 is confirmed by DNA sequencing.

(C) Cloning of C. reinhardtii HPPD2

The C. reinhardtii HPPD2 (CrHPPD2) coding sequence (SEQ ID No: 56) is codon-optimized for expression in E. coli and provided as a synthetic gene (Entelechon, Regensburg, Germany). The partial synthetic gene is amplified by standard PCR techniques using primers Ta1-3 and Ta1-4 (Table 7).

TABLE 7 PCR primers for CrHPPD2 amplification (SEQ ID NO: 74, 75) Primer name Primer sequence (5′ → 3′) Ta1-3 GGTGCGGGTGGCGCTGGCACC Ta1-4 TCAAACGTTCAGGGTACGTTCGTAGTCCTCGATGG

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-CrHPPD2 is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged CrHPPD2 is confirmed by DNA sequencing.

(D) Cloning of Glycine max HPPD

The Glycine max HPPD (GmHPPD; Glyma14g03410) coding sequence is codon-optimized for expression in E. coli and provided as a synthetic gene (Entelechon, Regensburg, Germany). The partial synthetic gene is amplified by standard PCR techniques using primers Ta2-65 and Ta2-66 (Table 8).

TABLE 8 PCR primers for GmHPPD amplification (SEQ ID NO: 76, 77) Primer name Primer sequence (5′ → 3′) Ta2-65 CCAATCCCAATGTGCAACG Ta2-66 TTATGCGGTACGTTTAGCCTCC

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-GmHPPD is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged GmHPPD is confirmed by DNA sequencing.

(E) Cloning of Zea mays HPPD

The Zea mays HPPD (ZmHPPD; GRMZM2G088396) coding sequence is codon-optimized for expression in E. coli and provided as a synthetic gene (Entelechon, Regensburg, Germany). The partial synthetic gene is amplified by standard PCR techniques using primers Ta2-45 and Ta2-46 (Table 9).

TABLE 9 PCR primer for ZmHPPD amplification (SEQ ID NO: 78, 79) Primer name Primer sequence (5′ → 3′) Ta2-45 CCACCGACTCCGACCGCCGCAGC Ta2-46 TCAGGAACCCTGTGCAGCTGCCGCAG

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-ZmHPPD is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged ZmHPPD is confirmed by DNA sequencing.

(F) Cloning of Oryza sativa HPPD

The Oryza sativa HPPD (OsHPPD; Os02g07160) coding sequence is codon-optimized for expression in E. coli and provided as a synthetic gene (Entelechon, Regensburg, Germany). The partial synthetic gene is amplified by standard PCR techniques using primers Ta2-63 and Ta2-64 (Table 10).

TABLE 10 PCR primer for OsHPPD amplification (SEQ ID NO: 80, 81) Primer name Primer sequence (5′ → 3′) Ta2-63 CCGCCGACTCCAACCCC Ta2-64 TTAAGAACCCTGAACGGTCGG

The PCR-product is cloned in vector pEXP5-NT/TOPO® (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. The resulting plasmid pEXP5-NT/TOPO®-OsHPPD is isolated from E. coli TOP10 by performing a plasmid minipreparation. The expression cassette encoding N-terminally His6-tagged OsHPPD is confirmed by DNA sequencing.

(G) Gene Synthesis and Subcloning

Other wildtype HPPD encoding genes, such as Hordeum vulgare (SEQ ID NO:1/2) or Picrophilus torridus HPPD gene (Seq ID NO: 39/40) were synthesized by Geneart (Regensburg, Germany) or Entelechon (Regensburg, Germany) and subcloned into a modified pET24D (Novagen) expression vector resulting in N-terminally His-tagged expression constructs.

Example 2: Heterologous Expression and Purification of Recombinant HPPD Enzymes

Recombinant HPPD enzymes are produced and overexpressed in E. coli. Chemically competent BL21 (DE3) cells (Invitrogen, Carlsbad, USA) are transformed with pEXP5-NT/TOPO® (see EXAMPLE 1) or with other expression vectors according to the manufacturer's instructions.

Transformed cells are grown in autoinduction medium (ZYM 5052 supplemented with 100 μg/ml ampicillin) for 6 h at 37° C. followed by 24 h at 25° C.

At an OD600 (optical density at 600 nm) of 8 to 12, cells are harvested by centrifugation (8000×g). The cell pellet is resuspended in a lysis buffer (50 mM sodium phosphate buffer, 0.5 M NaCl, 10 mM Imidazole, pH 7.0) supplemented with complete EDTA free protease inhibitor mix (Roche-Diagnostics) and homogenized using an Avestin Press. The homogenate is cleared by centrifugation (40,000×g). His₆-tagged HPPD or mutant variants are purified by affinity chromatography on a Protino Ni-IDA 1000 Packed Column (Macherey-Nagel) according to the manufacturer's instructions. Purified HPPD or mutant variants are dialyzed against 100 mM sodium phosphate buffer pH 7.0, supplemented with 10% glycerin and stored at −86° C. Protein content is determined according to Bradford using the Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, USA). The purity of the enzyme preparation is estimated by SDS-PAGE.

Example 3: Assay for HPPD Activity

HPPD produces homogentisic acid and CO₂ from 4-hydroxyphenylpyruvate (4-HPP) and O₂. The activity assay for HPPD is based on the analysis of homogentisic acid by reversed phase HPLC.

The assay mixture can contain 150 mM potassium phosphate buffer pH 7.0, 50 mM L-ascorbic acid, 100 μM Catalase (Sigma-Aldrich), 1 μM FeSO₄ and 0.2 units of purified HPPD enzyme in a total volume of 505 μl. 1 unit is defined as the amount of enzyme that is required to produce 1 nmol of HGA per minute at 20° C.

After a preincubation of 30 min the reaction is started by adding 4-HPP to a final concentration of 0.05 mM. The reaction is allowed to proceed for 45 min at room temperature. The reaction is stopped by the addition of 50 μl of 4.5 M phosphoric acid. The sample is filtered using a 0.2 μM pore size PVDF filtration device.

5 μl of the cleared sample is analyzed on an UPLC HSS T3 column (particle size 1.8 μm, dimensions 2,1×50 mm; Waters) by isocratic elution using 90% 20 mM NaH₂PO₄ pH 2.2, 10% methanol (v/v).

HGA is detected electrochemically at 750 mV (mode: DC; polarity: positive) and quantified by integrating peak areas (Empower software; Waters).

Inhibitors are dissolved in DMSO (dimethylsulfoxide) to a concentration of 0.5 mM. From this stock solution serial five-fold dilutions are prepared in DMSO, which are used in the assay. The respective inhibitor solution accounts for 1% of the assay volume. Thus, final inhibitor concentrations range from 5 μM to 320 μM, respectively. Activities are normalized by setting the uninhibited enzyme activity to 100%. IC₅₀ values are calculated using non-linear regression.

Example 4: In Vitro Characterization of Wildtype HPPD Enzymes

Using methods which are described in the above examples or well known in the art, purified, recombinant wildtype HPPD enzymes are characterized with respect to their kinetic properties and sensitivity towards HPPD inhibiting herbicides. Apparent michaelis constants (K_(m)) and maximal reaction velocities (V_(max)) are calculated by non-linear regression with the software GraphPad Prism 5 (GraphPad Software, La Jolla, USA) using a substrate inhibition model. Apparent k_(cat) values are calculated from V_(max) assuming 100% purity of the enzyme preparation. Weighted means (by standard error) of K_(m) and IC₅₀ values are calculated from at least three independent experiments. The Cheng-Prusoff equation for competitive inhibition (Cheng, Y. C.; Prusoff, W. H. Biochem Pharmacol 1973, 22, 3099-3108) is used to calculate dissociation constants (K_(i)).

-   -   Field performance of the HPPD enzyme, which is used as a         herbicide tolerance trait, may depend not only on its lack of         sensitivity towards HPPD inhibiting herbicides but also on its         activity. To assess the potential performance of a herbicide         tolerance trait a tolerance index (TI) is calculated using the         following formula:

${TI} = \frac{k_{cat} \times K_{i}}{K_{m}}$

Easy comparison and ranking of each trait is enabled by normalizing tolerance indexes on Arabidopsis wild-type HPPD.

Examples of the data obtained in an in vitro assay are depicted in Table 11 and in Table 12.

TABLE 11 Determination of michaelis constants (K_(m)) for 4-HPP, turnover numbers (k_(cat)), catalytic efficiencies (k_(cat)/K_(m)) and dissociation constants (K_(i)) for various HPPD enzymes. K_(m) [μM] k_(cat) k_(cat)/K_(m) K_(i) [nM] K_(i) [nM] TI TI Enzyme (4-HPP) [s⁻¹] [μM⁻¹ s⁻¹] (Inhibitor 1)* (Inhibitor 2)* (Inhibitor 1)* (Inhibitor 2)* Arabidopsis 13 12.9 1 15 20  15E−3 19.5E−3 Hordeum 26 11.5 0.44 3.7 11 1.6E−3   5E−3 *HPPD inhibiting herbicides used in this example are 2,4-dichloro-6-fluoro-3-methylsulfonyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 1) and 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2)

TABLE 12 Normalized tolerance indexes of various HPPD enzymes TI TI TI Inhibitor Inhibitor Inhibitor HPPD Enzyme 1* 2* 3* Hordeum 1 1 1 Rhodococcus 2.8 0.4 12.5 HPPD2 Rhodococcus 2.8 0.4 0.4 HPPD1 Kordia 1.2 0.4 3.1 Picrophilus 2.1 0.4 0.7 Avena 2.8 3.8 2.8 Lolium 4.2 3.0 1.7 Seq ID 67 5 12.3 3.8 Seq ID 69 1.4 3 0.7 *HPPD inhibiting herbicides used in this example are 2,4-dichloro-6-fluoro-3-methylsulfonyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 1) and 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2) 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3),

The reference SEQ ID NO:2 was included as a comparative control in a representative number of experiments and the values given in Table 12 are the average values from a number of experiments. The TI values given for various HPPD enzymes from different organisms are normalized to the value of the reference SEQ ID NO:2.

It can be seen from the above example that polynucleotides comprising a region which encode Rhodococcus HPPD1 or HPPD2 can be selected as transgenes which encode an inhibitor-resistant HPPD because it was found that those enzymes were more tolerant to benzamide-derivative HPPD-inhibiting herbicides than the reference Hordeum HPPD enzyme. In detail, the tolerance indexes of the Rhodococcus enzymes were 2.8-fold increased for Inhibitor 1 whereas a 12.5-fold increased tolerance was observed for Rhodococcus HPPD2 for Inhibitor 3 compared to the benchmark enzyme (SEQ-ID:2). It can be further seen that the enzyme encoded by a polynucleotide comprising the Avena HPPD was 2.8-fold more tolerant to Inhibitor 1, 3.8-fold more tolerant to Inhibitor 2, and a 2.8-fold more tolerant to Inhibitor 3 compared to the control wild-type Hordeum enzyme. The two transgenes comprising the Zea mays HPPD mutants (SEQ-ID:67, SEQ-ID:69) are of outstanding interest because those enzymes showed a good tolerance against all HPPD inhibitors tested in the present invention. It is evident that any HPPD enzyme that is resistant towards herbicides, even if this protein is not exemplified in this text, is part of the subject-matter of this invention.

Example 5: Rational Mutagenesis

By means of structural biology and sequence alignment it is possible to choose a certain number of amino acids which can either directly or indirectly be involved in the binding of “HPPD-inhibiting herbicides” and then to mutagenize them and obtain tolerant HPPD enzymes.

(A) Site-Directed Mutagenesis

PCR-based site directed mutagenesis of pEXP5-NT/TOPO®-AtHPPD is done with the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, Santa Clara, USA) according to the manufacturers instructions. This technique requires two chemically synthesized DNA primers (forward and reverse primer) for each mutation. Exemplified primers that can be used for site directed mutagenesis of AtHPPD (SEQ ID NO:52/53) are listed in Table 13.

TABLE 13 PCR primers for site directed mutagenesis of AtHPPD (SEQ ID NOs: 82 to 147) Primer Mutation name Primer sequence (5′ → 3′) AtHPPD HuJ141 GAGGATTCGACTTCGCGCCTTCTCCTCC Met335 → Ala HuJ142 GGAGGAGAAGGCGCGAAGTCGAATCCTC Met335 → Ala HuJ143 GAGGATTCGACTTCTGGCCTTCTCCTCCG Met335 → Trp HuJ144 CGGAGGAGAAGGCCAGAAGTCGAATCCTC Met335 → Trp HuJ145 GGAGGATTCGACTTCTTTCCTTCTCCTCCGC Met335 → Phe HuJ146 GCGGAGGAGAAGGAAAGAAGTCGAATCCTCC Met335 → Phe HuJ147 GTGACAGGCCGACGATAGCTATAGAGATAATCCAG Phe392 → Ala HuJ148 CTGGATTATCTCTATAGCTATCGTCGGCCTGTCAC Phe392 → Ala HuJ153 GACTTCATGCCTCCTCCTCCGCCTACTTAC Ser337 → Pro HuJ154 GTAAGTAGGCGGAGGAGGAGGCATGAAGTC Ser337 → Pro HuJ155 GATTCGACTTCATGGCTTCTCCTCCGCCTAC Pro336 → Ala HuJ156 GTAGGCGGAGGAGAAGCCATGAAGTCGAATC Pro336 → Ala HuJ157 CAGATCAAGGAGTGTCAGGAATTAGGGATTCTTG Glu363 → Gln HuJ158 CAAGAATCCCTAATTCCTGACACTCCTTGATCTG Glu363 → Gln HuJ159 CGGAACAAAGAGGAAGAGTGAGATTCAGACGTATTTGG Gln293 → Val HuJ160 CCAAATACGTCTGAATCTCACTCTTCCTCTTTGTTCCG Gln293 → Val HuJ169 CGTTGCTTCAAATCTTCCCGAAACCACTAGGTGACAGGCC Thr382 → Pro HuJ170 GGCCTGTCACCTAGTGGTTTCGGGAAGATTTGAAGCAACG Thr382 → Pro HuJ171 CAAATCTTCACAAAACCAGTGGGTGACAGGCCGACGAT Leu385 → Val HuJ172 ATCGTCGGCCTGTCACCCACTGGTTTTGTGAAGATTTG Leu385 → Val HuJ173 TGACAGGCCGACGATATTTCTGGAGATAATCCAGAGAGTA Ile393 → Leu HuJ174 TACTCTCTGGATTATCTCCAGAAATATCGTCGGCCTGTCA Ile393 → Leu HuJ175 GACTTCATGCCTGCGCCTCCGCCTACTTAC Ser337 → Ala HuJ176 GTAAGTAGGCGGAGGCGCAGGCATGAAGTC Ser337 → Ala HuJ177 GGCAATTTCTCTGAGTTCTTCAAGTCCATTGAAG Leu427 → Phe HuJ178 CTTCAATGGACTTGAAGAACTCAGAGAAATTGCC Leu427 → Phe HuJ185 GGAACAAAGAGGAAGAGTGTGATTCAGACGTATTTGG Gln293 → Val HuJ186 CCAAATACGTCTGAATCACACTCTTCCTCTTTGTTCC Gln293 → Val Ta2-55 GAGGATTCGACTTCAACCCTTCTCCTCC Met335 → Asn Ta2-56 GGAGGAGAAGGGTTGAAGTCGAATCCTC Met335 → Asn Ta2-57 GAGGATTCGACTTCCAGCCTTCTCCTCC Met335 → Gln Ta2-58 GGAGGAGAAGGCTGGAAGTCGAATCCTC Met335 → Gln Ta2-59 GGAACAAAGAGGAAGAGTAACATTCAGACGTATTTGG Gln293 → Asn Ta2-60 CCAAATACGTCTGAATGTTACTCTTCCTCTTTGTTCC Gln293 → Asn Ta2-61 GGAACAAAGAGGAAGAGTCACATTCAGACGTATTTGG Gln293 → His Ta2-62 CCAAATACGTCTGAATGTGACTCTTCCTCTTTGTTCC Gln293 → His Ta2-126 GGAACAAAGAGGAAGAGTGCGATTCAGACGTATTTGG Gln293 → Ala Ta2-127 CCAAATACGTCTGAATCGCACTCTTCCTCTTTGTTCC Gln293 → Ala Ta2-140 GGAACAAAGAGGAAGAGTCTGATTCAGACGTATTTGG Gln293 → Leu Ta2-141 CCAAATACGTCTGAATCAGACTCTTCCTCTTTGTTCC Gln293 → Leu Ta2-138 GGAACAAAGAGGAAGAGTATAATTCAGACGTATTTGG Gln293 → Ile Ta2-139 CCAAATACGTCTGAATTATACTCTTCCTCTTTGTTCC Gln293 → Ile Ta2-150 GGAACAAAGAGGAAGAGTTCGATTCAGACGTATTTGG Gln293 → Ser Ta2-151 CCAAATACGTCTGAATCGAACTCTTCCTCTTTGTTCC Gln293 → Ser Ta2-194 GAGGATTCGACTTCCACCCTTCTCCTCC Met335 → His Ta2-195 GGAGGAGAAGGGTGGAAGTCGAATCCTC Met335 → His Ta2-196 GAGGATTCGACTTCTACCCTTCTCCTCC Met335 → Tyr Ta2-197 GGAGGAGAAGGGTAGAAGTCGAATCCTC Met335 → Tyr Ta2-190 GAGGATTCGACTTCAGCCCTTCTCCTCC Met335 → Ser Ta2-191 GGAGGAGAAGGGCTGAAGTCGAATCCTC Met335 → Ser Ta2-192 GAGGATTCGACTTCACACCTTCTCCTCC Met335 → Thr Ta2-193 GGAGGAGAAGGTGTGAAGTCGAATCCTC Met335 → Thr Ta2-188 GAGGATTCGACTTCTGTCCTTCTCCTCC Met335 → Cys Ta2-189 GGAGGAGAAGGACAGAAGTCGAATCCTC Met335 → Cys Ta2-215 GGATTCGACTTCATGCGTTCTCCTCCGCC Pro336 → Arg Ta2-216 GGCGGAGGAGAACGCATGAAGTCGAATCC Pro336 → Arg Ta2-200 GAGGAATTAGGGATTTGGGTAGACAGAGATG Leu368 → Trp Ta2-201 CATCTCTGTCTACCCAAATCCCTAATTCCTC Leu368 → Trp Ta2-198 GAGGAATTAGGGATTATGGTAGACAGAGATG Leu368 → Met Ta2-199 CATCTCTGTCTACCATAATCCCTAATTCCTC Leu368 → Met Ta2-204 GGTGGTTTTGGCAAACACAATTTCTCTGAG Gly422 → His Ta2-205 CTCAGAGAAATTGTGTTTGCCAAAACCACC Gly422 → His Ta2-202 GGTGGTTTTGGCAAATGCAATTTCTCTGAG Gly422 → Cys Ta2-203 CTCAGAGAAATTGCATTTGCCAAAACCACC Gly422 → Cys Ta2-217 GGTGGTTTTGGCACAGGCAATTTCTCTGAG Lys421 → Thr Ta2-218 CTCAGAGAAATTGCCTGTGCCAAAACCACC Lys421 → Thr

Exemplified primers that can be used for site directed mutagenesis of HvHPPD (SEQ ID NO:1/2) are listed in Table 14.

TABLE 14 PCR primers for site directed mutagenesis of HvHPPD (SEQ ID NOs: 148 to 155) Primer Mutation name Sequence (5′ → 3′) HvHPPD Ta2-279 GGGAGGGTTTGACTTTCA Leu320 → His TCCACCTCCGCTG Ta2-280 CAGCGGAGGTGGATGAAA GTCAAACCCTCCC Ta2-246 GGCTTCGACTTCTATCCA Leu320 → Tyr CCCCCGCTG Ta2-247 CAGCGGGGGTGGATAGAA GTCGAAGCC Ta2-248 GGGTTCGGCAAATGCAAC Gly407 → Cys TTCTCCGAGCTG Ta2-249 CAGCTCGGAGAAGTTGCA TTTGCCGAACCC Ta2-281 GGAGGGTTTGACTTTCAT Pro321 → Ala GCACCTCCGCTG Ta2-282 CAGCGGAGGTGCATGAAA GTCAAACCCTCC

Mutant plasmids are isolated from E. coli TOP10 by performing a plasmid minipreparation and confirmed by DNA sequencing.

The combination of single amino acid substitutions is achieved by a stepwise mutagenesis approach.

(B) In Vitro Characterization of HPPD Mutants

Purified, mutant HPPD enzymes are obtained by the methods described above. Dose response and kinetic measurements are carried out using the described HPPD activity assay. Apparent michaelis constants (K_(m)) and maximal reaction velocities (V_(max)) are calculated by non-linear regression with the software GraphPad Prism 5 (GraphPad Software, La Jolla, USA) using a substrate inhibition model. Apparent k_(cat) values are calculated from V_(max) assuming 100% purity of the enzyme preparation. Weighted means (by standard error) of K_(m) and IC₅₀ values are calculated from at least three independent experiments. The Cheng-Prusoff equation for competitive inhibition (Cheng, Y. C.; Prusoff, W. H. Biochem Pharmacol 1973, 22, 3099-3108) is used to calculate dissociation constants (K_(i)).

Field performance of the optimized HPPD enzyme, which is used as a herbicide tolerance trait may depend not only on its lack of sensitivity towards HPPD inhibiting herbicides but also on its activity. To assess the potential performance of a herbicide tolerance trait a tolerance index (TI) is calculated using the following formula:

${TI} = \frac{k_{cat} \times K_{i}}{K_{m}}$

Easy comparison and ranking of each trait is enabled by normalizing tolerance indexes on Arabidopsis wild-type HPPD.

Examples of the data obtained are depicted in Table 15 and in Table 16.

TABLE 15 Normalized tolerance indexes of various HPPD mutants generated in the Arabidopsis HPPD (SEQ ID: 53). Arabidopsis TI TI HPPD Inhibitor TI Inhibitor variant 1* Inhibitor 2* 3* Wildtype 1 1 1 M335H, 0.6 0.8 0.2 P336A M335H, 0.2 1.1 0.3 P336G, E363Q F381I 4.6 0.6 0.1 F381L 1.2 0.8 0.2 M335H, 0.5 0.9 0.1 P336G *HPPD inhibiting herbicides used in this example are 2,4-dichloro-6-fluoro-3-methylsulfonyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 1) and 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2) 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3), n.d. not determined.

TABLE 16 Normalized tolerance indexes of various HPPD mutants generated in the Hordeum HPPD (SEQ ID NO: 2). TI TI TI Hordeum Inhibitor Inhibitor Inhibitor HPPD variant 1* 2* 3* Wild-type 1 1 1 L320H 4.6 4.5 1.9 L320H, 3.7 3.6 14.3 P321A L320N 5.2 0.6 n.d. L353M, 1.9 1.2 0.9 P321R, L320N L353M, 2.5 3 n.d. P321R, L320Q F404L 1.6 0.9 1.8 L250M 3.1 0.8 1 F377L 11.8 2.1 2 S252T 1.8 7.3 11.1 R309K 2.6 2.1 3 *HPPD inhibiting herbicides used in this example are 2,4-dichloro-6-fluoro-3-methylsulfonyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 1) and 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2) 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3), n.d. not determined.

A number of conclusions can be derived from the data in Tables 15 and 16. The properties of HPPD mutants indicated that certain amino acid substitutions within the coding sequence provided significant improvements relative to HPPD SEQ ID NOS: 2 and 53 in respect to the tolerance indexes for HPPD-inhibiting herbicides.

It can be seen from the results depicted in Table 15 that the substitution of phenylalanine at position 381 in SEQ ID NO:53 by isoleucine provided an improvement to the HPPD enzyme. This particular mutant had an increased tolerance index for Inhibitor 1 relative to the reference enzyme (SEQ ID NO:53)

The results depicted in Table 16 showed that mutations introduced in the Hordeum HPPD sequence (SEQ ID:2) resulted in significant improvements in comparison to the benchmark enzyme and a tolerance for benzamide-derivative herbicides could be observed. In more detail, it can be seen that the substitution of leucine to histidine at position 320 in SEQ ID NO:2 provided significant improvements to the HPPD enzyme compared to the control. This particular mutant had a 4-fold increased tolerance for Inhibitor 1 and Inhibitor 2, whereas the tolerance for Inhibitor 3 was 1.9-fold increased in direct comparison to the control. It can be further seen, that the additional exchange of proline 321 to alanine resulted in 14.3-fold increased tolerance for Inhibitor 3, whereas the tolerance for the other tested inhibitors was ˜3.6-fold increased compared to the benchmark enzyme.

Thus, some mutants, preferably the mutant encoding a polynucleotide comprising barley HPPD where leucine 320 is exchanged to histidine and proline 321 is substituted by alanine, can be selected as mutants which encode an inhibitor-resistant HPPD and are useful for generating herbicide tolerant plants.

In addition, a polynucleotide comprising a region which encodes barley HPPD (SEQ ID NO:2) where argine 309 is exchanged to lysine, can be selected as one that encodes an inhibitor-resistant HPPD because it is found that the tolerance index of the mutant is improved against all inhibitors tested in the present invention.

It can be further seen that a polynucleotide comprising a region which encodes Hordeum HPPD (SEQ ID NO:2) in which serine 252 is exchanged to threonine can be selected as one that encodes an inhibitor-resistant HPPD enzyme because it is found that the tolerance index of the mutant is significantly improved against all inhibitors tested in the present invention.

It is evident that any mutation or combination of mutations which would make it possible to obtain a HPPD enzyme that is resistant to benzamide herbicides, even if this protein is not exemplified in this text, is part of the subject-matter of this invention.

Example 6 Preparation of Plants which Express Heterologous HPPD and/or HST Enzymes and which are Tolerant to “HPPD-Inhibiting Herbicides”

Various methods for the production of stably transformed plants are well known in the art. HPPD-inhibiting herbicide tolerant soybean (Glycine max) or corn (Zea mays) plants can be produced by a method described by Olhoft et al. (US patent 2009/0049567). Briefly, HPPD or HST encoding polynucleotides are cloned into a binary vector using standard cloning techniques as described by Sambrook et al. (Molecular cloning (2001) Cold Spring Harbor Laboratory Press). The final vector construct contains an HPPD or HST encoding sequence flanked by a promoter sequence (e.g. the ubiquitin promoter (PcUbi) sequence) and a terminator sequence (e.g. the nopaline synthase terminator (NOS) sequence) and a resistance marker gene cassette (e.g. AHAS) (FIG. 2). Optionally, the HPPD or HST gene can provide the means of selection.

Agrobacterium-mediated transformation is used to introduce the DNA into soybean's axillary meristem cells at the primary node of seedling explants. After inoculation and co-cultivation with Agrobacteria, the explants are transferred to shoot induction medium without selection for one week. The explants are subsequently transferred to shoot induction medium with 1-3 μM imazapyr (Arsenal) for 3 weeks to select for transformed cells. Explants with healthy callus/shoot pads at the primary node are then transferred to shoot elongation medium containing 1-3 μM imazapyr until a shoot elongates or the explant dies. After regeneration, transformants are transplanted to soil in small pots, placed in growth chambers (16 hr day/8 hr night; 25° C. day/23° C. night; 65% relative humidity; 130-150 mE m-2 s-1) and subsequently tested for the presence of the T-DNA via Taqman analysis. After a few weeks, healthy, transgenic positive, single copy events are transplanted to larger pots and allowed to grow in the growth chamber.

Transformation of corn plants is done by a method described by McElver and Singh (WO 2008/124495). Plant transformation vector constructs containing HPPD or HST sequences are introduced into maize immature embryos via Agrobacterium-mediated transformation. Transformed cells are selected in selection media supplemented with 0.5-1.5 μM imazethapyr for 3-4 weeks. Transgenic plantlets are regenerated on plant regeneration media and rooted afterwards. Transgenic plantlets are subjected to TaqMan analysis for the presence of the transgene before being transplanted to potting mixture and grown to maturity in greenhouse.

Arabidopsis thaliana is transformed with HPPD or HST sequences by floral dip method as described by McElver and Singh (WO 2008/124495). Transgenic Arabidopsis plants are subjected to TaqMan analysis for analysis of the number of integration loci.

Transformation of Oryza sativa (rice) are done by protoplast transformation as described by Peng et al. (U.S. Pat. No. 6,653,529)

T0 or T1 transgenic plant of soybean, corn, rice and Arabidopsis thaliana containing HPPD or HST sequences are tested for improved tolerance to HPPD-inhibiting herbicides in greenhouse studies.

Example 7: Greenhouse Experiments

Transgenic plants expressing heterologous HPPD or HST enzymes are tested for tolerance against HPPD-inhibiting herbicides in greenhouse experiments.

For the pre-emergence treatment, the herbicides are applied directly after sowing by means of finely distributing nozzles. The containers are irrigated gently to promote germination and growth and subsequently covered with transparent plastic hoods until the plants have rooted. This cover causes uniform germination of the test plants, unless this has been impaired by the herbicides.

For post emergence treatment, the test plants are first grown to a height of 3 to 15 cm, depending on the plant habit, and only then treated with the herbicides. For this purpose, the test plants are either sown directly and grown in the same containers, or they are first grown separately and transplanted into the test containers a few days prior to treatment. For testing of T0 plants, cuttings can be used. In the case of soybean plants, an optimal shoot for cutting is about 7.5 to 10 cm tall, with at least two nodes present. Each cutting is taken from the original transformant (mother plant) and dipped into rooting hormone powder (indole-3-butyric acid, IBA). The cutting is then placed in oasis wedges inside a bio-dome. Wild type cuttings are also taken simultaneously to serve as controls. The cuttings are kept in the bio-dome for 5-7 days and then transplanted to pots and then acclimated in the growth chamber for two more days. Subsequently, the cuttings are transferred to the greenhouse, acclimated for approximately 4 days, and then subjected to spray tests as indicated.

Depending on the species, the plants are kept at 10-25° C. or 20-35° C. The test period ex-tends over 3 weeks. During this time, the plants are tended and their response to the individual treatments is evaluated. Herbicide injury evaluations are taken at 2 and 3 weeks after treatment. Plant injury is rated on a scale of 0 to 9, 0 being no injury and 9 being complete death.

Tolerance to HPPD-inhibiting herbicides can also be assessed in Arabidopsis. In this case transgenic Arabidopsis thaliana plants are assayed for improved tolerance to HPPD-inhibiting herbicides in 48-well plates. Seeds are surface sterilized by stirring for 5 min in ethanol+water (70+30 by volume), rinsing one time with ethanol+water (70+30 by volume) and two times with a sterile, deionized water. The seeds are resuspended in 0.1% agar dissolved in water (w/v). Four to five seeds per well are plated on solid nutrient medium consisting of half-strength Murashige Skoog nutrient solution, pH 5.8 (Murashige and Skoog (1962) Physiologia Plantarum 15: 473-497). Compounds are dissolved in dimethylsulfoxid (DMSO) and added to the medium prior solidification (final DMSO concentration 0.1%). Multi well plates are incubated in a growth chamber at 22° C., 75% relative humidity and 110 μmol Phot*m-2*s-1 with 14: 10 h light: dark photoperiod. Seven to ten days after seedling growth inhibition is evaluated by comparison to wild type plants. Tolerance factor is calculated by dividing the plant growth IC50 value of transgenic plants containing a HPPD and/or HST sequence by that of wildtype plants.

Additionally, T1 and T2 transgenic Arabidopsis plants can be tested for improved tolerance to HPPD-inhibiting herbicides in a greenhouse studies. Herbicide injury scoring is done 2-3 weeks after treatment and is rated on a scale of 0 to 100%, 0% being no injury and 100% being complete death.

TABLE 18 Greenhouse testing of transgenic Arabidopsis plants (T2). Injury evaluations, on a scale of 0-100%, were taken two weeks after herbicide treatment. Each data point represents a mean value of at least two independent transgenic lines. Selected transgenic lines are shown in FIG. 3. Transgene AtM335H, Dose HvL320H, P336A, Herbicide [g/ha] None P321A HvL320H E363Q AtF381I RjHPPD Inhibitor 12.5 94 8 33 47 40 46 2* 6.25 98 7 18 7 25 13 3.125 87 5 12 7 20 12 1.56 86 0 0 0 n.d. 2 *HPPD inhibiting herbicide used in this example is 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2), n.d. not determined.

Transgenic Arabidopsis plants were sprayed with a range of doses from 1.56-12.5 g/ha with the HPPD-inhibiting benzamide herbicide and injury evaluations were taken two weeks after treatment. It can be seen from the above example that plants comprising a polynucleotide encoding for HPPD can be selected as plants tolerant to benzamide-derivative herbicides because it was found that transgenic plants had a broader tolerance to the HPPD-inhibiting herbicide than it was the case for the untransformed wild-type plants. As depicted in Table 18, control plants were severely injured by all doses of herbicide applied, with at least 86% of leaf material being damaged at the lowest application rate. For example, the HPPD mutant version with three amino acid substitutions such as methionine 335 to histidine, proline 336 to alanine, and glutamate 363 to glutamine (numbering corresponding to SEQ ID: 53), exhibited a significant tolerance against the HPPD inhibitor tested in the above example. Application of 12.5 g/ha active ingredient resulted in 47% total leaf damage in transgenic plants expressing the mutated version of Arabidopsis HPPD whereas the injury in the wild-type plants reached 94%, indicating a 2-fold increased tolerance at this application rate. The tolerance factor of the triple mutant for the bezamide-derivative herbicide was significantly increased with lower application rates as the mutant showed only 7% leaf damage in contrast to 87-98% damage in wild-type control plants (Table 18). Thus, the polynucleotide comprising Arabidopsis HPPD with M335H,P336A,E363Q can be selected as a transgene that mediates tolerance for benzamide herbicides because plants encoding this particular transgene had an improved behavior in the spray test of the present invention.

In addition, transgenic Arabidopsis plants comprising a polynucleotide encoding SEQ ID NO:2 with leucine 320 exchanged to histidine are more resistant to Inhibitor 2 than the untransformed wild-type plants. The combined mutation of leucine 320 to histidine and proline 321 to alanine resulted in a HPPD inhibitor resistant plant line which had an outstanding tolerance factor for Inhibitor 2 at the highest rate active ingredient applied. Compared to the control, plants expressing Rhodococcus HPPD (SEQ ID NO:46) are more resistant to HPPD inhibitors tested in the present invention because transgenic lines expressing this HPPD enzyme did show only 2% leaf damage with the lowest application rate. In addition, when the active ingredient was applied with the highest concentration, the transgene conferred 2-fold tolerance for Inhibitor 2 compared to the untransformed wild-type control.

It is evident that any mutation or combination of mutations which would make it possible to obtain a HPPD enzyme that is resistant to benzamide-derivative herbicides, even if this protein is not exemplified in this text, is part of the subject-matter of this invention.

TABLE 19 Greenhouse testing of transgenic Corn plants (homozygous T2). Injury evaluations, on a scale of 0-100%, were taken two weeks after herbicide treatment. Corresponding pictures are shown in FIG. 4. Dose AtL385V, I393L Herbicide [g/ha] WT Event 1 Event 2 AtM335H Inhibitor 62.5 40 3 6 3 3 * 125 63 7 10 4 250 86 10 47 6 * HPPD inhibiting herbicide used in this example is 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3).

Transgenic corn plants were sprayed with doses from 62.5-250 g/ha with the benzamide-derivative HPPD-inhibiting herbicide and injury evaluations were taken two weeks after treatment. It can be seen from the above example that transgenic corn plants expressing a polynucleotide comprising a mutant HPPD enzyme can be selected as ones which are resistant to benzamide-derivative herbicides because it was found that transgenic plants had a broader tolerance to the HPPD-inhibiting herbicide than it was the case for the untransformed wild-type control. As depicted in Table 19, control plants were severely injured by all doses of herbicide applied, with 86% of leaf material being damaged at the highest rate applied. For example, corn plants carrying a transgene encoding for the HPPD mutant version with amino acids leucine 385 substituted by valine and isoleucine 393 exchanged to leucine (SEQ ID: 53) exhibited a significant tolerance against the HPPD inhibitor depicted in the above example. Application of 250 g/ha active ingredient resulted only in 10% leaf damage (event 1) in transgenic plants which gave in direct comparison with wild-type plants (injury value is 86%) an 8-fold increased tolerance at this application rate. In addition, transgenic corn plants comprising a transgene encoding the mutated version of Arabidopsis HPPD with methionine 335 exchanged to histidine, are tolerant for the benzamide-derivative inhibitor tested in the present invention. Those plants had a 14-fold increased tolerance compared to non-transgenic control plants.

It is evident that any mutation or combination of mutations which would make it possible to obtain a HPPD enzyme that is resistant to benzamide-derivative herbicides and can be used to generate crop plants tolerant for benzamide-derivative herbicides, even if this protein is not exemplified in this text, is part of the subject-matter of this invention.

Table 20: Greenhouse testing of transgenic Soy plants (T2). Injury evaluations, on a scale of 0-100%, were taken two weeks after herbicide treatment. Corresponding pictures are shown in FIG. 5.

TABLE 20 AtL385V, AtP336A, Transgene AtHPPD I393L E363Q, AtM335H Dose Event Event Event Event L385V, Event Event Herbicide [g/ha] none 1 2 1 2 I393L 1 2 AtM335Y GmHPPD1 Inhibitor 31.25 49 10 13 NA 20 30 10 14 9 15 3* 62.5 68 16 23 NA 35 30 21 29 45 29 125 79 44 40 NA 38 50 33 31 46 46 *HPPD inhibiting herbicide used in this example is 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3).

Transgenic soy plants were sprayed with doses from 31.25-125 g/ha with the benzamide-derivative HPPD-inhibiting herbicide (Inhibitor 3) tested in the present example and injury evaluations were taken two weeks after treatment. It can be seen from the above example that transgenic soy plants expressing a polynucleotide comprising a mutant HPPD enzyme can be selected as one which mediates resistance to benzamide-derivative herbicides because it was found that transgenic plants had a broader tolerance to the HPPD-inhibiting herbicide than it was the case for the untransformed wild-type control. As depicted in Table 20, control plants were severely injured by all doses of herbicide applied, with 79% of leaf material being damaged at the highest application rate. For example, soy plants carrying a transgene encoding for Arabidopsis HPPD (SEQ ID: 53) had an improved tolerance for the HPPD-inhibiting herbicide tested in the above example. Application of 31,25 g/ha active ingredient resulted only in 10-13% of leaf damage in two independent transgenic plant lines. Thus, in direct comparison with wild-type plants (injury value is 49%), a 4-fold increased tolerance could be observed after spraying with 31,25 g/ha. In addition, transgenic soy plants comprising a transgene encoding the Glycine max HPPD were more tolerant than nontrangenic control plants for the benzamide-derivative herbicide tested in the present invention. Those plants had a comparable tolerance as it was found for transgenic soy plants expressing Arabidopsis HPPD.

Therefore, the example shown above clearly demonstrates that one can select a polynucleotide comprising Arabidopsis HPPD or Glycine max HPPD to generate transgenic plants that are more tolerant to treatments with benzamide-derivate herbicides. It is evident that any other polynucleotide encoding a wild-type or mutated version of the HPPD enzyme can be used to generate crop plants tolerant for benzamide-derivative herbicides, even if this protein is not exemplified in this text and is part of the subject matter of this invention. 

The invention claimed is:
 1. A plant, or seed thereof, that expresses a mutagenized or recombinant mutated hydroxyphenyl pyruvate dioxygenase (mut-HPPD) comprising a variant of the wild-type Hordeum HPPD amino acid sequence of SEQ ID NO:2, or of the amino acid sequence of a wild-type homologue HPPD, wild-type orthologue HPPD, or wild-type paralogue HPPD thereof (i) having an amino acid sequence with at least 90% identity to SEQ ID NO: 2 over the entirety length, and (ii) having HPPD activity, wherein the amino acid sequence of the variant differs from that of the wild-type HPPD amino acid sequence in that it comprises at least one substitution in which: the amino acid corresponding to or at position 320 of SEQ ID NO:2 is Gln, His, or Tyr substituting for leucine; the amino acid corresponding to or at position 321 of SEQ ID NO:2 is Ala, or Gly substituting for proline; or the amino acid corresponding to or at position 278 of SEQ ID NO:2 is His, Asn, or Ser substituting for glutamine; and wherein said plant, expressing said mutagenized or recombinant mut-HPPD, possesses a phenotype of increased herbicide tolerance to a compound selected from 2,4-dichloro-6-fluoro-3-methylsulfonyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 1), 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(1-methyltetrazol-5-yl)benzamide (Inhibitor 2), or 2,4-dichloro-6-fluoro-3-methylsulfanyl-N-(2-methyl-1,2,4-triazol-3-yl)benzamide (Inhibitor 3), as compared to the corresponding wild-type variety of the plant.
 2. The seed according to claim 1, wherein said seed further comprises a seed treatment comprising an HPPD-inhibiting herbicide.
 3. The seed according to claim 2, wherein said HPPD-inhibiting herbicide comprises a benzamide herbicide. 